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1.1 Kinetoplastid Parasites 
Kinetoplastid parasites are a family of Trypanosomatids that cause a 
number of diseases worldwide; Leishmaniasis, Chagas disease and African 
Sleeping sickness are collectively termed as neglected parasitic diseases 
(NTDs). In the current study the main focus will be on 2 main infections: 
Leishmaniasis - caused by Leishmania species and African sleeping 
sickness - caused by T. brucei, Figure 1.1.  
There are 700,000 to 1 million cases of Leishmaniasis that are registered, 
with 26,000 to 65,000 deaths annually, whereas sleeping sickness causes 
10,000 reported cases annually and Chagas disease is reported to have 6 to 










The main countries that are at risk are 3rd world countries with tropical and 
sub-tropical regions where the health system is not well developed. 
Figure 1.1: Phylogenetic tree of Kinetoplastid parasites. (2) 
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Kinetoplastid organisms are characterized by having single flagellum and 
containing a particular organelle called kinetoplast.  
 
1.2 Leishmaniasis  
Leishmaniasis is a parasitic disease that is a widely distributed and causes 
endemic waves of outbreak in 100 countries in the regions of Asia, Africa, 
Latin America and even Southern Europe, Figure 1.2. More than 300 
million people are at risk to develop this health condition.  
 
Leishmaniasis is a tropical health condition that mainly predominates in 
countries with poorly developed health system. Also, factors such as 
climate and environment can have a significant effect on disease 
transmission and occurrence. Infection is transmitted by female 
phlebotomine sandflies.  
There is a significant discussion on the treatment of Leishmaniasis and 
other tropical diseases that can be used in order to control its transmission 
as well as the development of a new cases worldwide. Nowadays, there is 
an increased risk of infection as the modern world is more dynamic in 
Figure 1.2:  Leishmaniasis distribution across the world, (World Health Organisation) 
(WHO) 
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terms of tourism and immigration, and global warming could also be a 
factor to the disease being more widespread and being able to be 
transmitted to other European countries (World Health Organization).  
There are 3 types of Leishmaniasis, Figure 1.3: visceral – which is the 
most dangerous condition with fever, splenomegaly, weight loss, 
hypertrophy of liver and spleen; disfiguring mucosal – causes skin, mouth 
and nose ulcers and cutaneous type which is known of causing only skin 
ulcers.  
Treatments for Leishmaniasis include use of pentavalent antimonial 
(meglumine antimoniate & sodium stibogluconate), paromomycin, 
A B 
C 
Figure 1.3: 3 types of Leishmaniasis. A) visceral (WHO), B) disfiguring 
mucosal (3) C) cutaneous (4) 
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Figure 1.4: Current drug candidates for treating leishmaniasis. A) meglumine 
antimoniate, B) paromomycin, C) sitamaquine, D) amphotericin B, E) miltesfosine, F) 
pentamidine. ChemicalBook.com  
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However, there are certain drawbacks of current treatments, such as: 
drug’s potency against infection, effectiveness on late stages, rising 
resistance and its cost. Historically, a Dihydroartemisinin (artesunate) 
derivative was the therapy recommended by WHO (World Health 
Organization) and is also often used to treat Plasmodium falciparum 
malaria in tropical and subtropical countries (5).  
 
1.3 Mechanism of host cell invasion in Leishmaniasis 
Transmission occurs by sand fly where parasitic amastigotes are 
transmitted during blood feeding of fly from the infected animal. In the gut 
of sand fly, amastigotes are transformed into infective metacyclic 
promastigotes (6). After that, promastigotes migrate into the pool of host 
blood during sand fly feeding (7). When sand fly bites the host, it 
stimulates immune system response of the host where neutrophils migrate 
to the site of infection to engulf promastigotes, followed by migration of 
cells away from the site of infection (8). Promastigotes survive in a 
parasitic specific vacuole where they are transformed into amastigotes by 
dividing and breaking the cell. Amastigotes that were released after cell 
burst start infecting phagocytes causing infection. The last step in the cycle 
characterized by sand fly is taking up infected phagocytes during blood 
feeding, Figure 1.5. 
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1.4 Trypanosomatids  
Another class of kinetoplastid parasites is trypanosomatids where T. cruzi 
is causing American sleeping sickness (Chagas disease) and T. brucei that 
is causing African sleeping sickness disease. These 2 infections are also 
health conditions that are lack of the effective drug treatment, where only 4 
– 5 drugs are available on the market. There are 2 stages in the sleeping 
sickness: initial and late stages. Neurological conditions such as tremor, 
incontinence and GCS can be observed at both stages of disease where 




Figure 1.5: Schematic representation of Leishmania life cycle. (9) 








Germanin (suramin) and Pentam (pentamidine) are the only 2 drugs that 
can inhibit further infection development as they are acting on the initial 










When the condition has reached its final stage a very toxic drug is 
prescribed – Arsobal (arsenical melarsoprol), where side effects can lead to 
mortality in 5 to 10% cases. Unfortunately, as in case of Leishmaniasis 
there is no drug treatment that will act at both early and late stages, with 
less serious side effects. The Trypanosoma genus causes disease among 
Neurological Sign  % Early   % Late 
Gait Ataxia 63 52 
Tremors 60 69 
incontinence 20 15 
neuropathy 29 31 
somnolence 57 55 
gcs<15 14 14 
gcs<12 0 10 
Table 1.1: 2 stages of sleeping sickness disease. Neurological conditions 
during 2 stages. GCS – Glasgow Coma Scale, (10)  
A 
B 
Figure 1.6: Drugs that are used during initial stage of infectious, A) Germanin, B) 
Pentam. (10) 
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domestic animals as well as humans. The main transmission route is by the 
blood – sucking tsetse fly between animals and humans. If left untreated it 
can be fatal. Chagas disease is caused by T. cruzi where transmission 
happens from the animal to the host by bedbugs that have fed on 
contaminated faeces. The disease might not show any obvious symptoms 
however some patients can suffer from the physiological alteration in the 
heart as well as in the intestines and oesophagus (11).  
 
1.5 Mechanism of the host cell invasion in T. brucei 
In the case of the T. brucei parasite, it is transmitted by the tsetse fly, 
Glossina spp, Figure 1.7.  Trypanosomes develop in the gut of the fly and 
then transfer towards the salivary glands before infecting a new host 
organism. When the parasite is in the new host it is in its slender variation 
form, in the bloodstream, before its further transformation into a stumpy 
form (12). In the bloodstream Trypanosoma can survive due to alteration 
of the host cell immune response by mimicking its antigens, like variant 
surface glycoproteins (VSG) that are connected with 
glycosylphosphatidylinositol (GPI). When T. brucei is transferred into its 
procyclic form the VSG is replaced by procyclin (13). Parasites then move 
through the salivary gland of the fly where epimastigotes forms and 
attaches to the wall of the glands. Trypanosomes start dividing, increasing 
its number to be released into the gland of lumen before infecting a new 
host. At different stages of the trypanosome life cycle there are 
morphological changes where kinetoplast has different cellular 
localization. When trypanosome is in the bloodstream the kinetoplast 
locates closer to the end of cell; during its procyclic stage it is in the 
middle, between the cell nucleus and the end of the cell; during the 
epimastigote stage it is closer to the cell nucleus. However, it is still 
unclear why such morphological changes occur during each trypanosome 
   9 
life cycle where the whole life cycle of trypanosome is very regulated (14). 
Procyclin coat of the trypanosome forms after 2 hours of migration 
followed by kinetoplast migration where DNA starts its synthesis for 6 to 
12 hours. Later, this stage is followed by continuation of proliferation 
stage where cells develop its mitochondrial properties. There is still some 
debate regarding the trypanosome life cycle in the mammalian 
bloodstream where most experiments have been performed in strains that 
have been modified in the laboratory. However, there is a known factor of 
changing slender into a stumpy form under the influence of SIF (stumpy 
induction factor) (15). Also, this process is believed to be regulated by the 






 Figure 1.7: Schematic representation of T. brucei life cycle. (Centres for 
Disease Control and Prevention) 
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1.6 Cyclic Adenosine Monophosphate (cAMP) pathway in 
kinetoplastids 
Second messengers are intracellular molecules that respond to any changes 
within the cell that are caused by extracellular molecules first messenger 
stimuli. Secondary messengers are important in cell signalling as they 
control processes such as cellular differentiation, proliferation and cell 
apoptosis. Kinetoplastids have cAMP as 2nd messenger that plays a vital 
role in parasitic survival, Figure 1.8. It has been shown that the genome of 
T. brucei has more than 70 genes and pseudogenes for encoding adenyl 
cyclases (ACs). The role of cAMP has been investigated with respect to 
parasite life cycle and what role it plays in infection development (16).  
 
 
Figure 1.8: Schematic representation of secondary messenger signaling (cAMP) 
in kinetoplastid parasites. (17) 
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1.7 Proteins of cAMP pathway as a potential drug target 
One of the cAMP regulatory targets is PKA (protein kinase A), that 
controls phosphorylation of substrate proteins, this in turn acts on ion 
channels and can further activate other enzymes. Studies on Leishmania 
showed that parasite has a critical dependency upon cAMP. The 
knockdown of the Hem-AC gene (globin-coupled heme containing 
adenylate cyclase) from the L. major led to cell death due to elevated level 
of 2nd messenger in the cell system as this protein directly stimulates 
adenylate cyclase activity. T. cruzi also showed a dependency upon cAMP 
and the knockdown of the same gene led to a fatal effect (18).  
In 2013 Gould et al investigated in more detail the downstream effectors in 
the T. brucei and found genes that were directly related to the cAMP 
signalling such as CARP1-CARP4. These genes were believed to be a part 
of cAMP signalling cascade and were important in regulation of secondary 
messenger activity, where its knockdown led to cell death. However, it is 
still unclear what exact function they perform in the signalling cascade. 
CARP2 and CARP4 were observed in flagellar proteome (19, 20, 21). It 
was suggested by many findings that the flagellum is a very important 
organelle for parasitic survival and can potentially act as a drug target for 
inhibition of infection (22). Another kinase, MAPK (mitogen – activated 
protein kinase) is also present in kinetoplastid and performs the function as 
a chemoattractant in response to second messenger signalling. As in 
mammals it has also been proven that MAPK is important in interactions 
with PKA and PDE functioning. There are still debates regarding how vital 
it is for parasitic survival and it has also been suggested that it plays an 
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1.8 Cyclic nucleotide phosphodiesterases PDEs as a drug target 
One of the biggest discoveries regarding possible new targets in 
kinetoplastids was targeting cyclic nucleotide phosphodiesterases (PDEs) 
in order to inhibit parasitic infection. PDEs are a class of enzyme that 
catalyse secondary messengers, such as 5’, 3’ – cyclic adenosine (cAMP) 
and guanosine – monophosphate (cGMP). These 2nd messengers are 
hydrolysed by PDE enzyme, where cAMP converts into 5’ – AMP and 
cGMP into 5’ – GMP. cAMP and cGMP are very important in controlling 
signal transfer where it’s amplitude, duration and localization, play a vital 
role in the cell signalling and proliferation. There are 11 known PDE 
families in humans and according to variations in posttranslational 
modifications there are approximately 100 PDE polypeptides with 
different localizations and functioning (24). The 3D structures of catalytic 
domain of human PDEs are highly similar, however the amino acid 
similarity among them is only 30 – 40%, Figure 1.9 (25).  
 
 
Figure 1.9: 3D structure of hPDE5 enzyme with highlighted amino acid residues of 
catalytic domain. (103) 

















The PDE enzymes are important for breaking phosphodiester bond and are 
significant focus of clinical research. PDEs are involved in different roles 
and can be found in healthy and/or in leukemic lymphocytes performing 
various functions (26). PDEs have been implicated as potential therapeutic 
targets in health conditions such as: hypertension, depression, heart 
diseases, asthma, schizophrenia and infections that are caused by parasites. 
The most well-known drugs targeting PDE inhibition are: Pletal 




Figure 1.10:  PDE – targeting drugs  
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(sildenafil) as well as Cialis (tadalafil) and Levitra (vardenafil) acting on 

















Kinetoplastid parasites contain several PDE class I genes which codes for 
4 genetically different class I PDEs, Figure 1.11. However, among the 
kinetoplasts species genes are highly conserved, Figure 1.11 (27). There 
are 4 distinct PDEs in parasites: PDEA, PDEB (codes for highly conserved 
PDEB1 and PDEB2, with different subcellular location) (28, 29, 30, 31), 
PDEC (dual-substrate PDE with FYVE domain on N site) (32, 33) and  
PDED that has only been identified as a DNA sequence.  There were a 
number of studies that confirmed PDEs as an essential protein for parasitic 
life cycle and causing infection. These studies included those that showed 
that PDEB1 and PDEB2 knock down altered the normal cell proliferation  
Figure 1.11:  encoded parasitic PDEs (PDEA, PDEB, 
PDEC and PDED). The blue boxes represent catalytic 
domains. (18) 
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and produced multiflagellated cells that eventually went to lyse stage. One 
possible explanation could be the localization of PDEB1 and PDEB2 in the 
paraflagellar rod, which is vital for motility and parasite life cycle in the 
host organism (34).   
T. cruzi PDEC was considered to be a potential drug target among the 
PDEs in that kinetoplast. PDEC has a FYVE domain (4 cysteine rich 
proteins that bind to phosphatidylinositol 3-phosphate) that is followed by 
2 coiled – coil regions. It has been shown by Schoijet et al that this domain 
is vital for cell survival as well as its mobility in general. PDEC acts in cell 
osmosis and is triggered when the hypo osmotic stress releases active 
metabolites that are essential for cells secret water through pocket in the 
flagellum (35).  Therefore, inhibition of the parasitic PDEC will eventually 
lead to the cell mortality. Another RNAi study showed that genes PDEB1 
and PDEB2 in T. brucei are essential for parasitic life cycle (36). The 
experiment has been performed on RNAi (RNA interference) where its 
construct is induced by tetracycline and was incorporated into the T. brucei 
genome. The wild type strain of trypanosome is resistant to tetracycline 
but when trypanosome genome was altered, PDEB1 and PDEB2 activity 
was inhibited by RNAi. Experiments showed that when there was an 
absence of the tetracycline inducer in the system, tetracycline – repressor 
system was bound to the DNA operator and inhibited the expression of 
double stranded interfering RNA. These enabled trypanosomes to 
proliferate and cause infection in the host organism. Studies showed that if 
animals were given tetracycline prior to the infection, the tetracycline 
repressor complex was leaving the DNA operator to promote expression of 
interfering RNA to alter the PDE functioning.  Inhibition of the PDE 
directly resulted on secondary messenger activity where increased cAMP 
level led to cell death (37).  
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1.9 Human PDE5 as a drug target     
PDE5 is a human enzyme that catalyses secondary messenger cGMP into 
its metabolite GMP. This action follows by calcium and inositol 
triphosphate to stimulate calcium release from the intracellular stores. This 
process regulates signal transduction in cellular environment. Inhibition of 
the PDE5 results in the high concentration of cGMP in the cell where 
calcium level would be decreased proportionally to cGMP resulting in 
relaxation of smooth muscles, Figure 1.12. 
PDE5 can be found in different tissues of human body while the most    
predominant tissues are corpus cavernosum and retina. The 1st PDE5 
inhibitor was Sildenafil that was prescribed to patients with erectile 
dysfunction and pulmonary arterial hypertension (39). PDE5 is also 
important for other systems, where it controls significant processes: 
vascular relaxation and improvement of pulmonary hypertension, 
improvement of cardiomyocyte stiffness and contractility, increasing 
eNOS activity where insulin signalling is improved in endothelial cells, 
improving insulin sensitivity in muscles and increasing aromatase activity, 
adipogenesis and insulin sensitivity.  
Sildenafil was first produced in 1980 and introduced into the market in 
1998 by Pfizer, where the primary aim was to treat arterial hypertension 
Figure 1.12: the mechanism of action of PDE5, catalysis of cGMP, (38) 
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and angina pectoris. It was suggested that inhibiting PDE5 would result in 
coronary vasodilation which was significant for patients with CAD 
(coronary artery disease). Early studies reported penile erection as a side 
effect, this unexpected observation became the primary condition for 
which the drug was developed.  
 Sildenafil Tadalafil Vardenafil Avanafil 
Available 
doses (mg) 
25-50-100 5-10-20 2.5-5-10-20 50-100-200 
Effectiveness  60 min 15-30 min 30 min 15-30 min 
Lasting 
(hours) 
4-8 h 24-36 h 2-8 h 1-6 h 
Food 
interaction 
High - fat Not 
significant  
High - fat Not significant  
Alcohol 
interaction 










2C19 and 2D6 
3A4 3A4, 3A5, 
2C9 
3A4, 2C 
Excretion 77 – 88% feces: 
minor in urine 
70 % feces 
30% urine 
91 – 95 % 
feces 
minor in urine  
62 % in feces 
21 % in urine  
 
 
After sildenafil, 3 other drugs were introduced into the market, Table 1.2. 
In 2003 Vardenafil and Tadalafil were prescribing to patients with ED 
disfunction. In 2010, Vardenafil (Staxyn) was used in the form of ODT 
(oral disintegrating tablet) and was proved to be easier in its administration 
to the patient.  In 2008, Eli Lilly got an FDA approval to administer 
Tadalfil once a day only, followed by its use to treat BPH (benign prostatic 
Table 1.2: Pharmacokinetics and pharmacodynamics of PDE5 inhibitors 
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hyperplasia) in 2011. In 2012, Avanafil was introduced into the market 
where drug has an advantage of its fast action. Nowadays, Sildenafil and 
Tadalafil are also in use to treat PAH (pulmonary arterial hypertension) 
using such names as Revatio and Adcirca (40).   
 
1.10 X–ray structures of T. brucei, Leishmania and T. cruzi 
PDEs 
Structural and sequence comparisons have shown that parasitic PDEs are 
very similar to human PDEs as well as being conserved among 
themselves. TbrPDEB1 and LmjPDEB1 were the first parasitic PDEs for 
which X–ray crystallographic structures were determined.  
In 2007 the crystal structure of LmjPDEB1 was solved, where the catalytic 
domain was comprised of residues 582-940, and the residues 597-931 were 
visible in solved apo crystal structure (41). LmjPDEB1 structure has 16 α-
helices however no β-strands, Figure 1.10. PDE catalytic domain have 2 
divalent metal ions, located at the bottom of the active site. Zn interacts 
with His685/His722/Asp835 as well as with 2 molecules of water. Mg in 
its turn interacts with Asp722 as well as with 5 other water molecules. 
Figure 1.13 shows that human PDE and parasitic PDEs are very similar in 
terms of metal ions localization.  
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The overlay of LmjPDEB1 crystal structure with the human PDE crystal 
structure showed root-mean-square deviation value of approximately 1.3-
2.0 Å for all α - Carbon atoms of PDEB1 structure, PDE2A apo structure, 
PDE3B in complex with IBMX (3-isobutyl-1-methylxanthine, PDE4D2 in 
complex with  
 
IBMX, PDE5A1 in complex with IBMX, PDE7A1 with IBMX, PDE7A1 
with IBMX, PDE9A2 with IBMX and finally PDE10A2 in complex with 
secondary messenger cAMP. Superposition of parasitic PDEs with human 
PDEs reveals high similarity in protein 3D structure (42). 
Studies showed that H9 helix and H loop of LmjPDE residues 729-754 as 
well as M loop of residues 858-882 had a shift in its localization by 3 Å for 
carbon α atom from human PDE. Therefore, it can be concluded that since 
H/M loops were playing a significant role in protein ligand interaction this 
led to further discovery of selective antiparasitic inhibitors (43, 44).  
  
Figure 1.13: X-ray structure of L. major PDEB1. A) diagram of the L. major 
PDEB1 catalytic domain. B) overlapping of parasitic PDEB1 with human 
PDE4(green).  (94) The pdb code was absent for current structures from the review 
paper.  
M loop  
M loop  
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1.11 Studies on parasitic P – Pocket in kinetoplastid parasites  
Structural studies of parasitic PDEs have identified a specific pocket in the 
parasitic PDE that is located next to the active site and is very close to the 
actual ligand binding site (45) termed the P – pocket, Figure 1.14.  
The P – pocket was observed in LmjPDEB1 and also when the TbrPDEB1 
3D structure was solved, indicating that this unique feature may be 
common to all kinetoplastid parasite PDEs (47). Since the primary aim of 
this thesis was to help develop new anti-parasitic drug candidates, it was 
also proposed that this unique P – pocket feature can be used as a primary 
ligand interaction target in order to make compounds selective for parasite 
over human PDEs.  
Figure 1.15 represents P – pocket binding site, where the open cavity was 
found between H14, H15 helixes and M loop. Conserved residues were: 
Gln874, Val840 and Phe877 (hydrophobic clamp), Phe844 and Phe880 
(shown as sticks). Hydrophobic clamp is formed between 2 hydrophobic 
residues, such as Val840 and Phe877 and is considered as a usual binding 
Figure 1.14: Schematic representation of catalytic domains in A) T. brucei 
PDEB1, representing p pocket and B) active site of human PDE4 where there 
was no gap in the surface and only Q2 is present. (46) 
A B 
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site for PDE inhibitors.  The P – pocket residues were: Ala837, Thr841, 
Tyr845, Asn867, Met868, Glu869 and Leu870 (represented as lines), 
Figure 1.14 (76). 
 
1.12 Ligand – Protein Interactions 
There are a variety of ligand – protein interactions that play an important 
role in the binding mode, such interactions are: hydrophobic interactions, 
hydrogen bonds, - stacking, salt bridges. Amide stacking and cation- 
interactions, Figure 1.16, (49).  
Data from 2015 suggested that among data that was analysed there were 
more hydrophobic interactions in high efficiency ligands (49). The amount 
of hydrogen bonds in such highly efficient ligands were less. One possible 
explanation could be, that when ligands are optimized in the drug design 
process it is simpler to increase potency through non-directional 
hydrophobic interactions over improving binding energy by specific, 
directional hydrogen bonding.  Fragments bind to the protein with higher 
ligand efficiency (LE = (ΔG)/N) (32), than many larger ligands with more 
polar interactions in fragment – protein complexes on average with 
Figure 1.15: Schematic representation of catalytic domains in T. brucei PDEB1, 
representing p pocket: its residues and 2 metals Mg and Zn, (PDB code 4I15) 
(76) 
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doubled amount of hydrogen bonds per atom and higher proportion of 
electrostatic interactions. 
Since fragments are inherently weak binders they are tested at high 
concentrations where it is important, they have high polarity to ensure to 
have high solubility. In comparison to the final drug compounds, 
fragments are also more flexible in terms of their binding poses in order to 
allow optimal polar interactions as usually affinity increases are gained by 
introduction hydrophobic interactions.  
   
1.12.1 Introduction of Hydrophobic Forces  
Hydrophobic forces are characterized by interactions of carbon and carbon, 
halogen or sulphur atoms. There are 5 different types of hydrophobic 
forces, where the interaction between the receptor aliphatic carbon and 
aromatic carbon of ligand were the most predominating type of 
hydrophobic forces. This shows that aromatic rings are important for 
ligand binding mode, where benzene ring is the most common used ring 
Figure 1.16: Bar chart representing how often each type of interaction occurs 
among protein-ligand complexes from PDB, (49) 
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(50, 51). Amino acids that are the most common in formation of 
hydrophobic interactions are: Leucine, Valine, Isoleucine and Alanine. 
One of the common features is the formation of hydrophobic interactions 
between aliphatic or aromatic carbon in the protein with chlorine or 
fluorine atoms in the ligand and between sulphur atom of Methionine with 
aromatic carbon atom in the ligand. It was also proved by Valley et al in 
2012 that hydrophobic interaction between Methionine and aromatic 
carbon atom of the ligand yields additional energy of 1 – 1.5 kj (52). A 
buried methyl of a ligand in a hydrophobic region of a protein is calculated 
to provide approximately 0.7 kj which can translate to an increase of 
binding affinity by as much as 3.2 – fold (53). By occupying the 
hydrophobic clamp, methyl group displaces water molecules that are in the 
ligand binding site hence potentially increases the ligand potency through 
an increase in entropy of the system (54).  
 
1.12.2 Hydrogen Bonds  
The most common hydrogen interactions are between N – H and O, 




It has been shown by de Freitas that proteins were mostly acting as H – 
donors. Arginine is more likely to form H – bonds then the Lysine due to 
Figure 1.17: Hydrogen Bonds, (studyorgo.com) 
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the fact that it has 3 N – atoms in its structure of a sidechain. In O – H and 
O bond formation, compound was a donor where the acceptor more often 
was the Aspartic acid where H – bonds were charged, whereas in case of 
Asparagine, Glycine and Glutamine there were neutral bonds formation. 
Water molecules in the protein structure act as a very important regulator 
for H – bonds formation. The usual separation of atoms between each 
other during H – bond formation is 3.0 Å. The free energy of H – bond 
interactions is -1.5 – 1.5 kj to – 4.7 – 1.5 kj. One of the most important 
factor that influence H – bond interaction strength is the H – interaction 
environment i.e. if it is solvent exposed, or shielded in a hydrophobic 
environment (55). In some experiments, it has been shown that by addition 
of polar atoms into the ligand optimal H bonding interactions resulted in 
enhanced binding affinity of ligand by more than 500-fold (56).  
 
1.12.3  - stacking interactions 
The most common example of a  - interaction between ligand and 
proteins is exemplified by the interaction of the delocalized aromatic ring 
of Phenylalanine an aromatic ring of a ligand. A similar interaction is 
observed by residues Tyrosine in 36.8% cases (data was studied from 
Protein Data Bank), followed by Tryptophan in 8.7% cases and Histidine 
in 5.1% cases. Such  - stacking interactions play a crucial role in the drug 
design approach as they provide significant binding energy. However, it 
has been shown that decreasing the number of aromatic rings in the ligand 
structure leads to improvement of other physiochemical properties, such as 
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1.12.4 Weak Hydrogen bonds 
Current type of interactions is characterized by the formation of bond 
between C – H and O, where C atom is aromatic and where O atom from 
proteins act as electrons acceptors. Such amino acids as Glycine, Aspartic 
and Glutamic acids were found the most often to be acceptors where 
Leucine was acting as a donor in most of the cases. The distance between 
atoms was found to be 3.4 Å (49). Interactions between C – H and O are half 
less in magnitude strength in comparison with NH and O=C bonds. It has 
been shown that such interactions are very important for molecules 
recognition as well as protein folding and how stable it is (58, 59, 60).   
 
1.12.5 Salt Interactions  
Salt bridges arise by the formation of bond between positively charged N 
atom of the protein structure with a negatively charged O coming from the 
ligand or vice versa. It has been shown that Arginine amino acid played a 
role of cation in most of the salt bridges interactions (61). The analysis of 
such interactions revealed that there was higher density of O with negative 
charge around the ω N atom than with the secondary amine ε N. As 
motioned before in Section 4.2.1.4, as with hydrogen bonds the strength and 
binding energy of salt bridges is dependent on the local environment. Current 
paper didn’t mention approximate bond energy.  
1.12.6 Amide  - stacking interactions 
Such interactions are characterized by the amide group of the amino acid 
backbone  - stacking with the aromatic ring of a ligand or the amide of a 
ligand staking with an aromatic amino acid residue. There are 2 types of 
interactions here, such as face-to-face and edge-to-face. Glycine and 
Tryptophan are examples of where this can occur within a protein 
structure. It was suggested by Duan et al in 1999 that  - stacking 
   26 
interactions are important for protein structures as well as being vital for 
drug – protein binding mode (62). Current paper didn’t mention 
approximate bond energy. 
1.12.7 Cation  - interactions 
These interactions are characterized by the formation of bond between N 
positively charged atom of the protein and aromatic ring of the ligand 
where the interaction is electrostatic due to the presence of a negatively 
charged electron cloud (63). Arginine is one of the most often amino acid 
involved in such interactions. Cation  - interactions are important for the 
protein stability and functionality (64).  
1.12.8 Halogen Interactions 
Current interactions are characterized by the formation of bond between C 
– X and Y, whereas X represents Cl, Br and I atoms; while Y represents 
such atoms as O, N, S, Figure 1.18.  
 
The protein side chain or its backbone provides Y atom for interaction 
while X atom is coming from the ligand. This type of interaction arises 
when there is σ-hole from any of the halogen atom and a nucleophile 
which acts as an acceptor (66, 67, 68). Even though that fluorine is the 
halogen it doesnt form halogen bonding due to the fact that it has higher 
electronegativity and is less polarizable then 3 previosly mentioned 
Figure 1.18: Halogen Interactions, (65) 
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halogens (69). Among 3 halogens that form halogen interactions Cl atom 
is the most observed, followed by bromine and then iodine (70, 71). The 
value of the angle in halogen bond formation is 156° and is characterized 
as a linear arrangement, where the O atom is acting as an acceptor more 
often than any other atoms. The main reason why halogens are introduced 
into the ligand structure is to improve membrane permeability and 
metabolic stability of the compound.  
1.13 Review of previous Medicinal Chemistry design of selective 
parasitic PDEs inhibitors over human PDEs. 
This section describes two recent papers focused on the design of novel 
parasitic PDE inhibitors (73).  
Since NPD – 001 was the most potent PDE inhibitor it was tested against  
 
Table 1.3: analogs of series 1. Potency values against hPDE4.  a- logIC50 on TbrB1 
(n=2, +- 0.2), b- logIC50 on human PDE4B1 (n=2, +-0.2). (72) 
Figure 1.19: hPDE4 and TbrPDEB1 inhibitors: NPD-001 and NPD-340, (73) 
   28 
other families of PDEs, where the tail group of it was used, Figure 1.19. 
Among many human PDEs where the inhibitor only showed some kind of 
interaction with high drug concentration, human PDE4 was inhibited at the 
same potency as parasitic PDEs. Therefore, it was assumed that hPDE4 
was the main target that would be used for comparison of inhibitor 
selectivity. NPD – 001 series compounds were potent against human PDE4 
whereas no selectivity was observed between the parasitic PDE and the 
human PDE. Hence, the next step was to synthesize new tool compounds 
where phenylpyridazinones were tested against hPDE4, Table 1.3.  
Table 1.3 represents phenylpyridazinones compounds that were tested to 
identify its potency against human and parasitic PDEs. Analysis revealed 
that there was 100 – fold variation in the inhibition of potency against 
TbrPDEB1 whilst in human PDE4 the variation was only 8 – fold. 
Comparing compound 5 and 1 showed the significance of tetrazole 
presence in the chemical structure where 80 – fold difference in affinity 
against the parasitic TbrPDEB1 was observed. The ratio between IC50 of 
parasitic and human PDEs was calculated for different compounds, Table 
1.3, highlighting the differences from 6 – 1000 hence pointing out that 
selectivity between human and parasitic PDEs is possible. As a result, it 
can be concluded that the optimization of parasitic PDEs inhibitors is not 
possible with this series of compounds and further experiments would be 
required, (72).  
Another inhibitor analogue, NPD – 340 that also has an effect on parasitic 
T. brucei PDEB1 was studied (73). However, the main disadvantage was 
that it had a higher potency against human PDE4 than towards parasitic 
PDEs. Blazer et al performed a docking analysis where dialkoxyphenyl 
moiety from both NPD – 001 and NPD – 340, Figure 1.16, was linked to 
Gly874 of parasitic PDE by forming hydrogen bond and appeared to be 
found in the hydrophobic clamp of the active site.  
   29 
It was shown that these compounds were interacting with PDE utilizing 
their tetrazole group. NPD – 001 was found in binding pocket of active site 
in TbrPDEB1 with the dialkoxyphenyl interacting with Val840 and 
Phe877. In comparison to the previous study, Blaazer et al research 
revealed another binding feature such as that the side chain of the inhibitor 
was out of the P – pocket, while in the previous study it was suggested to 
have interaction with Phe880 (73). Analysis of the binding region revealed 
that hydrophobic clamp was the most favourable anchor region for ligands 
allowing flexible side chains orientated towards the P – pocket.  Hence it 
was concluded that synthesizing derivatives with different alkyl linker 
would eliminate such problem as the selectivity. Another finding was 
made regarding the observation of the ligand binding into the hydrophobic 
clamp by mainly aromatic groups, whereas hetero-aryl groups were 
orientated towards parasitic P-pocket in TbrPDEB1. Therefore, it was 
concluded by Blazer et al that replacing flexible linker of NPD – 001 of the 
dialkoxyphenyl ring will enable the inhibitor to be more flexible in order 
to be directed towards the P – pocket.  
A set of experiments were performed where 3 – 6 biphenyl derivatives of 
NPD-001, Table 1.4, were used in crystallization with TbrPDEB1 and 
human PDE4, Table 1.4. Derivative 3 and 4 showed higher selectivity 
towards parasitic PDEB1. 

















Analysis of bindings of compounds NPD-001 and NPD-340 (pdb code 
absent) revealed that hydrophobic clamp was interacting with the linker 
where it was directing towards such aromatic residues as Phe880 in 
TbrPDEB1 (73). Therefore, it was decided to synthesize analogues with 
the substitution of flexible region at position 3 with the introduction of the 
phenyl ring that will perform a function of biphenyl system and will be 
vectoring towards P – pocket.   
In conclusion, parasitic PDEs and human PDEs as much as they were 
similar, they were still structurally different hence resulting in different 
binding mode and ligand potency.  
Screening has showed differences in selectivity between human and 
parasitic PDEs. The potency was increased nearly 10 – fold in TbrPDEB1 
when carboxamide part was introduced in the para – position of inhibitor 5 
Table 1.4: Synthesised biphenyl derivatives with introduction of 
biphenyl linker into NPD-001 at position 3 (73)  
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as compared to the meta substituted acid, Table 1.5. The next step was to 
synthesize derivatives based on the scaffold of inhibitor – 5 in order to 
enhance its inhibitor selectivity between human and parasitic PDEs. By the 
addition of the methoxyethyl group (compound 7) the selectivity was 
improved by 7 – fold while the potency was unchanged. Derivatives 8 and 
9 showed increase in potency against parasitic PDEB1 with Ki values of 
100 nM and 99 nM. The inhibitor – 8 was also more selective towards 
TbrPDEB1 then to human PDE4B1 by 10 – fold, Table 1.5. Derivative – 9, 
Table 1.5, was more selective against TbrPDEB1 by 19 – fold and it was 
concluded that glycinamide inhibitors were more in favour to be used 
against parasitic PDEs. Derivatives 10 – 13, Table 1.5, were synthesized 
with the addition of N – methyl, N, N – dimethyl and N – isopropyl side 
chains on the P – pocket tail. However, such changes decreased the 
inhibition activity of the compounds. Compounds 12 and 13 were 
alkylated as a result hydrophobicity of inhibitors was changed whereas 
potency and selectivity were decreased. Compound – 14 was less selective 
and showed to have less inhibitory activity. Derivatives 16 and 17 of 
compound – 8 were extended by the addition of hydroxyethyl and 
methoxyethyl groups respectively which gives increase in the selectivity 
by 8 – fold.  
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Table 1.5: derivatives 7-17, studies on SAR in parasitic pocket of TbrPDEB1 
(73). 
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It was further suggested by Blazer et al, to perform crystallization of the 
TbrPDEB1 with derivatives 8 and 9. High – resolution structures were 
obtained at resolutions of 1.8 Å and 2.0 Å respectively, Figure 1.20. The 




Figure 1.20 represented 2 crystal structures where compounds 8 and 9 are 
bound.  According to the ligand protein interaction Gly874 interacted with 
both ligands where ligands were bound to the hydrophobic site by biphenyl 
tail of methoxyphenyl ring of the compounds. Both compounds were 
directed towards the P – pocket where the inhibitor 8 was bound to the 
protein via interaction of glycinamide tail with Tyr845 and forming 3 – 
Hydrogen interactions between water molecules and Thr841, Met861, 
Leu870, Gly873 and Gly874.  
Figure 1.20: T. brucei PDEB1 crystal structure with A) derivative 8 B) 
derivative 9, (73) 
Figure 1.21: comparison of crystal structure T. brPDEB1 with NPD-001 and 
crystal structure with compound 8. 
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Next suggestion was to align these 2 inhibitors to see the differences in 
binding mode and their orientation toward the P – pocket.  
Figure 1.21 represented 2 aligned crystals structures where inhibitor – 8 
(yellow) showed a tail direction towards the P – pocket. Derivative – 9 
(blue) showed different structural confirmation where hydrogen bonds 
were formed with Tyr845, Glu869, Thr841, Met861, Leu870 and Gly874. 
Another important characteristic that was studied by Blazer et al was the B 
factor of the P – pocket where the data showed that parasitic pocket was 
very flexible in comparison to the rest of the protein structure. 
Unfortunately the exact data was not mentioned in the paper. Glycinamide 
tail of compounds 8 and 9 showed electron density that was weaker in 
comparison to the rest of the molecule what suggested that inhibitor was 
more flexible in the P – pocket. These findings suggested that further 
experiments were important where the main focus would be orientated on 
the modification of the aliphatic heterocyclic tail aiming to enhance its 
flexibility in the P – pocket.  
Table 1.6 showed newly synthesized derivatives where inhibitor 18 and 19 
showed less selectivity between the parasitic PDE and human PDE4B1 
with decreased inhibitory activity. Derivative 20 in comparison to 
inhibitors 18 and 19 was 3 times more selective towards the parasitic 
PDEB1 then to human PDE4B1. Compound 21 with (R)-pyrrolidin-3-ol 
addition to the compound structure was more selective (x 9 times) towards 
targeting the P – pocket as well as having higher potency level. Derivative 
22 showed 15-fold selectivity for TbrPDEB1, where derivative 24 was 10-
fold more selective fro parasitic PDEB1. However, compound – 22 was 
chosen as a preferable compound for analysing its interaction with 
TbrPDEB1 in the crystal form. The data came at 1.8 Å where 3-
hydroxypyrrolidine tail was directed towards the P – pocket by forming 
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hydrogen bonds with Met861 and Asp867, Figure 1.22. The overall mode 









Figure 1.22: crystal structure TbrPDEB1 with compound 22 (73) 
Table 1.6: analysis of aliphatic heterocycles potency and selectivity in T. brucei 
PDEB1 
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Further analysis revealed that compound – 8 showed increase of 
intracellular cAMP level in the bloodstream of trypanosomes at 100nm. 
Compounds 8 and 9 were considered to be as the most promising 
inhibitors from all the series of compounds that showed inhibitory activity 
against TbrPDEB1. However, further optimizations were required in order 
to consider these compounds as potential drug candidates against 
kinetoplastid parasites.  
 
1.14 IBMX-PDE interaction 
The ligand IBMX is a known nonspecific PDE inhibitor against human 
PDEs however it didn’t show the same level of potency against parasites. 
In LmjPDEB1, where the IC50 was only 580 µM ligand – protein 
interactions showed an H bond between O6 of the IBMX xanthine ring and 
Nε2 of amino acid Glu887 of LmjPDEB1, Figure 1.23. IBMX binding 
mode in parasitic PDEs was very similar to binding mode of ligand in 
human PDE, however IBMX position and its localization was slightly 
different to humans. 
The key glutamine was observed in all kinetoplastid PDEs with one 
exception. T. cruzi PDEC and T. brucei PDEC, where it was replaced by 
Serine residue. 
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1.15 The Main Aim of Current Thesis  
In current thesis the main aim was to analyse parasitic PDEs from Leishmania 
species and T. brucei as well as to study human PDE5 drug – binding mode in 
more details. Since nowadays there are still no effective treatments to treat 
patients with current infectious this question is still under investigation whether 
we can develop selective inhibitors that will cause less side effects and would 
be more potent against parasitic PDEs. In the 3rd chapter the aim would be to 
express, purify and analyse parasitic PDED where no preliminary data was 
obtained before and only DNA sequence was available at that time. Therefore, it 
was important to find out if these proteins can also be considered as a potential 
drug target that play a vital role for parasite survival. The 4th chapter would be 
orientated on drug design approach where hPDE5 protein was used as a target. 
The aim was to develop a Fluoro fragment library and where strong binders 
would be identified not only by 1 technique but by several techniques, such as: 
Xchem, NMR, SPR and manual crystallization. Another aim in current chapter 
was also to try and use Xchem platform which is one of the latest development 
by Diamond Synchrotron. This is a high throughput method where high number 
Figure 1.23: A) interaction of IBMX with L. major PDEB1 at active site. B) 
overlapping of parasitic (green) and human(gold/blue) PDEs and its interaction with 
ligand. (73) 
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of crystals can be shot and analysed. The 5th and the 6th chapters were about 
TbrPDEB1 as a drug target where different biophysical techniques were used 
with 2 libraries, such as DSI-Poised and Chembl. Previous results showed that 
Xchem didn’t identify many fragments as binders while other techniques did 
hence, one of the idea was to improve and develop general Xchem protocol that 
can be used for different proteins. Also, in a collaboration with VU university it 
was possible to synthesise new derivatives that would be more selective and 
possibly potent against TbrPDEB1.  








Investigating protein structure, and its function with biophysical and 
biochemical techniques requires a significant amount of high quality 
protein that can be produced by recombinant over – expression followed 
by a series of purification steps, where the protein of interest is isolated 
from the mixture of other host proteins expressed in bacterial, insect or 
mammalian cells. The choice of the different methods used to express 
and purify proteins, is dependent on the nature and properties of protein.   
 
2.2 Materials and Methods  
In this chapter, the experimental techniques used in this thesis will be 




Most chemicals, DEAE-sephacel and antibiotics were purchased from 
Sigma – Aldrich Ltd. Other materials were purchased from manufacturers 
as follows: IPTG and ampicillin from Melford Laboratories Ltd; disposable 
and empty PD10 columns from Amersham Biosciences; MiniEluteTM Gel 
Extraction Kit, QIAprep Spin Miniprep Kit, and QIAquick Gel Extraction 
Kit; restriction enzymes were purchased from Promega and from New 
England Biolabs, Inc; cloning vectors from Novagen; tryptone, yeast,  
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bacterial agar from Oxoid Ltd, QuickChange II Site – Directed 
Mutagenesis Kit from Agilent Technologies; Roche FastStart High Fidelity 
PCR System from Roche Diagnostics GmbH. 
 
2.2.1.2 Bacterial strains 
Bacterial strains were purchased from Novagen, Invitrogen or Promega. 
Strains (or plasmids) were purchased or provided by Jane Munday 
(University of Glasgow) and Dr Susanne Schroeder (University of Kent). 
Strains Genotype and/or 
phenotype 
Description Reference 
T7 Express E. coli fhuA2lacZ::T7 gene1 [lon] 







suitable for T7 
protein expression. 
There are no 
proteases Lon and 




BL21 (DE3)  fhuA2 [lon] ompT gal (λ DE3) 
[dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B 
int:(lacI::PlacUV5::T7 gene1) 
i21 ∆nin5 
Suitable for T7 
expression, deficient 




BL21(DE3) pLysS F- ompT hsdSB (rB-, mB-) gal 
dcm (DE3) pLysS (CmR) 
Controlled by lac 
UV5 promoter, 
deficient in proteases 
Ion and OmpT 
Promega  
RosettaTM  2 (DE3) F- ompT hsdSB(rB- mB-) gal 
dcm (DE3) pRARE2 (CamR)  
 
Derivative of BL21, 
suitable for 
expression of 
proteins with rare 
codons, supply 
tRNA for 7 codons 
(AGA,AGG, 
AUA,CUA, GGGA, 




F- ompT hsdSB (rB- mB-) gal 






expression of T7 





Table 2.1: Bacterial Strains  
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Name  Plasmid  Description  Reference or 
source  
pET15b  pET15bTEV_L. infantum_PDED Promoters: AmpR, lac1 
HisTag-N-terminus 
Ampicillin resistance  
 
Novagen  
 pET15bTEV_L. donovani_PDED   




 pET28a_L. infantum_PDEB1   
 pET28a_L. donovani_PDEB1   
pColdI pColdI_L. infantum_PDED Promoter: cold-shock 
protein A 
Induction at low 
temperature 
Lac operator 
Ampicillin resistance  
Takara 
 pColdI_L. donovani_PDED   
pColdTF pColdTF_L. infantum_PDED Chaperone TF (trigger 
factor) 
Takara 
 pColdTF_L. donovani_PDED   
pOPINF pOPINF_L. infantum_PDED Mammalian/bacterial/insect 
expression 
His-Tag N-terminus 




pOPINJ pOPINJ_L. infantum_PDED GST – fusion tag  
pOPINM pOPINM_L. infantum_PDED MBP – fusion tag   
pOPINS3C pOPINS3C_L. infantum_PDED SUMO – fusion tag   
pGKJE8 dnaK-dnaJ-grpE-groES-groEL  Takara 
pGro7 groES-groEL  Takara 
pKJE7 dnaK-dnaJ-grpE  Takara 
pGTF2 groES-groEL-tig  Takara 
pTf16 tig  Takara 
 
2.2.1.3 Primers 
A list of all primers used for amplification in this study can be found in Table 
2.3. All primers were obtained from Invitrogen Life Technologies.  
 














Table 2.2: Plasmids that were used during this research.  




















































































































2.2.1.4 Commercial screens for DNA work 
-  PCR: Fast Start High Fidelity PCR System 
- Kits: QIAprep Spin Miniprep Kit, Thermo Scientific GeneJet Gel 
extraction kit 
-  Restriction enzymes: Promega 
- Agarose gel: Melford agarose high purity, SYBR safe DNA gel stain 
10,000 x concentration in DMSO 
 
2.2.1.5 Media and Solutions for Bacterial Work 
Luria – Bertani (LB) broth: Tryptone                       10 g 
                                          Yeast extract                 5 g 
          NaCl                              5 g 
Made up to 1 L with dH2O and autoclaved. 
 
Super LB broth:                          Tryptone                        32 g 
                                         Yeast extract                  20 g 
                                         NaCl                               5 g 
Table 2.3: List of primers that were used during current study 
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Made up to 1 L with dH2O and autoclaved. 
 
Luria – Bertani agar: 
15 g of Bacterial agar were added to 1 L LB broth before autoclaving. 
 
The following, filter – sterilised supplements, were added prior to use: 
 1 M MgCl2     12.5 mL 
 1 M MgSO4                     12.5  mL 
 20 % (w/v) glucose            20 mL 
 
All solutions were made up separately and autoclaved before being mixed 
(filter sterilised), except antibiotics which were added post autoclaving.  
Terrific Broth (TB): 
                                                      Tryptone                        12 g 
                                            Yeast extract                  24 g 
                                                      Glycerol                         5 g  
 
Additive  Stock Concentration  Final Concentration  
MgSO4 1M in dH2O 2mM  
Sucrose  1M in dH2O 25mM 
Glucose 1M in dH2O 25mM 
Glycerol 1M in dH2O 10% 
Table 2.4: Additives List 








2.2.1.6 Media and Solutions for DNA work 
 
TE Buffer:                    Tris – HCl, pH 8.0 10  mM 
                                                    EDTA, pH 8.0   1  mM 
 
 
6 x DNA Loading Buffer:        Bromophenol blue (w/v)       0.25%  
                                        Glycerol (v/v)                        50%             
                                        TE Buffer (v/v)                      50%  
 
 








Antibiotic  Stock Concentration Final Concentration 
Ampicillin 100 mg mL-1 in dH2O 100 g mL-1 
Kanamycin 50 mg mL-1 in dH2O 50  g mL-1 
Chloramphenicol 34 mg mL-1 in dH2O 20 g mL-1 
Table 2.5: Antibiotics List 
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2.2.1.7. Solutions for Protein Purification 
2.2.1.7.1 PDED catalytic domain protein purification 
 
Standard Buffer for small scale expression: 
 
                                                             Tris – HCl, pH 7.5       20 mM  
                                                              NaCl                       100 mM 
                                                                      Imidazole                  10 mM 
                                                                      DTT                            1 mM 
 
 
- IMAC purification, Ni – NTA 
 
Resuspension buffer:                            Tris – HCl, pH 7.5      20 mM  
                                                              NaCl                       500 mM 
                                                                      Imidazole                  20 mM 
                                                                      DTT                            1 mM 
                                                                      Sucrose                     25 mM 
                                                                      Glycerol                     10 % 
                                                                      MgCl2                        2 mM 
 
Added protease cocktail (Roche) 
 
Wash Buffer:                                       Tris – HCl, pH 7.5       20 mM  
                                                             NaCl                       500 mM 
                                                                     Imidazole                  50 mM 
                                                                     DTT                            1 mM 
                                                                       
             
Elution Buffer:                                     Tris – HCl, pH 7.5      20 mM  
                                                              NaCl                       500 mM 
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                                                                      DTT                            1 mM 
                                                                      Sucrose                     25 mM 
                                                                      Glycerol                       20 % 
                                                                      MgCl2                         2 mM 
- IEC purification 
    IEC buffers:  Buffer A, Elution buffer of IMAC purification 
             Buffer B, Elution buffer of IMAC purification + 1M NaCl 
 
- SEC purification 
     SEC buffer:       Elution buffer of IMAC purification 
 
2.2.1.7.2 Solutions for T. brucei PDEB1 purification 
- IMAC purification  
Resuspension Buffer:                           Tris – HCl, pH 7.5       20 mM  
                                                              NaCl                        200 mM 
                                                              Imidazole                  10 mM 
                                                              Β-mercaptoethanol     2 mM 
                                    protease inhibitor cocktail tablet x2 (Roche) 
Buffer A: Resuspension Buffer deficient in protease inhibitor cocktail 
Buffer B: Resuspension Buffer deficient in protease inhibitor, 300mM 
imidazole 
Thrombin Cleavage Buffer:                 Tris – HCl, pH 7.5      20 mM  
                                                              NaCl                       100 mM 
                                                              Imidazole                  10 mM 
                                                              Glycerol                       5% 
                                                              Β-mercaptoethanol    2 mM 
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- IEC purification  
Buffer A:                                              Tris – HCl, pH 7.5       20 mM  
                                                              NaCl                        100 mM 
                                                                      Imidazole                  10 mM 
                                                                      Glycerol                       5% 
                                                                      Β-mercaptoethanol     2 mM 
Buffer B:                                              Buffer A + 1M NaCl 
 
Storage Buffer:                                     MgCl2                        1 mM                           
                                                              Tris-HCl, pH 7.5      20 mM  
                                                              NaCl                       500 mM 
                                                                      Glycerol                       5% 
                                                                      Β-mercaptoethanol    2 mM 
 
2.2.1.7.3 Solutions for PDE5 protein purification  
 
Lysis Buffer:                                         Tris – HCl, pH 7.5       50 mM  
                                                              NaCl                        100 mM 
                                                              DTT                            1 mM 
                                                             free protease inhibitor (tablet) 
 
Blue Sepharose buffer A:                     Bis – Tris, pH 6.4       50 mM  
                                                              NaCl                        50 mM 
                                                              DTT                           1 mM 
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Blue Sepharose buffer A, wash:          Buffer A+ 1M NaCl 
Elution Buffer:                                     Buffer A + 20 mM cGMP           
SEC buffer:                                          Bis-Tris, pH 6.4        50 mM 
                                                             NaCl                        500 mM 
                                                             DTT                            1 mM 
  
2.2.1.7.4 Solutions for protein acrylamide gels 
 
10x Running Buffer: Tris – HCl                                   30g L-1 
 Glycine                                     144 g L-1  
 
2x SDS Sample Buffer: 0.5 M Tris – HCl, pH 6.8 6.0  
 mL  
 Glycerol                               4.8 mL 
 SDS 10 % (w/v) 9.6 mL   
 Bromophenol blue 0.05 % (w/v)1.2  
 mL 
 dH2O 24.0 mL 
Add 14 µL -Mercaptoethanol per mL 2x SDS-Buffer. 
 
Fixing Solution:  Ethanol 300 mL 
 Acetic acid 100 mL 
               
Made up to 1L with dH2O.       
  
Coomassie blue stain: Trichloracetic acid (100 %)     250mL 
 Coomassie blue R250              0.60    g 
 SDS 0.10    g 
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 Tris – HCl      0.25    g 
 Glycine 0.15    g 
Made up to 500 mL 
 













2.2.1.9 Solutions for Western blot  
 
Bio-Rad western blot kit was used, where blocking buffer was provided.  
 
Transfer buffer:    TBS buffer (50 mM Tris – Cl, pH 7.6; 150 mM NaCl) 
 
Antibody:                                                    anti HisTag, Sigma-Aldrich 
 
Substrate:         
 
Stock:                                                           Methanol                    3 ml             
                                                                     4 – chloronaphthol       3 mg  
 
Working solution: 2.5 ml of substrate dissolved in TBS to a final volume 
of 25 ml, H2O2 (30%) 9 μL 




                               
SDS GELS 
Running gels 8 % 10 % 12.5 % 15 % Stacking gel 5 % 
dH2O (mL) 5.7 4.7 3.4 2.2 dH2O (mL) 3.4 
30 % Acrylamide (mL) 
Acryl/BisTM 29:1 
4 5 6.3 7.5 30 % Acrylamide (mL) 
Acryl/BisTM 29:1 
1.5 
1.5 M Tris-HCl, 
pH 8.8 (mL) 
3.8 3.8 3.8 3.8 0.5 M Tris-HCl, 
pH 6.8 (mL) 
1.9 
10 % (w/v) SDS (mL) 1.5 1.5 1.5 1.5 10 % SDS(w/v) (mL) 0.75 
10 % (w/v) APS (mL) 0.15 0.15 0.15 0.15 10 % (w/v) APS (mL) 0.075 
TEMED (mL) 0.01 0.01 0.01 0.01 TEMED (mL) 0.01 
Table 2.6: SDS gel Composition 
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2.2.1.10 Crystallization 
 
There were 3 types of crystallization experiment used in this thesis: Broad 
screening using a TTP Labtech Mosquito nanoliter dispensing robot and 
commercial sparse matrix screens, where a variety of different conditions 
are explored in order to find the most suitable environment for the protein 
to form a crystal lattice. After, manual optimizations are performed, 
where conditions identified from the previous step are explored to 
optimize crystals using manual pipetting in microliter crystallization drops 
in 24 or 48 well Linbro plates by handing drop vapor diffusion, whereas 
XChem ready crystallization – is the specific robotic nanoliter 
optimization of conditions to produce large numbers of drops for the latest 
high through crystallography methods in low volume drops in SwissCI 
plates.  
 
2.2.1.10.1 Commercial Crystallization Kits  
MacroSol™ MD1 – 22 
Morpheus® MD1 – 46 
3D Structure Screen MD1 – 13 
Stura FootPrint Screen MD1-20 
SG1™ Screen HT-96 MD1-89 
PACT premier™ MD1-29 
Wizard Classic 
JCSG-plus™ HT-96 MD1-40 
 
2.2.1.10.2 Manual Crystallization, hanging drop method 
Chemicals were used from Sigma-Aldrich, Melford and Fisher chemical 
Plates: Greiner Bio-One ComboPlate 24-Well protein crystallization plate 
for hanging drop application. 
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2.2.1.10.3 XChem Plates 
Plate type: Swiss CI XTAL (SD-3) 3 well midi 
 
2.2.1.11 NMR Solutions  
A Maybridge library of a selection of 589 fluorine containing fragment 
compounds was designed by the University of Kent and synthesized in 
Maybridge. 339 compounds had the Fluorine atom was attached to the 
aromatic ring, 3 compounds had Fluorine in a CF2 group and 247 
compounds where Fluorine was in CF3 group.  Fragments were shipped in 
powder form and then diluted in a d6DMSO to a concentration of 100μM.   
When mixtures were prepared the final ligand concentration in mixtures 
was 0.1 µM. For Fluorine fragment screening 1D NMR experiment was 
performed where 2 fragment mixtures were made, where mixture 1 was a 
control that didn’t contain any protein and the second mixture was with 
5µM of protein. In the final NMR screening set, there were 28 mixtures 
with 8-23 fragments in each mixture. In total 4 mg of PDE5 protein was 
used. The protein was in buffer that it was purified during SEC, Section 
2.2.1.6.3. The NMR instrument that was used: 600 MHz five channel 
Bruker Avance III spectrometer with a cryoprobe which can observe a wide 
range of biologically relevant nuclei at high sensitivity and a 24 place 
sample changer. The spectrometer is used for structural biology, molecular 
dynamics measurements, drug binding and discovery campaigns, 
metabolomics and the analysis of small molecules. 
 
2.2.1.12 SPR Solutions 
All SPR experiments were performed with a Biacore T200 surface Plasmon 
resonance biosensor instrument (GE healthcare). Proteins were immobilized 
on CM5 series S sensor chips. Consumables were obtained from GE 
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Healthcare. The neutravidin immobilization was run on HBS-N at a flow 
speed of 10 µL/min at 25 °C. The matrix of the sensor chip was activated by 
injecting, on all flow channels, a mixture of 0.1 M N-hydroxysuccinimide 
(NHS) and 0.4M 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide 
hydrochloride (EDC) at a flow rate of 10 µM for 420 seconds. Subsequently, 
neutravidin (0.30 mg/mL) in a 10 mM NaAc solution (pH 5.0) was injected 
for 120 seconds. Unreacted activated groups of the dextran matrix were 
deactivated by injection of ethanolamine. HCl (1 M) for 420 s. Bovine 
Carbonic Anhydrase was purchased from Sigma-Aldrich. The proteins were 
buffer-exchanged using a Amicon Ultra 0.5 mL centrifugal filter (Merck). 
EZ-Link Sulfo-NHS-Biotin (Thermo Fisher Scientific) was diluted with the 
protein. Biotinylated proteins were desalted using 0.5 mL Zeba Spin 
desalting columns (Thermo Scientific).  
 
2.2.1.13 Activity Assay  
PDELightTM HTS cAMP Phosphodiesterase Assay Kit, 500 Test 
Lonza stimulation buffer (Reaction buffer): 
  
-        50 mM Hepes 
-        100 mM NaCl 
-        5 mM MgCl2 
-        100 nM ZnCl2 
-        5% Glycerol 
-        Further pH adjusted with NaOH (10 M) to pH 7.8 
 
2.2.2 Methods   
2.2.2.1 Microbiological methods  
2.2.2.1.1 Sterilization  
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Before any media or solutions can be used with cells, they were 
autoclaved to sterilize them. Autoclaving was performed at 121 °C for 15 
minutes and 1 bar pressure. Temperature sensitive substances, such as 
antibiotics were added post autoclaving and then solutions were filtered 
through sterile filters (0.22uM).  
 
2.2.2.1.2 Bacteria’s Storage   
When cells were transformed with the plasmid of interest it was 
important to be able to prepare bacteria for long-term freezer storage. The 
bacterial culture was prepared whereby inoculation with 1:1 ratio with 
glycerol at final glycerol concentration 50%. The culture was then stored 
at – 80 °C.  
 
2.2.2.1.3 Bacteria Plates 
Bacteria stored at –80 °C were thawed at RT for 10 – 15 minutes used 
where bacteria were streaked onto appropriate plate containing antibiotic. 
Agar plates were incubated overnight at 37 °C.  
 
2.2.2.1.4 Liquid Cultures  
Bacteria were inoculated in liquid culture where the appropriate antibiotic 
was added into the corresponding media. Aerobic cultures were shaking 
at ~ 200 rpm in a 1L flasks at 37 °C.  
 
2.2.2.1.5 E. coli Competent Cells  
Single bacteria colonies were inoculated into 100 ml of LB broth and 
grown overnight at 37 °C shaking at ~ 200 rpm to OD600 of 0.3. Next, the 
bacterial culture was cooled on ice for 15 minutes followed by 
centrifuging at 850 x g at 4 °C. The supernatant was discarded, and the 
   55 
pellet was resuspended in solution containing 0.1M CaCl2 and stored on 
ice for 30 min followed by centrifugation. The supernatant was discarded, 
and pellet was resuspended in 0.25 ml of 0.1M CaCl2 with 25% of 
glycerol (v/v). Cells were aliquoted into Eppendorf tubes of volume 50 
L and stored at – 80 °C.  
 
2.2.2.1.6 Transformation of E. coli 
The 50 L aliquot of competent cells were thawed on ice for 10 minutes 
followed by addition of 1 L of plasmid DNA. After, it was incubated on 
ice for 20 minutes. The mixture was then heat-shocked at 42 °C for 42 
seconds. The cells were then cooled on ice for 2 minutes followed by the 
addition of 300 L SOC broth and grown for 1 hour at 37 °C shaking at ~ 
200 rpm. After cells were plated onto agar plate containing required 
antibiotic.  
 
2.2.2.2 Protein Construct Design  
DNA sequences were analysed by various software to identify site of 
catalytic domain boundaries in the full-length gene sequence. 
Blast searches using blasttp algorithm (protein – protein BLAST) were 
used to compare sequence of interest with known sequences in the 
ensemble database and 3D structures in the protein data bank. The Pfam 
software was used to analyze sequences and show possible domain 
boundaries. The goal was to identify the best possible construct, 
including purification tags, that will potentially give the best levels of 
expression as well as the highest protein yield as possible with limited 
flexible regions to aid crystallization. There were certain additional 
factors that need to be considered, in particular the beginning and end of 
the construct, where the hydrophobic acids have to be avoided as well as 
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not terminating the construct in the middle of secondary structural 
elements.  
 
2.2.2.3 Gene Amplification  
2.2.2.3.1. Polymerase Chain Reaction (PCR)  
PCR is a technique that used in genetics where the main aim is to amplify 
a gene of interest from the genome. The currently used technique was 
first introduced by Kary Mullis in 1983. The method is based on thermal 
cycling where DNA of interest can be amplified between 0.1 and even up 
to 40 kbp. The following figure 2.1 








There are several steps in thermal cycle to amplify DNA, Table 2.8: 
 initializing – the reaction where reaction is heated;  
 denaturation – where DNA disrupts (strands separation) by high 
temperature; 
 annealing – temperature decreased down to 50-65 °C when primers 
attach to each end of the DNA segment;  
 elongation – main function is performed by DNA polymerase where 
new amplified DNA strand is formed;  
 hold – the reaction temperature decreased down to 4 °C.  
 
Figure 2.1: schematic representation of PCR, (Wikipedia)  

















ddH2O 37.5 -32.5  
10 x PCR buffer (containing 18 mM MgCl2) 5  
DMSO 0-5  
5 mM dNTPs each 2  
10 M 5’ primer 2  
10 M 3’ primer 2  
DNA template 1  
Taq polymerase (5 U µL-1)    0.5  
Step Temp Time Cycles Function 




2 95 °C 30 secs 35 Denaturation 
of the 
amplified DNA 
3 55-58 °C 30 secs  Annealing of 
the primers 
4 72 °C 1 min per 
1,000 bp 
 Elongation 
5 72 °C 5 min 1 Final 
elongation 
Stop 4 °C HOLD   
Table 2.7: PCR reaction composition  
Table 2.8: PCR reaction temperatures  
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2.2.2.3.2. Gel Electrophoresis  
After the PCR reaction, the DNA product was loaded into agarose gel for 
analysis.  
 
2.2.2.3.3 Agarose Gel 
The agarose gel was prepared at concentration 1% (w/v) where agarose 
has been dissolved in 1xTAE buffer and an intercalating agent such as 
ethidium bromide with concentration being in solution of g mL-1. PCR 
products were mixed with loading dye of a final concentration being 20% 
(v/v) and loaded into agarose gel. Gel electrophoresis was run at 80V-
100V for 1 hour.  
 
2.2.2.3.4 Analysis of Agarose Gel 
The agarose gel was analysed using UV light where the fluorescent dye 
(ethidium bromide) absorbs UV radiation of 320 nm and re-emits at 590 
nm in a red-orange wavelength range. The dye is an intercalating agent 
that helps visualise the DNA fragments under UV trans illuminator. Gel 
pictures were taken through a red filter.  
 
2.2.2.4 Isolation and Preparation of DNA Fragments for 
Cloning 
2.2.2.4.1 Obtaining Product from Agarose Gel  
Each DNA fragment has a size and DNA markers enable choice of the 
required fragment that can be cut from the gel by using a scalpel. The 
next step was purification of DNA where QIAquick® Gel Extraction Kit 
(Qiagen) was used. Protocol provided with the kit was followed.  
 
2.2.2.4.2 Preparation for DNA Cloning and Ligation  








In order to perform a ligation of vector and DNA of interest, restriction 
digest have to be performed by same enzymes where complementary 
ends can be obtained. Ligation reaction has been performed at room 



















Reaction Compositions Amount (L) 
Insert 2.5 
vector 1.5 
2 x Rapid Ligation buffer (Promega) 5 
T4 DNA Ligase (Promega 3 U L-1) 1 
  









































Table 2.9: Ligation reaction composition 
Table 2.10: Restriction Enzymes List, (ProMega, BioLabs New England) 
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2.2.2.4.3 Plasmid Isolation 
DH10B™ E. coli cells were transformed with plasmid of interest. After 
12 hours of growth plasmid was isolated by using QIAprep® miniprep kit 
(Qiagen). The preparation was performed following miniprep kit 
handbook.  
 
2.2.2.4.4 Accessing Plasmid Integrity, Restriction Digest  
In order to check plasmid integrity and ensure there was no mutation in 
gene of interest, it was important to perform restriction digests where 
enzymes cut the sequence at specific sites. The reaction was prepared 
according to Promega information and incubated at 37 °C for 2 hours. 






ddH2O 4 L 4    L 
Restriction enzyme 1 1 L 0.5 L 
Restriction enzyme 2 - 0.5 L 
10 x Buffer 1 L 1     L 
Plasmid DNA 4 L 4     L 
 
         
2.2.2.5 Cloning 
2.2.2.5.1 Cloning into pET E. coli T7 Expression Vectors 
Vectors and amplified DNA fragments were digested at specific 
restriction sites where specific sequences have been introduced into 5’ 
and 3’ primers. After the gene of interest has been purified from the 
agarose gel and the vector has been digested, a ligation reaction was 
performed, Section 2.2.2.3.2. Competent E.coli DH10b cells were 
Table 2.11: Digest Protocol 
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transformed with ligated plasmid and plated onto LB agar plates 
containing appropriate antibiotic such as: ampicillin or kanamycin. 
Colonies were grown overnight after which 1 colony was inoculated into 
the liquid broth to amplify plasmid of interest. The next day, the 
restriction digest was performed followed by sequencing the plasmid by 
using Genewiz service to verify the DNA sequence. pET15b was 
modified in order to introduce TEV cleavage site by ThermoFisher 
Scientific (Lifetech). The gene of interest can be tagged either on N-
terminus or C-terminus with a 6 – histidine residues tag to aid 
identification and purification of any expressed protein.  
 
2.2.2.5.2 Cloning into pOPIN vector suite  
The pOPIN vector suite allows expression of the gene of interest in 
multiple hosts: bacteria, insect and mammalian cells. As well as 
providing versatile vectors for expression recombinant proteins it also 
provides vectors with fusion tags, such as SUMO, GST, MBP and etc., 
that enhances protein folding. There were 4 vectors that were used: 
pOPINF, pOPINM, pOPINJ and pOPINS3C.  DNA of interest was 
directly cloned into the digested vectors by Sequence Ligation 
Independent Cloning (SLIC).  The protocol can be found below: 
 
 
 Stock concentration  Volume added  Final concentration  
Linearized vector (e.g., 5 kb)  100 ng/l  1 l  10 ng/l  
Insert 1 (PCR product, 
e.g., 1 kb)  
40 ng/l  1 l  4 ng/l  
Insert 2 (PCR product, 
e.g., 1 kb)  
40 ng/l  1 l  4 ng/l  
10X BSA   1 l  1X  
10X NEB Buffer 2   1 l  1X  
Table 2.12: SLIC protocol reagents, (77) 
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2.2.2.5.3 Cloning into pCold expression vectors: pColdI and 
pColdTF 
This expression system uses a cold shock expression method. There are 
several different vectors: pColdI and pColdTF. PCR product of catalytic 
domain was cloned into a digested vector with appropriate restriction 
enzymes where complementary ends were formed. The ligation method 
was followed as given in section 2.2.1.4.1.  
 
2.2.2.6 Protein Expression and Purification  
2.2.2.6.1 Production of recombinant protein in E. coli 
E. coli cells were transformed with the recombinant plasmid of interest 
and transformed onto a plate containing the appropriate antibiotic. The 
following day, 1 colony was inoculated into 20 ml starter culture and left 
growing overnight at 37 °C, shaking at ~ 200 rpm. The next day, the 
starter culture was used for inoculation 1L 2YT or TB broth with 
antibiotic and grown at 37 °C shaking at ~ 200 rpm until the OD600 
reached 0.6-0.7. When the culture reached the required OD600 value the 
cells were chilled on ice for 30 minutes after that an induction agent 
IPTG was added, varying in concentrations from 0.2 mM to 0.5 mM to 
induce protein expression. In studies with co-expressing chaperones 2 
other inducers were added, such as arabinose and tetracycline. Cells were 
expressing the protein of interest from 12 hours to 48 hours at different 
temperatures: from 19 °C to 21 °C. After, cells were centrifuged at 3500 
x g for 20 minutes at 12 °C. The supernatant was discarded, and pellet 
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2.2.2.6.2 Cell Lysis   
2.2.2.6.2.1 Sonication 
Harvested cells were disrupted by sonication (Sonics Vibracell Ultrasonic 
processor) for 6 times 45 seconds each round and followed by 30 seconds 
break after each round. After, cells were centrifuged at 35,000 x g for 25 
minutes at 4 °C.  
 
2.2.2.6.2.2 Cell Disruption 
Harvested cells were resuspended in appropriate buffer and passed 
through a cell disrupter (Stansted Fluid) that was operating in range of 
12,000 – 14,000 psi. The sample was then centrifuged at 35,000 x g for 
30 minutes at 4 °C and the supernatant retained for gel analysis and 
protein purification.  
 
2.2.2.6.3 Protein Purification  
2.2.2.6.3.1 Immobilized Metal – Affinity Chromatography 
(IMAC) 
The main principal of protein separation from a mixture of other proteins. 
There are several types of affinity chromatography: affinity 
chromatography, IMAC and tagged protein purification (e.g. Glutathione: 
GST fusion approach).  The overall process can be characterized as 
competitive binding where the folded protein of interest has a freely 
available additional tag that allows it to bind to a specific resin while 
contaminant proteins flow through the column without any interaction 
with the resin. The bound protein of interest is then displaced from the 
column by eluting with an appropriate ligand. In the current study metal 
affinity chromatography was used where a HexaHis-Tag has been fused 
with the recombinant protein on its N/C-terminus in order to bind to 
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divalent nickel metal in resin. Ni-NTA resin uses nitrilotriacetic acid 
(NTA) as well as tetradentate chelating ligand where NTA binds to Ni 
ions by forming 4 interactions. His-Tag contains polyhistidine residues 
that has a strong binding affinity to metal ions. Imidazole ring of histidine 
forms bonds by its electron donor groups with metal ion. As a result, the 
protein of interest will interact with immobilised metals while the 
contaminants are flowing through the column. To elute protein 
competitive binder is used, such as imidazole which at high concentration 
substitute protein and protein of interest elutes or changing of pH of the 
column buffer (74).  
IMAC can give 95% purity if there is a lot of protein of interest in 
mixture. It has also been shown that IMAC could be used when different 
expression systems have been used to express a protein of interest such 
as: Escherichia coli, mammalian cells and baculovirus infected insect 
cells.  
 
2.2.2.6.3.1.1 Fusion His-Tag with Recombinant protein 
In some experiments, it is possible to use longer tags with higher number 
of His residues if purification method required more vigorous washing 
before eluting the recombinant protein. The main reason is to improve the 
purity and final protein yield.  The protein constructs chemistry and its 
region of interest dictates where the tag has to be placed, it can be either 
on C terminus or N terminus, as folding can inhibit protein metal 
interaction where His – Tag will be buried inside the protein so it won’t 
be recognised by divalent metal. Sometimes protein tags can interfere 
with the recombinant protein functioning and folding, therefore it is 
advisable to use short purification tags in order to overcome such 
problem. His – Tag was incorporated into the expression vector by 
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polymerase chain reaction (PCR) as it has been performed in current 
study as well as directed mutagenesis.  
 
2.2.2.6.3.1.2 IMAC resin 
Initially iminodiacetic acid (IDA) was used as a matrix that interacts with 
divalent metals by 3 sites. However, there was a main disadvantage that 
made using this matrix as less preferable. Metal ions have a weak 
interaction with the resin hence resulting in decrease in purity as well as 
protein yield. The latest development of new matrix with using nickel 
nitriloacetic acid and cobalt carboxymethyl aspartate that are linked to 
resin. In comparison to previous matrix this 2 interacts with divalent 
metals by 4 sites while leaving the other 2 available for recombinant 
protein to attach by its His-Tag, Figure 2.2. 


















One of the main advantages of using such a robust system is that it can 
tolerate a wide variety of conditions where different buffers can be used 
as well as the presence of detergents. Another benefit of using IMAC is 
the fact that resin can be reused many times as long as it is cleaned and 
regenerated properly so the efficiency of protein purification won’t be 
affected. The binding efficiency of Ni-NTA is 5-10 mg/ml of 
recombinant protein with affinity being Kd=10−13 M whereas Co-CMA 
has lower binding affinity however higher level of specific binding 




Figure 2.2: Formation of bonds between His-Tag and divalent metal ions. A) Ni-
NTA (75) B) Co-CMA (76) 
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2.2.2.6.3.1.3 Protein Purification Process  
There are two types of purification methods that can be performed by 
using IMAC technique: purification under native and denatured 
conditions. Native conditions are used when imidazole in elution buffer 
as a competitive binder where active proteins are eluted. If protein 
doesn’t experience any misfolding and aggregation this method can be 
used. However, in the case of purifying protein that exhibit some 
difficulties in folding and forming aggregates it is advisable to use 
denatured conditions. However, proteolytic and phosphatase enzymes 
functioning can be affected (77). Later on, the misfolded proteins can be 
refolded by using dialysis although this is often a difficult and low 
yielding procedure (78). In current study, native gel was used.  
 
2.2.2.6.3.1.4 IMAC purification process 
There are two ways how IMAC can be performed, either by batch 
incubation or prepacked column. In current study, prepacked column was 
used in all experiment’s protein purification. Since the resin has a high 
affinity to His-Tag there is a minimum amount of resin required to 
successfully purify protein. In current experiment 5 ml column were 
used. Such chemical additives as sodium chloride and imidazole can be 
used in binding buffer to reduce nonspecific bindings of contaminant 
proteins that don’t have His-Tag incorporated into their protein structure. 
When the lysate has been loaded into the column containing the protein 
of interest, further step of wash can be performed where imidazole 
concentration can be increased while not disrupting the interaction 
between divalent metal ions and His-Tag of protein. The last step is the 
elution where 2 different methods are used: lower pH down to 4.5-5.3 
and using competitive binder with high concentration so the interaction 
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between the tag and the metal will be broken and protein of interest will 
be eluted. In the current study, high concentration of imidazole was used 
as lowering pH can damage the protein and our main focus was to work 
on a completely novel target and protein that hasn’t been expressed and 
purified before. It is also important to maintain a buffer condition where 
no chelating agents can interfere with metal ions as the divalent ions will 
be stripped out of the column resulting in decrease of protein purity (79).  
 
2.2.2.6.3.2 Protein Purification According to its Charge and 
Hydrophobicity 
There 2 types of purification: hydrophobic based qualities purification 
and ion exchange chromatography (IEC). The first method is based upon 
protein separation according to its hydrophobicity where hydrophobic 
interaction chromatography media contains both hydrophobic and 
hydrophilic regions. Contaminant proteins are aggregated during the 
purification and as a result increases the purity of protein of interest. The 
second method that was used in the current study is IEC where proteins 
are separated according to its ionic charge. This method has been 
introduced in 1960 whereas prepacked columns are in use where resin is 
positively charged to separate negatively charged protein of interest 
which are also called anions. While negative charged resin is used to 
separate positively charged proteins that are also called cations. The 
technique is highly popular since it is useful for purification not only of 
proteins but also small peptides and nucleic acids as long as the molecule 
has a net ionic charge. IEC can still be used even if there is a very small 
difference in charge between proteins in mixture. Another advantage of 
this technique is a high loading capacity.  
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2.2.2.6.3.2.1 Principle of Separation 
The main principle of protein separation is based on isoelectric focusing 
of protein where isoelectric point (pI) plays a crucial role in separation 
protein of interest from the contaminants. pI is defined as the pH when 
the protein of interest does not have any net charge. pH > pL identifies as 
the condition when protein has net negative charge and pH < pI when 
protein has a net positive charge. The protein charge is directly depending 
upon specific groups in protein structure that are responsible for net 
charge of the protein while also having different pKa numbers which are 
acid ionization constants. pH plays a crucial role where proteins that 
contain in its structure basic and acidic groups will change their charge 
with the change of pH. Such proteins called amphoteric. Titration curve 
shows how the charge of protein relates to the pH of the environment, 
Figure 2.3. From the curve in this Figure it can be seen that change of pH 
directly correlates with change in charge of protein. Increase of pH value 
leads to decrease in net charge to more anionic form. 
This relationship between pH and net charge of protein enabling IEC to 
be very useful technique to elute protein of interest. As well binding 
according to protein charge other interactions can take an action, such as 
van der Waals interactions and small nonpolar bonds.  
 
2.2.2.6.3.2.2 IEC Purification  
At the beginning the prepacked column has to be equilibrated in the same 
buffer as your sample is to equilibrate the stationary phase. In the current 
study sodium chloride was used with 100mM concentration as a starting 
buffer. It is very crucial for protein to be exactly in the same buffer with 
100mM salt to ensure that the protein will bind and not flow through the 
column with other contaminates.  












After the protein mixture is loaded into the column where the protein of 
interest will bind to the column and contaminants will flow through. As it 
has been mentioned earlier opposite charged molecules will bind to the 
column media thus increasing the amount of recombinant protein of 
interest in the column. The 3rd step is washing of column with higher 
concentration of salt (1 M) in order to remove non-specific binding which 
will ultimately result is purer elution. The very last step and the most 
important in the whole process is the elution itself where the ionic 
strength will be increased by increasing the concentration of sodium 
chloride where the sodium ions will act as some competitive binders with 
protein of interest leading to disruption of interaction between protein and 
media resulting in protein of interest being eluted. There are two types of 
elution: step elution where buffer with high concentration of salt is 
applied directly into the column and gradient elution where salt 
concentration is increasing gradually resulting in purer sample as by 
knowing the ionic strength of your protein we can predict the 
approximate percentage of salt that is required to elute exactly that 
protein.  After the purification column has to be washed and regenerated 
Figure 2.3: Titration curve. Figure represents 3 theoretical protein 
titration curves where each curve shows how the net surface charge of 
the protein is changing due to pH change.    
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so the next protein run can be performed. The schematic representation of 
























2.2.2.6.3.2.3 Factors Affecting IEC Purification  
I. Resolution – tells us how well the protein is separated from other 
contaminants in the mixture. This can be visualised by how the peaks are 
separated on the chromatogram. The description for resolution is the 
Figure 2.4: Schematic representation of anion exchanger, GE Healthcare manual 
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width between to elution peaks in contrast to the distance from point A to 
point B of each peak base.  
II. Efficiency – is described as how well a prepacked column can separate 
recombinant protein of interest from other contaminants that are present 
in the mixture. Efficiency directly correlates with column packing where 
any alteration is column zones will change its efficiency. The main 
reason that leads to loss of efficiency, is when a column is continuously 
flushed with mixtures full of molecules like proteins or peptides, so it is 
very important to clean and regenerate columns properly after each use. 
Another possible reason for reduced efficiency is the quality of column 
packing where uneven distribution of matrix can lead to poorer protein 
purity.  
III. Selectivity – is described as how selective the column matrix is to the 
protein of interest. Many factors influence it such as environment pH, 
how strong protein is bonded with matrix, and buffers that are used to 
elute protein. pH plays a crucial role in selectivity since it dictates the 
differences in protein charge and other contaminants. As it was 
mentioned above, step elution is used when a high concentration of salt is 
directly applied into the column to elute the protein. This method is used 
if the protein PI is known so the pH and ionic strength you expect it to 
elute at can be estimated. Gradient elution is useful when the target has 
not been purified before, to help establish the elution conditions that are 
required for that particular protein. The principle of the method is that the 
pH and salt concentration is slowly increasing so the molecules with 
weakest ionic strength interactions will elute, first followed by other 
proteins that have stronger interactions with the media. This method is a 
useful additional step if IMAC chromatography did not yield high purity 
of sample.  
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2.2.2.6.3.2.4 IEC media 
The column is packed with a special matrix that enable purification of 
protein according to its net charge. The properties of IEC media allow 
them to have a charge opposite to theprotein of interest and form ionic 
interactions. There are many pores, to enable high binding affinity and a 
large surface area, for the required protein to bind. The inherent physical 
strength of media itself makes it as a safe component to use in 
purification, as it keeps a constant volume (no compression under 
pressure) thus the elution step won’t be disrupted. Also, the process is 
fast and with the constant flow rate. This can minimise errors and hence 
improve the accuracy of the whole experiment. There are several types of 
media that can be used in packing the column. In the current study the 
column was prepacked with sepharose beads where agarose forms 
interactions with each other at various cross linking to enable efficient 
purification. The first stage in IEC is when the column is equilibrated at a 
particular pH and ionic strength to enable protein of interest to bound. 
The exchanger groups are linked to oppositely charged ions, such as 
chloride or sodium. This stage is followed by injecting the sample where 
protein of interest replaces the charged ions and binds to the resin. This is 
followed by washing the column with the starting buffer where unbound 
contaminants can be eluted form the column. The final step is the elution 
of the desired protein where buffer composition is slightly changed in 
order to replace protein with opposite charged ions hence eluting protein. 
This happens by increasing ionic strength of buffer by increasing the 
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2.2.2.6.3.3 Size Exclusion Chromatography (SEC) 
A third method that has been used extensively during this thesis is 
separation of proteins according to its size and shape where prepacked 
column has porous gel that according to protein masses will elute proteins 
at different time. This technique has been firstly proposed by Synge and 
Tiselius (80), where scientists recognised the pattern when smaller 
molecule have an ability to enter pores while the proteins with larger 
molecular weight tend to pass through quicker. The difference between 
SEC and IE or IMAC is that the chemical environment doesn’t play any 
role in SEC.  SEC is similar to the previously described purification 
approaches with the first step being column equilibration, followed by 
injection of the protein of interest which is then eluted by using the same 
buffer as the one used for equilibration. The key property of column that 
is that the matrix is formed of spherical beads. Large molecules will elute 
first as they cannot enter the pores of matrix due to their size. This is the 
reason that protein aggregates can easily be purified out from the sample. 
Smaller folded protein molecules will elute last as they can enter pores, 
so it takes longer for lower molecular proteins to travel down the column. 
SEC is a useful technique for purification of recombinant protein of 
interest, analysis of protein aggregation and also buffer exchange. 
Usually SEC is the last step in protein purification as this method yields a 
protein of high purity and removes aggregates. 
Separation - before performing any biophysical studies, such as X-ray 
crystallography or NMR, it is important to see that protein is in 
homogenous state and there are no contaminants and aggregates that will 
interfere with the experiment.  
Buffer exchange – different proteins require different buffer environment 
in order to be used further studies or for storage purposes. The “gentlest” 
way to buffer exchange the protein of interest is to use SEC column.  
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2.2.2.6.3.3.1 SEC Optimization  
There are certain factors that can alter protein purification. Recombinant 
proteins can form ionic bonds with columns mobile phase that ultimately 
can change elution results due to shift in retention time, peak being not 
able to distinguish between aggregate and target protein (81, 82). Also, 
there are certain physical factors that can influence protein elution, such 
as column volume, flow rate to load the column with the protein mixture 
and its volume.  
 
2.2.2.7 Protein Detection and its further Characterization  
2.2.2.7.1 Western Blot  
Protein samples were run on standard SDP – PAGE. Gels were then placed 
between transfer membrane and paper. An electric field is used to transfer 
protein from the SDS – PAGE onto the membrane. When the electric field 
transfer was done the membrane was placed into a tray where it was 
incubated with milk powder for 2 hours at 4 °C. After incubation, the 
membrane was washed 2 x 10 mins with TBS – Tween buffer to remove 
any milk solution left. The next step was to incubate the membrane with 
the primary antibody in dilution of 1:2000 in 10 ml of TBS buffer. The 
membrane was left shaking for 1 hour at Room Temperature. After 
incubation, the membrane was washed with TBS – Tween buffer to 
remove all antibodies. Simultaneously the substrate was prepared where 6 
ml of methanol was added to 4 – chloronaphthol from the freezer. This 
mixture was then added to TBS – Tween where hydrogen peroxide (H2O2) 
25 l was added into the solution as the last additive. The substrate was 
added and was agitated on a rocker until stained bands would appear (2-10 
mins).  
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Further Analysis of sample – a number of analysis techniques can be used 
to assess the final protein sample e.g. mass spectrometry, multangular light 
scattering, Circular Dichroism (CD) and small angle scattering (SAXS) 
which can reveal more details on secondary structure, post translational 
modifications, shape and aggregation 
 
2.2.2.7.2 Enzymatic Activity Assay  
PDEs in combination with adenylate cyclase controls cAMP second 
messenger signalling. The main function of PDE is to hydrolyse cAMP to 
adenosine monophosphate (AMP). PDELight™   is a commercial assay 
which uses a bioluminescent method to detect hydrolysis of cAMP. A 
detection (AMP-DR) reagent is used to identify the breakdown of cAMP 
into AMP. AMP-DR directly converts AMP into ATP. The luciferase 
enzyme uses light that is emitted from ATP and luciferin, Figure 2.5. 
  
Light intensity is directly correlated with the amount of AMP being 
formed. Therefore, according to the light intensity it is possible to link it 
to the PDE concentration and activity in the reaction.  
The following protocol was provided by the University of VU. 
 
I. Storage of PDEs and preparation of reagents 
  
PDEs Thawed aliquots on ice were diluted with Lonza 
Stimulation Buffer (S.B.) (50mM Hepes, 100mM 
NaCl, 5mM MgCl2, 0.1mM ZnCl2, 5% glycerol, 
volume adjusted with MiliQ, pH 7.8) to a 
Figure 2.5: Schematic representation of cAMP hydrolysis, Lonza manual  
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suitable working concentration (section 2). Kept 
on ice. 2.5µl/well required. 
 
cAMP Thawed 10mM aliquot(s) were diluted with 
Stimulation Buffer to required concentration.  
Kept on ice, to allow to reach R.T. 15mins before 
use.  5µl/well required.  
 
AMP control  Thawed 10mM aliquot(s) were diluted with 
Stimulation Buffer to required concentration.  
Kept on ice, allowing to reach R.T. 15mins 
before use.  5µl/well required.  
 
Detection Reagent In the dark, sufficient number of aliquots were 
thawed and diluted to 80% with Reconstitution 
Buffer. 5µl/well required.  Kept in the dark on 
ice, allowing to reach R.T. 15mins before use. 
 
 
II. Determining a suitable working PDE concentration. 
Prepared PDE dilution series in S.B.: 1:10, 1:100, 1:1000, 1: 10,000 and 1: 
100,000. 
In triple (reaction volume 15µl): 
 
2.5µl of diluted PDE 
Spin plate 
+ 
2.5µl S.B. containing 6% DMSO 
Spin plate, cover and incubate at room temperature for20min 
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+ 
            5µl Detection Reagent (diluted to 80% with R.B.) 
Spin plate 
+ 
5µl cAMP at 10µM (cAMP is 1/3 final volume so prepare 30µM) 
Note time ‘0’ and Spin plate 
Controls: 
1.  AMP - 5µl of cAMP were replaced with 5µl AMP (at the same 
concentration i.e. 10µM) 
2.  No PDE - 2.5µl of PDE were replaced dilution 2.5µl of S.B. 
 
2.2.2.7.3 X – ray Crystallization 
2.2.2.7.3.1 Introduction 
Crystallization by definition as a separation biophysical technique where 
solid phase is separated from a mother liquor and where crystals occur 
with an ordered internal arrangement of molecules, ions or atoms (83).  
There are 3 steps in crystallization process: nucleation where crystalline 
condition is appearing, growth and growth cessation. Different particles 
crystallize at different speed and some such as protein can be difficult to 
crystallize. There are two types of forces that directly influence 
crystallization: atomic and intermolecular forces. Types of crystallization 
can vary where several methods are existing in order to reduce solubility: 
cooling, antisolvent additions, evaporation and reaction (precipitation).  
For a protein to precipitate the equilibrium has to be transformed into a 
supersaturated state where the amount of energy that was obtained during 
entering that state can be released during formation of precipitation, 
Figure 2.6.  











There are certain techniques that can be used to transfer solution into a 
supersaturated state, such as: batch, vapour diffusion and liquid – liquid 
diffusion. Vapour diffusion is the most common technique in use where 
sitting drop (VD – SD) or hanging drop (VD – HD) techniques are in use. 
This technique is characterized by mixing protein with the precipitant in 1 
drop and that is equilibrated against a reservoir mixture that is double in 
concentration of the precipitant mixture. During equilibrium water, leaves 
the protein drop into the reservoir by using air – gap separations and 
leading to a gradual increase in concentration of protein – precipitant 
mixture thus resulting in supersaturated state.   
The batch crystallization method is described as an under – oil method 
where protein of interest is mixed with the precipitant mixture and is 
covered by a paraffin oil (84). One of the main disadvantages is the 
problem of the sample drying out due to the fact that plastic is permeable 
to water molecules.  By using capillaries and/or membranes excess 
distribution mixture can be reduced hence resulting in decrease of mass 
transport. This method is called free interface diffusion method (FID) 
where the protein and the precipitant are in state of equilibrium before 
protein crystallization (85).  Another technique that is also used is known 
Figure 2.6: Crystallization phase diagram. (86) 
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as batch crystallization which is the counter – diffusion method (CD) 
where the system is moved towards supersaturation instead of 
equilibration (87). In current study VP – SD method was used. 
 
2.2.2.7.3.2 Crystallisation Screening  
To obtain a crystal structure of a novel target it is normal to first use 
commercial sparse matrix screens that contain a wide variety of different 
conditions that are known to have previously given crystals.  There are a 
variety of screens obtained from Molecular Dimension where used on the 
Mosquito robot. The main advantages of using the Mosquito are low 
protein consumption, pipetting accuracy and speed. The crystal plate is 
then stored at different temperatures for the best suitable environment for 
the protein to crystallize. Usually it takes at least 24 hours for nucleation to 
appear, however it all depends upon the nature of protein and 
crystallisation conditions where some proteins can strongly precipitate and 
yield no crystals and others simply remain in solution. To analyse 
crystallisation drops a stereo light microscope is used. Different phases can 
be observed. The main difficulty in choosing the most suitable condition is 
the identification of conditions that after manual optimization will produce 
crystals suitable for X-ray diffraction if there are no obvious crystals in the 
initial trials.  After analysis of the crystallisation drops, results can be 
plotted in a phase diagram with different zones according to protein 
solubility. There are 9 scores whereas each represents protein 
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Score  Protein State  Description 
0 Protein wasn’t 
precipitated  
- Drop remained 
clear for 2 weeks 
- Concentration of 
protein had to be 
increased   
 
1 There were 
non-protein 
particles  
- Bacterial growth  















- White/transparent  
- Conditions must 
be optimized  
5 Phase 
separation  
- Droplets in drop 
with oil skin 































2.2.2.7.3.3 Manual Screening  
In the current study the hanging drop vapour diffusion method was used 
where protein is mixed with precipitant solution and the mixture is placed 
in vapour equilibration where each drop was placed with a reservoir 
containing the same precipitant. 500 μl of reservoir was used where the 
drop concentration was lower where the volume was 2 μl or 4 μl in 
protein to precipitate ratio 1:2, 2:2 or 2:1. Equilibration occurred by water 
leaving the protein drop and diffusing back to the reservoir. This result in 
increase of supersaturation where the concentration of both protein and 




Figure 2.7: Hanging drop, Vapour Diffusion Method. Hampton Research, solutions 
for crystal growth manual 
Table 2.13: Crystallization phases diagram, Molecular Dimensions Manual  
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2.2.2.7.3.4 XChem  
At Diamond Synchrotron, there is a new X – ray development that 
enables users to perform high through put crystallography experiments 
where up to 1000 compounds can be screened individually in less than a 
week. The entire process includes soaking of crystals, harvesting and data 
collection. Data analysis can be performed on site or remotely through a 
NoMachine interface. Another advantage of using XChem platform is 
data analysis pipeline where PanDDA map analysis allows users to 
identify even very weak binders such as fragment compounds bound to 
the target protein.  
The 1st step in preparation of an XChem experiment is to purify protein of 
high purity where protein is in homogenous state in order to produce high 
quality protein crystals that will sustain soaking with high concentration 
fragment long duration soaks.  
The 2nd step after protein was purified is to crystalize it in PSI plates that 
are suitable for ECHO – dispensing in Diamond Synchrotron. Protein 
plated by mosquito using specifically designed protocol for that.  
The 3rd step was to choose library of interest, where 2 libraries were used: 
DSI – Poised (provided by Diamond), Fluoro – fragment library 
(provided by Maybridge) and also a selection of fragments from 
ChEMBL.  
The 4th step was to perform soaking using the ECHO dispensing system 
that was located on site.  
The 5th step was to harvest crystals by using microscope to visualize it 
and loops for fishing it.  
The 6th step was data collection where crystals were screened individually 
automatically. 
The 7th step is analysis of collected diffraction data where XChem 
explorer was used. There are several stages in the analysis, which are: 
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loading data sets, reprocessing data, running DIMPLE to solve the 
protein structure using its apo model that was provided by the user, 
creating the ligand restraints, finding hits (PanDDA), PanDDA analysis, 
PanDDA inspect and final step was model fitting by using Coot. 
The 8th step is solving and refining the structures by using CCP4 and its 
modelling in Coot.  
 
2.2.2.7.4 Nuclear Magnetic Resonance  
Each fragment was Quality Controlled (QC) before its run with the 
protein of interest in order to identify that it would not degrade or become 
contaminated during the actual run. Fragments with a singular fluorine 
should exhibit 1 fluorine in a 19F CPMG experiment. Fragments with 2 
fluorine’s in 2 different positions should display 2 fluorine peaks in a 19F 
CPMG experiment. If the spectra showed any other additional small 
peaks it was considered as a contaminant or compound degradation, 
hence that fragment was abandoned from further analysis. 
 
2.2.2.7.5 Surface Plasmon Resonance  
All experiments were performed with a Biacore T200 surface Plasmon 
resonance biosensor instrument (GE healthcare). Proteins were immobilized 
on CM5 series S sensor chips. All solutions were freshly prepared, degassed, 
and filtered. The neutravidin immobilization was run on HBS-N at a flow 
speed of 10 µL/min at 25 °C. The matrix of the sensor chip was activated at 
a flow rate of 10 µM for 420 seconds. Subsequently, neutravidin (0.30 
mg/mL) in a 10 mM NaAc solution (pH 5.0) was injected for 120 seconds. 
Unreacted activated groups of the dextran matrix were deactivated by 
injection of ethanolamine. HCl (1 M) for 420 s. 
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The proteins were buffer-exchanged and diluted to 0.5 mg/mL and injected 
on the flow channels until 3000 RU in the same buffer at 15 °C. Biocytin 
(0.05 mg/mL) was injected for 120 seconds on all flow channels at 15 °C. 
All compounds were dissolved in DMSO and diluted to 100 µM in 0.5 M 
Tris-HCl (pH 8.0), 150 mM NaCl, 4 mM MgCl2.6H2O, 100 nM ZnCl2, 5% 
glycerol (v/v), 2 mM 2-Mercaptoethanol, 0.005% Tween-20 (v/v), 2% 
DMSO (v/v). A 6-point concentration range of each compound was 
prepared in a dilution series and measured in multicycle experiments. 
Compounds were injected for 60 seconds and their dissociation was 
monitored for 300 seconds. All titrations were run at 25 °C at a flow speed 
of 50 µL/min. Data analysis were performed with BIAcore evaluation 
software 2.0. Signals were subtracted from reference surface and blanc 
injections. DMSO correction was performed. The affinity was determined 
by fitting a Langmuir binding equation to steady state binding signals at 
different concentrations. 
 
5.5.1 SPR sensograms representation 
The most common method that is used in SPR analysis is the use of 
Langmuir model where the experiment is characterized by 1:1 interaction of 
ligand and a protein. There are 2 main states in the reaction: association 
constant (𝑘𝑎, 𝑀
−1𝑠−1) and the dissociation constant (𝑘𝑑, 𝑠
−1). Equation 1 
represents the process. 
 
                      A+B 
 
 
The equilibrium constant - 𝐾𝐷 (M) is calculated using 2 kinetic constants: 
- 𝐾𝐷 = 𝑘𝑑/𝑘𝑎 
𝑘𝑑  
AB Equation 1 
   86 
In order to relate the interaction between ligand and the protein of interest 
















In the Figure 5.34, Equation 2 represents the association constant while 
Equation 3 represents dissociation constant. The baseline state is followed 
by association state where the molecules of the protein or ligand of interest 
are flowing over the ligand surface and the rate of the complex formation 
is measured. Therefore, Equation 2 forms a derivative equation of such 
process: 
 
                        𝑅𝑡 = 
𝑅𝑚𝑎𝑥[𝐴]
𝐾𝐷+[𝐴]
 [1 -𝑒−(𝑘𝑎[𝐴]+𝑘𝑎)𝑡] 
E2 E3 
Time  
Figure 5.34: Reference sensogram of SPR experiment representing 3 states: 
baseline, association and dissociation. E2 – equation 2, E3 – equation 3. 










Equation 3 represents the dissociation phase where the amount of protein 
or ligand of interest in the flow cell is reduced by introducing running 
buffer into the system instead of the analyte sample. This equation 
represents how quickly the system has reached a particular point during the 
experiment as a dissociation phase.  
When the data has been obtained there are certain rules that should be 
followed in order to present the results.  To calculate 𝐾𝐷 value the 
following equation would be used: 
 






The equation 5 represents the equilibrium state during the experiment 
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The equilibrium response (𝑅𝑒𝑞) is measured at different protein/ligand 
concentrations followed by its plotting onto the graph, Figure 5.35. 𝑅𝑒𝑞  is 
proportional to the analyte concentration at its low concentartions but 
when the concentration increases the value is approaching its theoretial 
maximum of 𝑅𝑒𝑞 (Protein interaction analysis, Guide to SPR Data 
Analysis on the ProteinON XRP36 System, BioRad manual).   
 
  
Figure 5.35: SPR sensogram of experiment representing running protein at different 
concentrations to identify equilibrium constant, A) measurement of 𝑅𝑒𝑞   over a 








Expression and Purification of  
Parasitic PDEDs from  
L. infantum, L. donovani and T. brucei 
3.1 Introduction  
The results presented in the current chapter describe the study of 
recombinant protein production of PDED from L. infantum, L. donovani 
and T. brucei. At the beginning of the current study only the DNA 
sequence was available with no experimental data on the protein encoded. 
Figure 3.1 represents PDED full length sequence alignment between the 
3 species stated above.  
Figure 3.1: Multiple protein sequence alignment of PDED from L. infantum, L. 
donovani and T. brucei, MultAlin software was used, 
(http://multalin.toulouse.inra.fr/multalin/) 
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Some preliminary work has been reported on PDEB1 from L. major (88), 
where a catalytic domain crystallization construct in Leishmania has been 
analysed, however, it was important to study other parasitic PDEs as 
potential drug targets and the least well studied were PDEDs. L. infantum 
and L. donovani species cause visceral Leishmaniasis that can be fatal or 
cause serious medical conditions especially when there is a co-infection 
with HIV (World Health Organization, March 2019). It is hoped that 
further experimental data on PDED could help validate it as a drug target 
and could be used for the designing of a new or modified tool compound 
that may be effective for treatment of Leishmaniasis worldwide.   
According to the blast analysis, using blast.ncbi.nlm.nih.gov software, the 
Leishmania species showed 99% sequence similarity amongst the 
PDED’s while within the Trypanosoma, the sequence similarity was only 
49.28%. Cloning was initially pursued on 2 strains of Leishmania species 
namely: L. infantum and L. donovani. Software such as Pfam (collection 
of protein families and sequences alignments) and Phyre (software for 
protein 3D structure recognition) (https://pfam.xfam.org) were used to 
identify the most favourable constructs for protein expression, 
purification and its further characterization.  
 
3.2 Results  
3.2.1 Leishmania PDED  
Genomic DNA of L. infantum PDED was provided by the University of 
Antwerp where the full length of PDED from strain JPCM5 was 
amplified using the PCR technique, Section 2.2.2.2.1. There are 724 
amino acids in the full-length sequence. As mentioned, the Pfam software 
was used to define the catalytic domain location in the PDED full length 
sequence. According to Pfam the catalytic domain was located between 
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amino acids 461 and 695, which was also confirmed by visually 
comparing its sequence with other known PDE catalytic domain 
structures. In addition to this approach for construct design the Phyre 
(Protein Homology/AnalogY Recognition Engine) software was used to 
analyse a possible 3D protein structure based on already deposited 
structures of other proteins. This software was useful for analysing 
protein secondary structure where any disordered regions were identified. 
After identifying the location and sequence of catalytic domain a number 
of constructs were chosen to clone and express the protein. The catalytic 
domain constructs were designed with varying N and C termini. The first, 
and very important, step in structural biology is the identification of the 
appropriate construct that will produce high protein yield in a 
recombinant expression system which may be easily purified to produce 
homogeneous protein that then may result in a highly ordered crystal that 
diffracts well. Structure Based Drug Design (SBDD) approach requires 
the development of a robust crystal system to analyse possible binding 
modes between ligands and target protein. The final yield of purified 
protein can be influenced significantly by construct design, where tags, 
secondary structure and composition of hydrophobic and hydrophilic 
amino acids were taken into consideration at the beginning and end of the 
sequence as they could alter PDED expression levels, its solubility and 
stability during the purification (89).  
The first construct that was designed for PDED started at amino acid 394 
which was Glutamic acid and ended at the residue 714 which was a 
Lysine. Lysine and Glutamic acid were both charged hydrophilic amino 
acids also capable of formation of salt bridges. It had been proven 
previously by Boël G., et al that reduction of the use of rare codons 
(codon optimization) could play an important role in level of protein 
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expression (90).  The 3 constructs of catalytic domain of L. infantum 
PDED were designed, Figure 3.2. 
 
3.2.2 Cloning  
The catalytic domain was cloned using primers (Section 2.2.1.3, Table 
2.3) into a designed pET15b vector with the inclusion of a TEV cleavage 
site, for later removal of the purification tag Figure 3.3. 
 
For PDED construct insertion, 2 restriction enzymes were used: 
BamH1(G’GATCC) and NdeI (CA’TATG), Section 2.2.2.4.2. 
 
Figure 3.4: native pET15b plasmid, (www.addgene.org) 
Figure 3.2: Protein Sequence Alignment. 3 designed constructs of PDED catalytic 
domain from L. infantum. MultAlin software was used 
(http://multalin.toulouse.inra.fr/multalin/) 
Figure 3.3: designed TEV cassette for insertion into pET15b native vector, 
SnapGene software was used to design current construct  
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Figure 3.4 showed the DNA sequence of native vector pET15b that was 
used as a scaffold for designing modified version with TEV cleavage site, 
Figure 3.5.   
The main advantage of using this cassette is that TEV site is located on N 
and C terminus where the gene could be fused to a HisTag on either or 
both termini. PDED catalytic domain was then cloned into pET15bTEV 
modified vector. Details of the vector and vector containing PDED 
catalytic domain can be found further, Figures 3.5, 3.6. 
 
 
Figure 3.5: schematic representation of TEV cassette cloned into pET15b vector, 
Vector map was designed using SnapGene software 
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Amplification and cloning were performed by PCR and ligation methods, 
Sections 2.2.2.3 - 2.2.2.5. After cloning it was important to check the 
plasmid integrity, since any deletions or mismatch could result in 
different amino acids being translated and as a result different protein 
being expressed, so the plasmids were sent for sequencing. 
 
3.2.3 PDED expression   
Once the oligonucleotide sequences were confirmed, the next step was to 
analyse the level of PDED expression and its solubility. Initially a small-
scale expression and purification method was performed where standard 
conditions were used, Section 2.2.1.7.1. In that particular experiment E. 
coli T7 express cells were used.  
 
Figure 3.6: schematic representation of pET15b vector with inserted cassette 
containing TEV cleavage site and PDED catalytic domain. Vector map was 
designed using SnapGene software.   




















As shown in Figure 3.7, catalytic domain of PDED was expressed, 
however according to the SDS-PAGE it could only be detected in the 
pellet fraction. The main reason could be protein insolubility due to 
misfolding. Due to such poor soluble expression levels, additional new 












Figure 3.7: SDS-PAGE of Ni-NTA small scale expression of L. infantum PDED 
catalytic domain. The expected molecular weight -  37. 3 kDa.  
Abbreviation: S (supernatant), P (pellet), FT (flow through), E (elution) 
 
37 kDa 
     S        P     FT    E1      E2 




Figure 3.8: schematic representation of 3 designed constructs of PDED 
catalytic domain  
50 kDa 
25 kDa 
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Construct 2 was designed shorter then construct 1 where the start of the 
2nd construct was shorter by 10 amino acids, Figure 3.8. However, the 
level of expression of this construct was similar to the expression level of 
1st construct where PDED was only observed in the pellet fraction, 
meaning it was still insoluble. Construct 3 was designed to be shorter by 
47 amino acids than the 1st construct.  Again, similar expression levels 
were observed where no soluble material was obtained in the supernatant. 
Simultaneously, other lab members tried to express PDEDs from 2 other 
parasitic organisms, such as T. brucei and T. cruzi where multiple 
constructs of PDED catalytic domain were designed and no soluble 
protein was observed using an E. coli expression system. A variety of 
constructs with N and C terminal truncations, as well as some targeted 
surface entropy mutations, were performed but no soluble protein was 
obtained in all cases. As a result, it was concluded that unfortunately 
although using different length PDED constructs from 3 different species, 
the only PDED protein observed was in the pellet fraction with no 
improvement in protein solubility. Hence, the next step was to change the 
pET expression vector system and to use pOPIN vector suite.    
 
3.2.4 pOPIN vector suite  
An advantage of using the pOPIN expression system is that it is a 
versatile system that could be used with bacteria (E. coli), insect (baculo) 
and mammalian cells (HEK293). The pOPIN expression system is a 
direct cloning system using the SLIC method, Section 2.2.2.5.2. The 
pOPIN system has multiple vectors with different solubilizing tags that 
can be used: SUMO, MBP, GST tags and etc. The main reason behind 
using the pOPIN vector suit was to improve protein solubility and hence 
develop an expression system that would show a significant difference in 
expression of protein through utilization of the different fusions or tags. 
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The amplified full length and catalytic domain of PDED were cloned 
directly into a range of vectors, where the PDED constructs were fused to 
different fusion tags. Similar expression and purification conditions were 
used at small-scale to assess protein solubility and identify if any 
differences with previous expression system could be determined.  SDS-
PAGE gels showed no signs of soluble material in supernatant fraction in 
all constructs. Therefore, more sensitive western blot technique was used, 













As seen in Figure 3.9, only fraction 5 which was the pellet of PDED 
protein expressed in pOPINS3C had a band of the expected molecular 
weight of PDED_HisTag_SUMO construct at 51.4 kDa. However, the 





Figure 3.9: Western Blot analysis of small scale expression, Ni-NTA of 
catalytic domain of PDED from L. infantum using pOPIN vectors: pOPINJ, 
pOPINM and pOPINS3C 
Key: 
C – control  
L – marker ladder 
1 – pOPINJ, pellet 
2 – supernatant 
3 – pOPINM, pellet 
4 – supernatant  
5 – pOPINS3C, pellet 
6 – supernatant  
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pellet fraction also showed that there was degradation where multiple size 
bands could be visualized. Therefore, it was concluded that PDED 
solubility wasn’t improved using the new vector suit with fusion tags. 
This led to further exploration of alternative expression systems, such as 
the Cold Shock System.  
 
3.2.5 pCold Expression System 
The pCold expression system, which exploits the cold shock expression 
method was used for the expression of the catalytic domain of PDED 
since previous reports, (91), showed that cold shock system was suitable 
for expressing of difficult proteins that were prone to misfolding. The 
Cold shock system contains cold shock protein A that acts as a promoter 
in the protein expression, enhancing higher levels of protein expression. 
It was hoped that the use of this system would improve protein folding 
where the expression occurs more slowly at lower temperatures hence 
protein folding machinery might allow more soluble protein being 
produced. The lower temperature (15 °C) may also reduce the expression 
of the contaminants and reduce protease activity that could negatively 
affect protein yield. The cold shock expression system also allowed 
labelling with different tags and/or fusions, e.g. with chaperone Trigger 
Factor. Two vectors from pCold system were used: pColdI and pColdTF, 
where protein of interest was fused with solubilizing chaperone such as 
Trigger Factor (TF) in pColdTF vector. L. infantum PDED was cloned 
into 2 vectors: pColdI and pColdTF, Section 2.2.2.4. 
 













Figure 3.10: schematic representation of cloned PDED catalytic domain gene of L. 
infantum into pColdI vector. Vector diagram was designed using SnapGene software. 
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Trigger Factor (TF) is a prokaryotic ribosome – associated protein of 48 
kDa acts as a chaperone to enhance co-translational modifications of 
PDED in the hope it will improve its folding by reducing formation of 
Inclusion Bodies (IBs). 
For current study construct_1 of L. infantum was used, Figure 3.8.   
 
 
Figure 3.11: schematic representation of cloned PDED catalytic domain gene of L. 
infantum into pColdTF vector, Vector construct was designed using SnapGene software 












Figure 3.12 shows Ni-NTA purification of a small-scale expression 
where standard E. coli T7 expressed cells were used with standard 
expression conditions for this system, Section 2.2.1.7.1. Figure 3.12, 
highlights that use of the pColdTF expression vector yielded reduced 
insoluble material in the pellet fraction with expected molecular weight 
of TF_HisTag_PDED construct being 87.4 kDa, and some soluble 
material in a supernatant fraction.  Since this significant improvement in 
protein solubility was observed it was decided to proceed studies on L. 
infantum PDED construct_1 with the additional use of the Takara 
chaperones plasmid set, which could further improve soluble protein 
yields. 
pColdTF                pColdI 
 
     P      S       P      S 
Figure 3.12: SDS-PAGE of Ni-NTA small scale expression of L. infantum PDED 
catalytic domain in pColdI and pColdTF vectors. 
 Key: 1 – PDED in pColdTF pellet 
         2 -  PDED in pColdTF supernatant 
         3 - PDED in pColdI pellet 
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3.2.6 Takara chaperone plasmid set 
To further improve protein solubility Takara chaperone plasmid set 
would be used where PDED would be co-expressed with 5 different 
plasmids, Table 3.1. 
 
 
Table 3.1 represented characteristics of chaperone plasmids where each 
plasmid was carrying chloramphenicol resistance genes. Therefore, when 
competent cells were prepared (see Section 2.2.2.1.5) containing different 
chaperone plasmids it was possible to identify if the transformation was 
successful. Chaperones have araB and Pzt-1 promoter’s genes therefore 
chaperones and protein of interest could be expressed by using different 
induction agents, Table 3.1. 


































Pzt-1 Tetracycline Chloramphenicol 






Table 3.1: Takara chaperone plasmid set, Takara product manual  














Small scale expression (20 ml) was used to assess soluble expression 
levels, it was important to maintain the same number of cells in order to 
keep the results accurate and reliable for comparison with the 5 different 
chaperon plasmids. Co-expression of PDED were performed and western 
blot analysis was used. Primary antibody anti – HisTag was used in 
western blot analysis to identify the best co-expression system for PDED, 
Figure 3.14. TcrPDEB1, a protein with high level of soluble expression 
was used as a control. 
Figure 3.13: Schematic diagram of chaperones functioning during 
protein folding, (Takara chaperon plasmid manual) 























C            L       E7p     E7s       E8p     E8s      Tf2p   Tf2s   Tf16p  Tf16s    Gro7p    Gro7s 
Figure 3.14: Western blot of a small-scale co-expression of PDED catalytic 
domain in pColdI vector with 5 chaperone plasmids, where C – control and L – 
ladder marker, E – elution fraction  
37kDa 
Key:  
C – control 
L – ladder  
E7 – pKJE7 
E8 – pG-KJE8 
Tf2 – pG-Tf2 
Tf16 – pTf16 
Gro7 – pGro7 
S – supernatant  





Figure 3.15: SDS-PAGE of NI-NTA purification method of PDED 
(cloned in pColdTF) co-expression with Takara chaperon plasmid.  
            E7             E8             Tf2           Tf16                      Gro7 





E7 – pKJE7            E – elution fraction  
E8 – pG-KJE8 
Tf2 – pG-Tf2 
Tf16 – pTf16 
Gro7 – pGro7 
P – pellet 
S – supernatant  
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According to the western blot analysis, Figure 3.14, and SDS-PAGE as a 
measure of solubility of PDED in pColdTF, Figure 3.15, the highest level 
of PDED expression was observed with co-expression with the plasmid 
pGro7.  Chaperone plasmid pGro7 contained 2 chaperones GroES and 
GroEL that were cytoplasmic chaperones. GroEL is a prokaryotic protein 
that is found in prokaryotic cytosol where the main function is to hold 
and fold protein with cooperating factors GroES, Hsp10 and Cpn10 and 
being an ATP consumer. GroES is a sHTP type of chaperone and is 
found in the cytosol with the main function being holding and preventing 
protein aggregation during stress response. Both GroES and GroEL are 
ATP dependent (92). After the preferred expression system was 
identified, it was important to purify protein of high quality and high 
yield, in order to perform biochemical, biophysical and structural 
analysis, such as crystallization. Therefore, the next stage was to scale up 
and express larger quantity of cells and further optimization of expression 
and purification conditions including different fermentation strategies 
with different additives.  
 
3.2.7 Optimization of Protein Expression and Purification 
The 1L co-expression of PDED with chaperone plasmid was induced 
under the same conditions as small scale culture, Section 2.2.1.7.1, in order 
to see if the expression level would be consistent, but also with additives to 
investigate optimization of protein yield and quality. Different 
concentrations of the inducing agent arabinose were tested from the range 
of 1mg/ml to 5 mg/ml where Gro-ES and Gro-EL genes of chaperones 
were induced. There were 2 pCold expressing vectors used: 
pColdI_PDED_cd and pColdTF_PDED_cd. After comparing results of 
expression from both vectors using 5 different concentrations of arabinose 
it was concluded that pColdI need higher concentration of inducer then 
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pColdTF vector, as using 4 mg/ml of arabinose in pColdTF co-expression 
led to decrease in amount of protein solubility. The optimum concentration 
for pColdTF was found to be 1.5 mg/ml while for pColdI the optimum was 







Salts NaCl, KCl 100-500mM Maintaining 
ionic 
strength 
Detergents Triton x-100 0.1%-1% Solubilizing 



















Ligands IBMX  Stabilization 
Metal ions Mg, Zn 1-10mM Stabilization 
and 
Solubilizing 
  Table 3.2: Additives used in buffers optimization, (93) 
 
Table 3.2 detailed the list of additives that were used in different 
variations and at different concentrations to improve protein expression 
yields. To compare additive’s effects on PDED expression, small scale 
culture (20 ml) was used with equal number of cells. The best results 
were obtained with buffer composition such as: 20mM Tris pH 7.5, 
500mM NaCl, 1mM DTT, 25mM sucrose, 10% (v/v) glycerol and 2mM 
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MgCl2. This buffer showed the most promising results in terms of PDED 
expression and amount of soluble protein being produced in the solution, 











Figure 3.16: IMAC purification of PDED catalytic domain, pColdI expression 
vector, co-expression with pGro7. Molecular Weights:  PDED – 37.2 kDa, 
GroEs/GroEl – 70kDa 
    P         S        FT      E        E        E       E      E          E        E       E  
PDED_HisTag 
GroES_GroEL 
Figure 3.17: IMAC purification of PDED catalytic domain, pColdTF 
expression vector, co-expression with pGro7. Molecular Weights:  
PDED_TF_HisTag – 87.4 kDa, GroEs/GroEl – 70kDa 
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After finding an appropriate purification conditions, where soluble PDED 
catalytic domain was obtained it was important to analyse protein quality 
and activity by biophysical and biochemical techniques, such as: protein 
crystallography and enzymatic activity assay.  
 
3.2.8 Enzymatic Activity Assay and Further Optimizations 
A key experiment was to assess PDED enzyme activity after 1st step of 

































PDED_cd activity, pColdI_PDED 
Figure 3.18: enzymatic activity assay of PDED that’s was expressed in 
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According to Figure 3.19, PDED that was co-expressed in pColdTF 
vector with GroEL and GroES chaperones had 4.5 times higher activity 
level in comparison to pColdI protein.  PDED that was expressed in 
pColdTF vector was fused to trigger factor, which may prevent the 
protein degradation resulting in a more stable and active PDE to catalyse 
cAMP hydrolysis. Based on the activity assay results it was decided to 
continue to progress scale up and purification of PDED fused with the 
trigger factor.  
The next step was to optimize purification conditions to maximize protein 
yield of correctly folded material. During each step of purification, i.e. 
IMAC, IEC and SEC, buffer conditions were varied in order to see which 
component would enhance solubility of protein and its expression level. 
Such techniques as IEC and SEC would be used in order to improve 
protein sample purity. The main reason behind was that only highly pure 
protein material can be used in crystallography. The gel filtration 
chromatography (SEC) was used as the last step in protein purification 
where protein would be analysed according to its size and how 
homogenous the sample was. Before proceeding towards analytical 
purification, it was necessary to cleave PDED from the HisTag_TF 
complex. Thrombin cleavage was performed overnight at 4 °C and 
followed by the 2nd run of IMAC purification where uncleaved PDED 
protein would be separated from HisTag_TF complex and other 
contaminants. In order to access protein quality after 2nd Ni-NTA 
purification, western blot analysis was performed, Figure 3.20. 
 
Figure 3.19: enzymatic activity assay of PDED that’s was expressed in 
pColdTF vector. Experiment was performed by using Lonza assay kit. 










The Figure 3.20 showed PDED state in the solution where 3 different 
cleavage conditions were analysed: incubation with thrombin at room 
temperature and 4°C for 2 hours and incubation of PDED with thrombin 
overnight at 4°C. According to the Figure above 3.20, samples incubated 
at room temperature and 4 °C showed protein degradation as different 
molecular weights fragments could be visualized from the western blot. 
The flow through sample that was supposed to contain only cleaved 
sample also contained uncleaved PDED that was still fused with 
TF_HisTag complex.  This experiment showed that thrombin cleavage 
was not efficient and PDED couldn’t easily be separated from uncleaved 
sample by this single step. One possible reason could be protein 
misfolding where aggregated parts of PDED were attached to soluble 
cleaved PDED, due to its high concentration in a protein sample, hence 
preventing cleaved protein separation.  
 




C – control 
RT – room temperature  
CL – cleaved  






Figure 3.20: Western blot analysis of PDED after thrombin cleavage. Purification 
was performed using affinity NI-NTA column. 
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3.2.9 Size Exclusion Chromatography 
Since the protein separation from HisTag_TF complex caused issues it 
was decided to try and separate PDED by directly using SEC 
chromatography. Two separate samples of secondary Ni-NTA 
purification, Figure 3.20, would be used on SEC. The chromatography 
diagram of SEC at absorbance of A280 nm would show peaks according 
to protein molecular weight where PDED could be eluted separately from 
other contaminants.  
 
This approach was also used to access how homogenous protein was and if 
this PDED construct was suitable for crystallization trials. According to 
the Figure 3.21 both runs A and B showed poor separation of protein from 
its aggregates and HisTag_TF complex. Both runs contained the protein of 
interest; however, aggregates were the predominant species in the sample. 
Also, after a short storage time, when sample was accessed on western blot 
there was more degradation, suggesting that aggregates parts in sample 
further promotes PDED degradation. Therefore, it was concluded that 
misfolding of PDED made this protein unsuitable for further analysis using 
crystallography. After investigation of several rounds of gel filtration it 
Figure 3.21: SDS-PAGE of elutions after SEC. 2 separate runs: A – 
uncleaved PDED from HisTag after 2nd run of IMAC and B – cleaved 
PDED after 2nd run of IMAC 
A                       Uncleaved                             B                            Cleaved  
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was still not possible to obtain highly pure PDED catalytic domain and the 
concentration of the cleaved sample decreased as protein tended to degrade 
after each purification run.  
 
3.2.10 N-terminal Region of PDED  
According to the previous results where the main focus was on catalytic 
domain of PDED, analysis of protein expression and its behaviour in 
solution revealed that PDED was insoluble and a number of 
optimizations were required, such as: cloning, expression and purification 
in order to solubilize protein and express it. Since PDEB contained 2 
domains upstream of the catalytic domain (Gaf-A and Gaf-B) it was 
suggested that PDED could potentially contain upstream domains that 
influenced its solubility and potentially regulate its PDED activity (94).  
Therefore, it was decided to express and check enzymatic activity of N-
terminal region of PDED to investigate if there are any unknown domains 
that could potentially have cyclic nucleotide phosphodiesterase activity. 
The sequence of N-terminal region was amplified by using PCR, Section 
2.2.2.3. and cloned into modified pET15b_TEV vector as described in 
Section 2.2.2.5, Figure 3.22. 
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The N-terminal region was expressed in Rosetta 2 (DE3) competent cells 
that were already transformed with chaperon plasmid pGro7. The choice 
of this chaperon plasmid was due to the fact that this system yielded the 
highest level of soluble protein material with co-expression with 
chaperones GroES and GroEL, Section 3.2.6 for the catalytic domain of 
PDED.  Preliminary attempts at expression of the N-terminal construct 
showed that half of the expressed material was in the pellet fraction 
suggesting that protein was misfolded similar to the catalytic domain 
PDED, Section 3.2.3. 
Although not fully purified the supernatant fraction was assessed for PDE 
enzymatic activity assay but no PDE activity was observed, suggesting that 




Figure 3.22: N-terminus of PDED L. infantum cloned into pET15bTEV. Vector 
construct was designed using SnapGene software.  
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3.2.11 L. infantum PDED, full length  
The full-length gene sequence of L. infantum PDED was cloned into 
pOPINF vector and expressed in E. coli cells, Section 2.2.2.5. Analysis of 

















Isoleucine AUA 2 
Leucine CUA 3 
Proline CCC 9 
Threonine ACG 22 
PDED was analysed in terms of the occurrence of rare codons. From 725 
codons in the full-length sequence of L. infantum PDED sequence, 61 
were rare codons. Therefore, it was suggested to use a bacterial strain that 
was particular in use for expressing proteins with rare codons. Rosetta™ 
2 (DE3) host strains (DE3) were a derivative of BL21 and were used to 
express proteins with higher numbers of rare codons. Figure 3.22 showed 
an SDS-PAGE where full length of L. infantum PDED was expressed 
using small scale expression method, Ni-NTA.   
Table 3.3: Sequence analysis of rare codons occurrence in L. infantum PDED full length 









The expected molecular weight of full length PDED was 85.3 kDa. 
According to the Figure 3.23, SDS-PAGE showed multiple bands around 
expected size however it wasn’t possible to determine if it was L. 
infantum PDED full length. However, despite the low signal, it was 
decided to continue with the purification to optimize purified yield. The 
same expression conditions of PDED catalytic domain were used for 








Figure 3.23: SDS-PAGE of IMAC purification of L. infantum full length 
PDED. Expression in Rosetta 2 (DE3) cells. P – pellet fraction, FT – 
flow through, W – wash fraction, E – elution fraction.  





                                                       S        FT       E 
Figure 3.24: SDS-PAGE of IMAC purification of full length PDED.  
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The expected molecular weights of proteins to be expressed were 70 kDa 
of GroES fused with GroEL and 85.2 kDa of full length PDED. According 
to the figure above there was good expression of the GroES - GroEL 
construct, whereas full length expression couldn’t be detected. Hence, the 
next step was to optimize growth conditions. Magnesium was used as an 
additional additive in the 2YT media during bacteria growth and further 
protein expression. Magnesium acts as cofactor for many enzymes and 
helps proteins to fold correctly, as well as it could also be found in cell 
walls. Magnesium Sulphate was also believed to act as an additive that 
suppress selective pressure on bacteria cells during proteins expression, 
hence promoting expression of high molecular weight proteins (95). The 
Rosetta 2 (DE3) cells, used in current experiment, were transformed with 
pGro7 plasmid for co-expression with PDED full length cloned into 
pOPINF vector, Section 2.2.2.4 and 2.2.2.5. Bacteria were growing in 2YT 
media and 2 different combinations of additives were used: 1st media - 
25mM sucrose and 2mM MgSO4; 2nd media - 12.5mM glucose and 2mM 
MgSO4. Cells were induced at OD600 0.6-0.7, where the cells could 
sustain a good level of protein expression. After induction, the cells were 
harvested. The 1L of cell culture with sucrose and magnesium gave 18 
grams of cells, while the same amount of cell culture with magnesium and 
glucose gave 14 grams of cells. The protein purification buffers used were 
the same as used in the case of PDED catalytic domain, Section 2.2.1.7, 
but with the addition of 100mM of ZnCl2 and 50mM Arginine. As PDEs 
are known to have 2 metal ions bound in the active site of the catalytic 
domain, the addition of Mg and/or Zn can improve protein solubility and 
help minimize misfolding of protein. Since the expressed protein was 
fused with HisTag, the IMAC purification method was used where elution 
fraction gave 15.8 mg of total protein where with full length L. infantum 
PDED protein was with the mixture of other host protein contaminants. 
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The purification of full length was performed similar to previous 
purification (Section 3.2.7.)  but with an increase of the concentration of 
imidazole in the wash buffer in order to remove more contaminants. Figure 









Figure 3.25 showed efficient tag cleavage and highlights this expression 
media was more preferable for full length PDED. The clear band on the 
gel, is at the expected molecular weight of full length PDED at 85.3 kDa.  
The sucrose media showed the highest level of protein solubility as 
compared to the glucose media.    
 
3.2.12 Leishmania Donovani PDED  
L. donovani PDED was the 2nd target protein where no preliminary data 
was available at that time. The PDED was amplified by PCR from the 
strain MHOM/IN/1983/AG8 that was provided by the University of 
Antwerp.   
Analysis of full-length sequence was performed by using Pfam and Phyre 
software where catalytic domain constructs were designed. The catalytic 
                                Sucr/MgSO4          Glu/MgSO4 
PDED_fl 
Figure 3.25: SDS-PAGE of IMAC, His-Tag cleavage of PDED 
full length  
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domain was cloned into pET15bTEV modified vector, Section 2.2.2.4, 
Figure 3.26. 
Small scale expression conditions were used as with L. infantum PDED 
catalytic domain, Section 2.2.1.7.1. The sequence alignment of L. infantum 
and L. donovani PDED revealed that PDED sequence was highly 
















Figure 3.26: L. donovani PDED catalytic domain cloned into 
pET15bTEV. Vector construct was designed by using SnapGene software. 
Figure 3.27: protein sequence alignment of PDED full lengths between L. 
infantum and L. donovani. MultALign software was used. 
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The Figure 3.27 shows the protein sequence alignment between L. 










The following results showed that catalytic domain of PDED in L. 
donovani was insoluble in solution and overexpressed protein was only 
observed in a pellet fraction. L. donovani PDED catalytic domain was 
cloned into pCold vector suite where 2 vectors were used: pColdI and 
pColdTF. The same expression and purification conditions were used as 
in Section 3.2.7, where L. infantum was expressed. Unfortunately, L. 
donovani expression didn’t reveal any differences in soluble yield when 
compared to L. infantum and the protein was also prone to aggregation as 
soon as it was cleaved from the trigger factor. Therefore, it was decided 
not to proceed further with the analysis of L. donovani PDED since the 
protein showed a similar pattern of poor expression and solubility. 
However, it was interesting to see if different species that cause another 
                     P1     P2     E 1     E2 
Figure 3.28: NI-NTA purification. SDS-PAGE of small scale expression of L. 
donovani PDED catalytic domain. P – pellet, E – elution, Molecular Weight: 
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parasitological disease would show any differences in protein behaviour 
since PDED proteins sequences are more diverse. The next study was to 
analyse protein expression of T. brucei PDED.  
 
3.2.13 Trypanosoma brucei PDED, catalytic domain  
The next protein target to analyse was a PDED from an alternative 
kinetoplastid, such as Trypanosoma brucei, the kinetoplastid that causes 
African trypanosomiasis.  The first step was to see how similar catalytic 
domains of PDED are between Leishmania and Trypanosoma. Figure 3.29 
shows the protein sequence alignment of PDED catalytic domains where 2 
sequences appear genetically distinct from each other with less than 60% 
identity. A similar broad approach to that performed in Section 3.2.1.5, 
was carried out with T. brucei PDED co-expression with 5 chaperones 




Figure 3.29 protein sequence alignment of PDED catalytic domains from L. 
infantum an T. brucei.  






Amplification and cloning steps were initially performed by Dr. Abhi 
Singh, where a construct of comprising residues 412-670 showed the best 
expression level. This construct was cloned into pET28a vector with 
HexaHisTag at the N-terminus. The pET28a_PDED_Tbr construct was co-
expressed with 5 chaperones plasmids. Figure 3.30. The most soluble 
C                1       2         3       4        5       6        7      8                            9     10   11     12      13   14  
Figure 3.30: NI-NTA small scale expression. SDS-PAGE small scale co-expression 
of catalytic domain PDED from T. brucei  
Key: 
1. pG - Tf2, TB media, ethanol, pellet 
2. supernatant 
3. pG-KJE8, TB media, ethanol, pellet 
4. supernatant  
5. pG - Tf22YT, sucrose, pellet 
6. supernatant  
7. pG - Tf22YT, ethanol, pellet 
8. supernatant  
9. pG-KJE8, TB media, ethanol, pellet  
10. supernatant  
11. pG-KJE8, 2YT media, sucrose, pellet  
12. supernatant  
13 - pG-KJE8, TB media, sucrose, pellet  
14 – supernatant  
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protein was obtained with its co-expression with chaperon plasmids: pG-
KJE8 and pG - Tf2.  
Small scale expression of T. brucei PDED catalytic domain revealed that 
the most preferable conditions for solubilizing of PDED protein was its co-
expression with chaperon plasmid pG-KJE8 in TB media in addition of 
25mM sucrose where sample 12 showed the highest amount of soluble 
protein with the least degradation pattern in comparison to other samples, 
Figure 3.30. The next step was to scale up expression in 2L of bacteria 
culture, where the same growth conditions were used. Attempts to purify 
T. brucei PDED catalytic domain, with a series of purification steps, such 
as: IMAC, IEC and SEC chromatography was planned. However, during 
the 1st step of purification (IMAC) PDED was found in a pellet fraction 
only indicating that misfolding mechanism was predominated leading to 
insoluble protein being produced. 
 
3.3 Conclusion  
PDED was a potential novel drug target that previously had not been 
characterized and expressed. Although PDEs were known to be an 
important enzyme that plays a crucial role in parasitic survival, since the 
late 1980’s, there was little information regarding the role of parasitic 
PDED and hence the focus of this study.  As previously mentioned, 
kinetoplastid parasites such as T. cruzi, T. brucei and Leishmania species 
have highly conserved sequences among each class of PDE: PDEA, 
PDEB, PDEC and PDED (96). Some preliminary work in amplification 
and cloning was done in T. cruzi and T. brucei where different constructs 
were designed with various mutations being introduced. The main issue 
with the initial PDED expression was its solubility in solution and the 
proteins only appeared in a pellet fraction and not in the supernatant hence 
further purification and characterization was not possible. As mentioned 
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earlier, preliminary work was done on parasitic PDEDs by Dr. Abhi Singh 
(T. brucei) and by Dr. Susanne Schroeder (T. cruzi) where multiple protein 
constructs yielded no soluble protein. 
In current study the primary focus was on Leishmania species, namely L. 
infantum and L. donovani. 
This chapter describes the first expression and purification of an active 
soluble parasitic PDED catalytic domain construct from L. Infantum. This 
protein could be expressed and purified and was active when it was fused 
to the trigger factor, however once cleavage was performed there was a 
significant loss in the activity due to protein degradation.  
Full length PDED was also expressed and purified however the protein 
was not sufficiently stable to perform enzyme assays.  
These results demonstrate that PDED protein folding machinery required 
significant optimization, including addition of fusion tags and chaperones 
as well as extensive investigation of expression and purification including 
additives.  The approach used for L. Infantum also yielded low levels of 
soluble protein for L. donovani PDED however the protein suffered from 
the same instability issues after removal of tags.  Further experiments 
utilizing similar approaches on T. brucei PDED yielded substantial 
improvements in soluble expression levels in a chaperone dependent 
manner but once again proteins were liable to degradation.  
In summary novel proteins were cloned, expressed, purified and 
characterized.  New protein expression approaches were developed, as 
standard approaches only yielded insoluble proteins. This approach 
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Chapter IV 
 
Developing and testing a Fluoro fragment library 
for use by NMR, X-ray crystallography and SPR, 
exemplified on human PDE5. 
 
4.1 Introduction  
This chapter describes the generation and initial analysis of a new 
fragment library of fluorinated fragments comparing hit rates using 
different biophysical screens. 
 
       4.1.1. Development of a Fluorine Labelled Fragment Library  
Substitution of hydrogen atoms by fluorine in drug compounds is a widely 
used approach in drug discovery, which can improve drug potency as well 
as its pharmacokinetic properties and metabolic stability. Fluorine 
containing compounds and fragments can also be exploited by fluorine 
NMR. The much simpler fluorine spectrum, compared with proton spectra, 
allow mixtures (or cocktails) of larger numbers of fragments to be 
screened, as compared to proton ligand observed NMR, thus reducing the 
time to analyse hundreds of potential fragments. We report here on the 
results of screening a library that was co-developed between the groups of 
Dave Brown at the University of Kent and Charles River, and Maybridge.  
The library selection was filtered from 5227 compounds of all fluorinated 
compounds in the Maybridge collection. The physicochemical property 
thresholds were used (97) ensuring certain criteria were met:  
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140 < MW <300, 
logP ≤ 3, 
rotatable bonds ≤ 4, 
rings ≤ 4, 
HBA/ HBD ≥ 3 
 
Overall 954 compounds were selected. Then fingerprints were calculated 
using MOE syl script written by Andrew Henry, Chemical Computing 
Group. The algorithm was based on that was of Vulpetti (98). The results 
were as follows: 317 clusters at 85% similarity and 768 clusters at 90% 
similarity. This was followed by removal of potentially mutagenic 






























































Figure 4.1 shows the properties of the final fluoro library selected after 
solubility and purity tests were checked using NMR spectra recorded for 
all individual compounds (work performed by Denisa Hoxha at CRL in 
Dave Brown’s lab). The majority of compounds showed good solubility 
(compounds that showed poor solubility in DMSO at 100 mM were 
Figure 4.1: Fluorinated Library Properties, Maybridge   
   127
excluded), Figure 4.2. The final fluorine file contained 421 compounds 
that were used in NMR, SPR and XChem experiments. 
 
 
Figure above 4.2 showed the proportion of precipitated compounds 
towards soluble compounds. As it was important to exclude fragments 
prone to precipitation from the final library list. When the library was 
compiled, it was important to test it on a well-behaved target on which 
fragment screening had previously been performed and for which a 
Low Solubility in DMSO
Soluble to 100mM in DMSO
Figure 4.2: Fluoro fragments solubility properties 
Precipitation (1mM in PBS / 5% DMSO)
Soluble (1mM in PBS / 5% DMSO)
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suitable soakable crystal systems for X-ray crystallographic follow up was 
already in place. There were two proteins selected that were used in SPR 
screening in collaboration with Steve Irving at Charles River, namely 
human PDE5 (catalytic domain) and human bromodomain - containing 
protein 4 (BRD4 - BD1). The fluoro library was screened by SPR at 100 
M against biotinylated proteins that were captured on a CM5 SPR chip 
derivatised with streptavidin. The following figure summarise the results 
for 2 proteins, Figure 4.3. The line that can be observed from the Figure 
4.3 was an arbitrary line that was used to define an Rmax value where 
“good binders” were separated from the “poorer binders”.  
According to the Figure 4.3, fragments from fluoro library were well 
behaved in the system and the majority of binders showed ‘square wave’ 
sensograms which is indicative of fast on/off binders. Fragments which 
exhibited non-specific binding effects were rejected from the final list of 
hits. The hit cut off for PDE5 was set at a normalised response of 38 RU 
for PDE5 as a relatively large number of hits were obtained (giving a hit 
rate of 5.9 %), while a lower hit rate (2.9 %) was observed for BRD4 – 
BD1 with an RU cut off of 3.2. The study also allows comparison of the 
hits and hit rates of the different biophysical techniques but also further 
analysis of the binding mode of fragments against human PDE5 which is 
of interest as these may be generic PDE binders.  
 
Figure 4.3: SPR screening of Fluoro fragment library using human PDE5 catalytic 
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4.2 Results  
4.2.1 NMR Data  
NMR fragment screens can be a very time-consuming process. In the 
current experiment the fluoro fragment library was used where large 
number of compounds would be screened in each mixture, in order to 
minimise the running time and consumables. Each mixture contained 
between 8 to 23 compounds. There were NMR constraints that had to be 
followed when composing the compound mixtures: maximum spectral 
window 30 ppm, ideally a minimum of 0.5 ppm between fragments, 
fragments to be mixed in a final volume of 650 l in D2O and final ligand 
concentration in mixtures was 0. 1 M (stock concentration of 100 M). 
After careful examination of each fragment and preparing mixtures, 28 
fragment cocktails were prepared. The example of mixture 14 is illustrated 
in Figure 4.4. 
There were 2 samples made of each mixture where 1 was without protein 
and used as a control and 2nd one with the PDE5 protein. The protein 
concentration was 5 M in the 650 l mixture, and the total protein usage 












 Figure 4.4: NMR Mixture 14 
































Each fragment mixture was run through the NMR 19F CPMG (spectra 
where Fluorine atom is used to identify a binding event) experiment where 
B 
A 
Figure 4.5: 19F CPMG experiment of mixture 14. A) overlay of mixture with 
and without PDE5 protein, B) drop in signal of binding. Key: Blue Peak – 
mixture without the protein, Red Peak – mixture with the protein 
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the total run time was 72 hours. To identify if there was binding of one or 
more fragments in a mixture, the peaks of two different NMR runs 
compared with the spectrum of mixture of fragments would be overlaid 
onto the spectrum of the equivalent mixture in the presence of the protein 
(hPDE5) to detect if there was any drop in the peak height, Figure 4.5 A 
and B.  
Figure 4.5 A represents the spectrum of mixture 14. The overlaid spectrum 
shows the peak intensity drop, where red peak is the run of mixture 14 
with the hPDE5 and blue peak is the mixture without the protein, Figure 
4.5 A.  Figure 4.5 B represents one of the peaks corresponding to one 
fragment from the whole mixture. It can be observed that there was a drop 
in the signal which means there was a binding between hPDE5 and the 
fragment. To identify the intensity of peak drop TopSpin software was 
used where integral values were calculated by using chemical shift’s 
values from NMR runs. A > 50% drop was considered as a strong binder 
and < 50% as a weak binder.  In the current example, the identified 
fragment bound to hPDE5 had a peak drop of 70.71% suggesting it was a 
strong binder.  
Out of 421 fragments that were run in mixtures by NMR, 101 fragments 
showed a peak intensity drop of > 95%. These fragments were classified as 
strong binders, however to further test this and study the interactions in 
more details X-ray crystallography was required.  
34 fragments were selected for further validation by X–ray 
crystallography, on the basis that those fragments were identified as strong 
binders by either NMR and/or SPR screens and some classified as such by 
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Fragment NMR SPR 
 19F CPMG Chemical Shift Kd (uM) % of max Response 
AW01202 -115.4 ppm 
 
  
















BTB05938 -108.8 ppm 
 
  
HTS05996 -109.5 ppm 
 
  
MO01209 -113.5 ppm 
 
  
HTS03409 -61.7 ppm 
 
  
CD04945 -116.2 ppm 
 
  
SP01339 -122.3 ppm 
 
  
SEW05128 -62.5 ppm 
 
  
RF00744 -110.6 ppm 
 
  
CD08996 -115.4 ppm 
 
  
MO07029 -119.9 ppm 
 
  
S11211 -112.6 ppm 
 
  






HAN00244 -70.5 ppm 
 
  












CD07436 -107.7 ppm 
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KM09455 -64.4 ppm 
 
  
RF04864 -73.6 ppm 
 
  
CD11422 -119.7 ppm 
 
  
KM02354 -117.6 ppm 
 
  
BTB07539 -121.7 ppm 
 
  




















SEW05363  ND 45.8 
BTB07539 
 
-121.7 ppm   
KM06103 
 




22 fragments out of 34 were identified as strong binders in NMR but not in 
SPR, 2 out of 34 fragments were selected for being strong binders in SPR 
but not strong binders by NMR, 10 were strong binders in both NMR and 
SPR screens. There were 11 compounds that were tested in both SPR and 
NMR screens, Table 4.1, and were further validated by manual 
crystallisation. 
 
4.2.2 Correlation between NMR and SPR Data  
The highest SPR response value was observed with fragment CD07988, 
where the NMR screen showed that it was a weak binder and hence wasn’t 
chosen for manual data collection. The lowest value for SPR run was 
Table 4.1: 32 selected hPDE5 Fluoro fragments by NMR and SPR screens 
for manual crystallization 
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obtained for fragment CC53013. That fragment wasn’t run on NMR due to 
the reason that it didn’t pass quality control (QC) test where each fragment 
was run individually and showed more then 1 peak meaning of possible 
contamination. The second lowest SPR data was obtained with fragment 
SPB02475 where NMR run also confirmed it was a weak binder. TG00013 
fragment showed the lowest Kd value. This fragment was run on NMR in 
mixture 22 where the chemical shift identified it as a strong binder. 
Another fragment that was also picked up by SPR and NMR screening was 
fragment SPB06580. RJF00210 fragment was also identified by SPR and 
NMR screens as a strong binder. Next fragment that was identified as a 
strong binder by NMR was RF04864 with SPR run couldn’t determine its 
Kd value.  RDR03354 was identified as a strong binder with NMR and 
SPR screens. HTS04838 was run in a mixture 18 where NMR chemical 
shift and SPR Kd values showed that it was a strong binder. Next fragment 
that was determined as a hit was HTS04341 with both screens, however 
NMR identified it as a weak binder. CD07436 was run on NMR and SPR, 
whereas SPR Kd value was not determined. Fragment CD04945 was 
identified as a PDE5 hit on NMR run but the SPR screen did identify it as 
a binder but no Kd value could be determine. BTB06033 was identified in 
both screens. Therefore, this compound was classified as a strong binder 
according to the data obtained from the two screens. BTB05106 was 
classed into a group of strong binders were both values from NMR and 
SPR suggested it. Next fragment that was used in both screens was 
fragment BTB02754 where SPR data was as well as NMR chemical shift. 
Fragment BTB00588 was identified as a strong binder with NMR and SPR 
runs. Current subchapter compared data, Table 4.2, that was obtained from 
SPR and NMR screens where one method determined compound as a 
stronger binder while the other one classified it as a weak binder. Those 
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fragments that showed different results were excluded from the manual 
crystallization.  
BTB00588 4.2 uM 50% 
CD07988 66.2 %, 340 uM 41% 
CC53013 22.9% X 
SPB02475 37.2% 38.14%. 
TG00013 0.9 uM 50% 
SPB06580 12 uM 50 % 
RJF00210 60 uM 50 % 
RF04864 X 50% 
RDR03354 32.5 uM 59.9 ppm 
HTS04838 69 uM 50% 
HTS04341 9.2 uM 117 ppm 
CD07436 X 107.7 ppm 
CD04945 X 50% 
BTB06033 178 uM 50% 
BTB05106 89 uM 50% 
BTB02754 60 uM 105.7 ppm 
 
 
4.2.3 Manual Soaking 
There were 34 fragments that were selected for manual X-ray soaking, 
where only 32 diffraction data was collected as other 2 soaks didn’t 
survive the shipment to Diamond Synchrotron. Initial human PDE5 
crystals were provided by Colin Robinson from Charles River company. 
New trays were created with similar reservoir conditions to the crystal 
trays. Fragments were created as singletons and were added to 50 µl of 
reservoir solution (-IPA) to a final concentration of 1 mM (stock =100 mM 
therefore 0.5 µl of fragment was added) to make a ratio of 1:3. Then, 1 
crystal was transformed to 1 µl of the fragment solution and left soaking 
for 1-2 days. After, crystals were transformed to a cryoprotectant (30% 
glycerol) and transferred to pucks. Out of 34 compounds 32 fragments 
from Table 4.1 gave diffraction data. The crystallographic data was further 
refined by other lab members. 
Table 4.2: comparison of SPR and NMR data 
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PDE5 X-ray structures were solved by other lab members hence the 3D 
structures were not included in current chapter.  
 
4.2.4 XChem Data  
XChem (https://www.diamond.ac.uk/Instruments/Mx/Fragment-
Screening.html) is a platform developed at the Diamond Light Source 
Synchrotron for high throughput, automated crystallography. Users to first 
identify suitable conditions (DMSO tolerance, ligand soaking time and 
ligand concentration) and then screen a large number of fragments once a 
suitable soaking crystal system has been established. Software developed 
for the platform, XChem explorer, combined with use of PanDDA maps 
also allows the identification of very week binding modes with as little as 
10% occupancy that are unlikely to be identified by NMR or SPR.  
The fluoro file were also analysed crystallographically by performing 
XChem on the library where just 376 compounds were selected to align 
with the 384 well low volume echo dispensing plates. The main aim was to 
further validate the final list of strong PDE5 binders. 











Figure 4.6: Summary representation of number of fragments that were validated by 
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Out of 376 compounds only117 soaks gave high quality diffraction data, 
representing 31 % of all fragments. 51 fragments were identified as binders 
through the XChem pipeline. Out of all fragments found in XChem only 2 
were also identified by either SPR and/or NMR techniques and only 1 
fragment – HTS04341 was identified by all 4 techniques, Figure 4.6.  
A clear observation is that XCHEM seemed to find a number of weaker 
hits (which were not listed in NMR or SPR experiments as these hit lists 
were focussed on strong binders) but failed to detect nearly all strong 
binders previously identified. A possible reason is crystal lattice disruption 
by more soluble potent binders at high soak concentrations and long soak 
times. 
 
4.3 Conclusion  
The chapter describes the development and testing of a fluoro – fragment 
library, with the aim of validating the library and examining if fragments 
would be detected by more than one biophysical technique. The 
compounds for the fragment library were provided by Maybridge and the 
initial step was to check fragments suitability for inclusion. It was very 
important to identify if fragments were soluble enough and testing there 
was no precipitation since encountering such problems during the actual 
experiment would reduce experimental accuracy.  The initial library was 
comprised of 590 fragments and was cut down to 421 fragments when 
each fragment was individually analysed on NMR spectra.  Since most 
fragments contained one Fluoro atom in its structure then 1 peak should be 
visualized on NMR spectra only. Obviously, there would be additional 
peaks for the two and three fluorine containing examples. If additional 
peaks would be obtained it would indicate that there were contaminations. 
The final list was made of 421 fragments that were used for compiling 
mixtures. Since only 1, 2 or 3 peaks would be observed from each 
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fragment it was suggested to combine 8 – 23 fragments in one mixture 
without spectral overlap, in order to minimise the NMR running time as 
well as protein consumption. After spectra analysis using TopSpin 
software 101 fragments were classified as strong binders with more than 
50 % drop in signal when hPDE5 was bound to Fluoro fragment. It was 
then important to see if the same fragments would be validated by SPR, 
XChem and manual crystallization. By comparing data that was obtained 
after performing SPR, XChem and manual crystallization, only 1 fragment 
was identified by all 4 biophysical methods. XChem gave the least positive 
data as only 2 fragments were identified as hPDE5 binders out of 376 
compounds that were loaded onto XChem pipeline. One of the main 
reasons could be crystal lattice disrupted by more soluble potent binders at 
high soak concentrations and long soak times. Even though, that hPDE5 
crystal system is believed to be a robust system for fragment screening, 
issues were encountered during the XChem, suggesting that experimental 
optimisations have to be done in order to make XChem more suitable for 
high throughput data collection with this protein target and fragment file.  
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Chapter V 
 
Biophysical Analysis of 
TbrPDEB1 using Biophysical techniques:  
XChem and SPR 
 
 
5.1 Introduction  
TbrPDEB1 is a validated drug target (99), where inhibitors of this enzyme 
lead to an increase of intracellular levels of the secondary messenger 
cAMP, causing the cell death. It has been shown by Seebeck et al that a 
dual knockdown of PDEB1 and PDEB2 led to altered cell division in 
parasite, resulting in the cell death and hence elimination of infection (18). 
Previous studies used human PDE inhibitors as a starting point for 
developing a new generation of antiparasitic drugs that could be potent and 
selective parasitic PDEs inhibitors (100). The most advanced PDE 
inhibitors that have been designed for antiparasitic treatment were 
piclimast derivatives developed by the group of Leurs at Vrije University 
of Amsterdam (VU) (46). However, a major challenge that still remains is 
to improve selectivity towards parasitic PDEs over human PDE isoforms. 
A key strategy would be to target the unique P – pocket found in parasitic 
PDEs that is absent in human PDEs.  
The aim discussed in the current chapter is to identify and analyse 
TbrPDEB1 ligand binding using 2 structural biology techniques, namely 
SPR and X – ray crystallography.  
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5.2 Crystallography with XChem using the DSI – Poised 
fragment library 
There were 466 fragments that were used during the XChem experiment 
where individual TbrPDEB1 crystals were soaked with a single fragment 
through use of the Labcyte Echo acoustic nanoliter dispenser. Then, there 
was a manual inspection performed by me to see how many crystals 
survived. During the process 20% of crystals were lost, presumably 
through lattice disruption by the fragment dispensed resulting in them 
dissolving or severely cracking; or mounting failed due to poor or reduced 
mechanical robustness. After mounting and cryo protection the crystals 
were cryo cooled to 100 degrees K and stored in unipucks prior to X-ray 
data collection on the I04-1 beamline at DIAMOND. Data sets were 
collected following automatic loop centring using a standard protocol of 
1800, 0.1degree oscillation images with 0.1 sec exposure. During data 
collection, some crystals were clearly too small in size to yield high 
resolution data sets and some suffered radiation damage leading to failure 
of the automatic data processing with the XIA2 pipeline. All together there 
were 466 fragment soaks and 50 soaks with simple DMSO as controls. 314 
crystals were mounted, cooled and exposed to the X-ray beam. XIA2 and 
DIMPLE analysis showed that out of 314 data sets, 21 data sets failed to 
process. The final number of diffraction data that were subjected for 
PanDDA inspection was 293. Out of 293 samples, 75 were rejected 
through manual inspection of the processing results by the fact that 
samples were probably non – isomorphous or diffraction limits were too 
low. The highest resolution was 1.7 Å and the lowest utilised was 3.5 Å. 
From the remaining 218 data sets, 136 samples were classified as 
interesting data with evidence of fragment binding manually observed. 
Further, more detailed manual inspection of the PanDDA maps resulted in 
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61 high confidence hits and 10 medium confidence hits. PanDDa is the 
Pan-Dataset Density Analysis that enables users to investigate the bound 
compound in details with less or no noise. This work was performed on the 
DIAMOND computational cluster. These positive data were then 
downloaded to our local Linux machine and further analysed using the 
CCP4 software suite. In some cases, the map was too weak to 
unequivocally place a ligand hence that data was omitted from further 
study. Follow up work was focussed on 20 data sets where each structure 
was refined and where the binding mode could be clearly observed.  
There were certain parameters that were controlled and discussed before 
the actual experiment based on initial XChem screening. The soaking time 
remained as in the test run with the DSI Poised library subset, which were: 
2 hours and 4 hours. Since compounds were diluted in a DMSO it was also 
important to be consistent with that as DMSO could also potentially 
destroy the crystal lattice. From the screening experiment run where 
TbrPDEB1 crystals were soaked with a small subset of the DSI – Poised 
library the statistics was as following: 
- 20% DMSO with 3 to 4 hours of soaking gave more mounting 
consistency (less crystal damage)  
- 40% DMSO with 3 to 4 hours of soaking time  
- 25% DMSO with 3 to 4 hours of soaking time  
- 20% DMSO give total cryo protection as well  
According to the statistics 20 % DMSO was the most preferable 
concentration for crystal to survive as well providing a cryo protection. 
Therefore, it was decided to use 20% of DMSO as a target concentration in 
soaking.  
It was previously reported that TbrPDEB1 forms a unique open cavity (P – 
pocket) between helix 14, helix 15 and the M – loop. That cavity was also 
observed in structures of LmjPDEB1 and TcrPDEC (41). As previously 
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mentioned since the P – pocket is a unique feature to parasitic PDEs it 
could be used as a selectivity feature for designing new drug candidates 
against parasitic PDEs. The binding site for TbrPDEB1 consists of the 
following residues: Gln874, hydrophobic clamp - Val840 and Phe877 and 
aromatic residues - Phe844 and Phe880. The P – pocket binding site is 
characterised by composition of such residues as Ala837, Thr841, Tyr845, 
Asn867, Met868, Glu869 and Leu870, Figure 1.15 (46).  
Therefore, in the current experiment, fragments will be subdivided into 2 
main groups: binders in hydrophobic clamp and “selective” fragments that 
bind in or towards the P – pocket.  
 
5.3 Ligand – Protein Binding Mode 







Figure 5.1: Ligand 0074, N-[4-(2-amino-1,3-thiazol-4-yl) phenyl] acetamide 
Characteristics: C11H11N3O5 
 
Figure 5.2: FLEV plot produced by COOT of the binding site of chain B, first 
binding site  




The 0074 fragment data set was selected for further refinement where the 
fragment was found in 3 binding sites: 2 in chain B and 1 in chain A.  
Figure 5.3: Surface representation of the ligand binding site with the ball and stick 
representation of TbrB1 – 0074 fragment with |2Fo-Fc|calc map at a counter level of 
1.2 , chain B, first binding site in the hydrophobic clamp 
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Figure 5.2 represents ligand binding site environment where 9 amino acids 
surround the 0074 ligand. Chain B has 2 binding sites, in the first case the 
ligand was bound to a hydrophobic clamp between residues Phe877 and 
Phe844, Figure 5.3. The ring structure of the 0074 compound forms 
hydrophobic interactions with Phe877. Other protein residues such as: 
Asp822, Tyr668, Asn825, Val840, Phe844, Gly873 and Met861 also in 
close proximity to the ligand. The benzene ring of 0074 offers substitution 
vectors towards P – pocket but further computational analysis is required 
in order to model a possible analogue that will grow towards the P – 
pocket to increase its selectivity.  
 
The second binding site was at chain B that could also be considered as 
novel, Figure 5.4. 
Figure 5.4: Surface representation of the ligand binding site with the ball and stick 
representation of 0074 fragment with |2Fo-Fc|calc map at a counter level of 1.2 , 
TbrPDEB1, second binding site, B chain  


















Figure 5.5 represents the second binding site environment where Arg811 
forms an interaction with the benzene ring of the 0074 ligand. In this 
binding mode, the ligand is surrounded by amino acids: Ala807, Arg774, 
Arg811, Asp778, Ser775, Leu771, Met814, Glu698 and His810. The 
benzene ring forms hydrophobic interaction with the Arg811 side chain 
and the positively charged guanidine group of the Arg811 positioned over 
the carbonyl moiety of 0074. On the other side of the ligand there is a 
hydrogen bond between a water molecule and the NH2 group of the 4-
methylthiazol-2-amine ring structure of 0074 fragment, Figure 5.4.  
The third binding site appeared in chain A, is also in the hydrophobic 
clamp Figure 5.6. 
Figure 5.5: FLEV plot produced by COOT of the binding site, chain B, 
second binding site  
















Figure 5.6 Surface representation of the ligand binding site with the ball and stick 
representation of 0074 fragment with |2Fo-Fc|calc map at a counter level of 1.2  , T. 
brucei PDEB1, chain A hydrophobic clamp 
Figure 5.7: FLEV plot produced by COOT of the binding site of chain A, 
3rd binding site  
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Figure 5.6 represents the 0074 ligand binding site at chain A, and Figure 
5.7 shows the amino acids that surround the ligand.  
The fragment was bound to the characteristic binding site likewise in chain 
B. The benzene ring is located near Phe877 ring forming strong 
hydrophobic interactions. It can also be seen in the Figure 5.6, there were 
also 2 well-ordered water molecules.  
Out of 3 binding events, 2 were found occupying hydrophobic clamp that 
was formed by Val840 and Phe877 and the distal aromatic residues such as 
Phe844 and Phe880.  
 
TBrB1 – Ligand 0209 Crystal structure 
The next fragment data set of interest, from a novel binding mode point of 
view was 0209, Figure 5.8, where 2 binding sites were observed, in chain 
A and chain B respectively, Figure 5.10 and 5.11.  
Figure 5.8: Fragment 0209, 4-(2-phenoxyacetyl) piperazin-2-one  
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Figure 5.9 represents the binding environment of ligand 0209 in molecule 
B using Coot’s FLEV tool to highlight ligand protein interactions. The 
fragment is in the hydrophobic clamp which is a standard binding site. The 
benzene ring of the ligand was directed towards the P – pocket allowing 
the potential to utilise this vector for the design of new ligands to 
synthesise that may directly interact with the P – pocket residues. There 
were also additional interactions between the protein and the ligand that 
forms hydrogen interaction. The second interaction was shown to be 
between the hydrogen atom of benzene ring and oxygen atom of Asp822 
forming a CHO Hydrogen bond (101). 
Figure 5.9: FLEV plot produced by COOT of the binding site of chain B, first 
binding site  
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There is also a water molecule next to the Phe844 residue which also 
Figure 5.10: Surface representation of the ligand binding site with the ball and stick 
representation of 0209 fragment with |2Fo-Fc|calc map at a counter level of 1.2  , 
T. brucei PDEB1, Chain B hydrophobic clamp 
Figure 5.11: Surface representation of the ligand binding site with the ball and stick 
representation of 0209 fragment with |2Fo-Fc|calc map at a counter level of 1.2  , 
T. brucei PDEB1, Chain A hydrophobic clamp  
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improves stability and binding interactions between the ligand and the 
protein.  
Figure 5.11 represents the binding mode in chain A where the fragment 
was located in the hydrophobic clamp and was also orientated towards the 
residues Met861 and Met868.  
 
Figure 5.12 represents the ligand 0209 binding environment in chain A 
where ligand was found at its normal binding site in the hydrophobic 
clamp.  
Figure 5.12: FLEV plot produced by COOT of the binding site of chain A, 
second binding site  
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TBrB1 – Ligand 0218 Crystal structure 
The next fragment that was analysed was 0218, Figure 5.13, which was 
located in the hydrophobic pocket and close to the residues such as 




Figure 5.13: Fragment 0218, N1 –[4-(acetylamino) phenyl]-2,2-
dimethylcyclopropane-1-carboxamide 
Figure 5.14: FLEV plot produced by COOT of the binding site of chain B, 
first binding site 
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As it can be seen in Figure 5.15, the fragment was located in the 
hydrophobic clamp of residues Val840, Phe844 and Phe877. Figure 5.14 
also indicates additional surrounding amino acids: Gly873, Gly874, 
Thr841, Val881 and Met785. In the binding site, there were 5 well – 
ordered water molecules where 2 out of the 5, formed direct hydrogen 
bonds with the fragment and 2 others formed hydrogen bonds to the side 
chain of the Thr841. These interactions are considered to contribute 
significantly to the binding affinity. Unlike other fragments 0218 has only 
1 binding site, in chain B which is the most preferable chain for inhibitors 




Figure 5.15: Surface representation of the ligand binding site with the ball and stick 
representation of 0218 fragment with |2Fo-Fc|calc map at a counter level of 1.2   , 
T. brucei PDEB1, Chain B hydrophobic clamp 
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TBrB1 – Ligand 0268 Crystal structure  
The next fragment that was analysed was 0268, Figure 5.16, where chain B 
showed a novel binding site, whereas chain A was bound to the fragment 
at the usual binding site.  
 
 
Figure 5.16: Fragment 0268, 2 – fluoro-N-[(1H-pyrazol-3-yl) methyl] aniline 
Figure 5.17: FLEV plot produced by COOT of the binding site of chain A, first 
binding site 
















Figure 5.18 represents the binding mode between TbrPDEB1 catalytic 
domain and 0268, where the fragment occupied the hydrophobic clamp in 
Figure 5.18: Surface representation of the ligand binding site with the ball and 
stick representation of 0268 fragment with |2Fo-Fc|calc map at a counter level of 
1.2  , T. brucei PDEB1, Chain A hydrophobic clamp  
Figure 5.19: FLEV plot produced by COOT of the binding site of chain B, 
second binding site 
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chain A. The fragment was in close contact with such protein residues as: 
Phe877, Met861, Thr841, Gly874, Val840, Ala937, Tyr668, Asp825, 
Iso823 and Asp822, Figure 5.17.  
 
 
The second binding event was in chain B where novel site was observed, 
Figure 5.20. 
The ligand was surrounded by amino acids, such as: Leu728, Met714, 
Arg664, Glu916, Asp712, His744, Leu741, Val740 and Tyr721, Figure 
5.19. There were also other hydrogen bonds between water molecules and 
the side chains of protein residues: Glu916, Leu915 and Arg918. Such 
hydrogen interactions improve binding and protein stability. This binding 
site has not previously been observed and as such was considered a novel 
site that required further investigation.  
 
 
Figure 5.20: Surface representation of the ligand binding site with the ball and stick 
representation of 0268 fragment with |2Fo-Fc|calc map at a counter level of 1.2  , 
T. brucei PDEB1, Chain B novel binding site  
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TBrB1 – Ligand 0269 Crystal structure  
The next fragment that was analysed was 0269, Figure 4.21, where ligand 

















The binding site was formed by amino acids: Tyr668, Asp825, Phe877, 
Met861, Gly873, Glu874, Thr841, Phe844, Val840 and Ala837, Figure 
Figure 5.21: Fragment TbrB1 – 0269, (R)-1-methyl-N-((tetrahydrofuran-2-yl) 
methyl)-4H-1-parazole-3-carboxamide  
Figure 5.22: FLEV plot produced by COOT of the binding site, binding site 
of chain B, 1st binding site 
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5.22. The fragment 0269 formed hydrogen bond between its carbonyl 
oxygen atom and the side chain of Met861 residue that forming a P –
pocket cavity. It is also forming hydrogen bond between one of the 
nitrogen atom of the imidazole ring and water molecule that was present in 
the binding site, Figure 5.23.  
There was also a formation of a hydrogen bond between a water molecule  
and the protein residue Thr841. Chain A, Figure 5.24 shows that ligand 
was bound in the hydrophobic clamp however some additional density was 





Figure 5.23: Surface representation of the ligand binding site with the ball and stick 
representation of 0269 fragment with |2Fo-Fc|calc map at a counter level of 1.2  , 
T. brucei PDEB1, Chain B hydrophobic clamp  

















Figure 5.24 represents the interactions formed between the fragment and 
the protein. The fragment 0269 formed a hydrogen bond interaction with 
one of the water molecule. An observed glycerol from the cryoprotectant 
and also formed a hydrogen bond with the water molecule as well, where it 
was present as a cry - protectant. There are also hydrogen bonds formed 
between the water molecules in the binding site.  
 
Figure 5.24: Surface representation of the ligand binding site with the ball and 
stick representation of 0269 fragment with |2Fo-Fc|calc map at a counter level 
of 1.2  , T. brucei PDEB1, Chain A hydrophobic clamp  
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TBrB1 – Ligand 0248 Crystal structure  
 
The last fragment that was analysed was 0248, Figure 5.25, where only 
one binding mode was observed in chain B, in the hydrophobic clamp.  
Figure 5.25: Fragment 0248, [(5-Methyl-isoxazole-3-carbonyl)-amino]-acetic acid 
methyl ester methyl 2-{[(5-methyllisoxazol-3-yl) carbonyl] amino} acetate 
Figure 5.26: FLEV plot produced by COOT of the binding site in chain B, 1st 
binding site  
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Fragment 0248 was surrounded by the amino acids: Phe877, Met861, 
Gly874, Val840, Phe844, Met785 and Val881, Figure 5.26. 
 
From the Figure 5.27 it can be seen that fragment was bound in the 
commonly observed binding site, where the hydrophobic clamp is thought 
to provide the majority of the protein ligand interaction energy. The 
fragment also formed an interaction with a DMSO molecule that was used 
for fragments solubilisation.  
After the analysis of the most interesting compounds, it was important to 
see which ones offered growth vectors towards the P – pocket to increase 
their potency and potential selectivity towards parasitic PDEs over human 
PDEs. 
 
Figure 5.27: Surface representation of the ligand binding site with the ball and stick 
representation of 0248 fragment with |2Fo-Fc|calc map at a counter level of 1.2  , 
T. brucei PDEB1, Chain B hydrophobic clamp  
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3 binding sites: 
chain A – 
hydrophobic clamp 
chain B – 
hydrophobic clamp 





2 binding sites:  
chain A – 
hydrophobic clamp 





1 binding site: 





2 binding sites: 
chain A – 
hydrophobic clamp 






2 binding sites: 




chain A – 
hydrophobic clamp 





1 binding site: 
chain B – 
hydrophobic clamp 
 
5.4. Computational Analysis of Fragments  
In a collaboration with Lorena Zara from the University of VU a 
computational analysis of 6 chosen ligands with vectors towards the P – 
pocket was performed.  
The fragment 0218 was a cyclopropane that was directed towards the P –
pocket and there was an aromatic interaction with residues Phe877 and 
Phe844, which formed a hydrophobic clamp, Figure 5.28. The idea behind 
the current fragment is to see whether it could be grown into the P – pocket 
where certain analysis was performed.  
Table 5.1: summarised table of TbrB1 fragments 



















Figure 5.28: Fragment 0218. A) Current Ligand protein binding mode B) Newly 










Figure 5.29: Synthesis of fragment 0218 towards P – pocket for interaction with Met868 
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Met868 residue was one of the residues that compose the P – pocket. 
It was suggested to use synthesis route above, Figure 5.29, to grow 
derivatives that would be vectoring towards the P – pocket. Computational 
enumeration of such ligands followed by a search of the Zinc database 



















The fragment 0209 has ligand bound in 2 chains: chain A and B, where in 
both chains fragment was interacting with the hydrophobic clamp. 
Docking analysis showed that fragment could be grown towards the P – 
pocket to interact with its residues, Figure 5.30.  
 
 







Table 5.2: 0218 fragments derivatives 
TbrBr1 - 0218 













































Figure 5.30: A) Ligand 0209, protein binding mode B, C) Docking pose 
M868 
Table 5.3: 0209 fragments derivatives 
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The next fragment that was subjected to computational analysis was 0074. 
The docking models of the Zinc molecules can be observed in the Figure 













Figure 5.31: A) Ligand 0074 protein binding mode B) ZINC3156385 docking C) 
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The second approach that was discussed in collaboration with the 
University of VU was the possibility to merge observed fragments 
structures from XChem in order to identify new derivatives that will be 
selective towards the P – pocket.  Thus, is exemplified in two cases with 
the merging of the fragments 0074 and 0209 with the fragment 0269 


















Table 5.4: 0074 fragments derivatives 
0074 0269 




























Synthesis and studies of current fragments would be the next step in current 
study.  
Figure 5.32: Merged compound of fragments 0074 and 0269 
0209 0269 
Figure 5.33: Merged compound of fragments 0209 and 0269 
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5.5 SPR data of fragments selected from the XChem run 
The six fragments that were considered suitable for generation of 
derivatives directed towards P – pocket that were used in SPR analysis.  
There were 5 compounds that were run on SPR that were used during 
XChem run, where it was important to see whether these compounds could 
also show any binding affinity towards parasitic PDEB1 and if there is any 
difference with human PDE4 binding affinity that was run in parallel.  
 
5.5.2 SPR data 
As it was mentioned earlier 6 compounds were analaysed by SPR on a 
Biacore T200: 0218, 0412, 0269, 0209 and 0074,  tested at 1 – 30 uM 
concentration ranges. There were 3 immobilised proteins that current 
ligands were tested against: TbrPDEB1, TbrPDEB2 and hPDE4.  
0218                        Proteins  





Table 5.5 represents SPR sensorgram of response of the 3 different 
proteins with 0218.  It can be observed that there was no detectable 
binding in all 3 cases. There was no assocition state where the complex 
was forming and hence there was no equilibrium state. Therefore, it can be 
concluded that current fragment was too weak and it couldn’t  be detected 
under these conditions by SPR.  
Table 5.5: SPR data spectra analysis of 3 proteins run with XChem hit 0218 ligand 
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Table 5.6 represents SPR binding analysis of 0412 against the three 
different proteins. Once again according to the results in Table 5.6 it can 
be seen that there was measurable binding in all 3 SPR runs.   
 
According to the Table 5.7, it can be observed that there was a slight 
difference to Tables 5.5 and 5.6 and there was a slight increase in the 
signal of SPR experiment with parasitic proteins and its highest 
concentration (30 uM) but not an interpretable sensorgram to calculate any 





0412                        Proteins  
 TbrPDEB1 TbrPDEB2 hPDE4 
 
   
0269                        Proteins  
 TbrPDEB1 TbrPDEB2 hPDE4 
 
   
Table 5.6: SPR data spectra analysis of 3 proteins run with XChem hit 0412 ligand 
Table 5.7: SPR data spectra analysis of 3 proteins run with XChem hit 0269 ligand 
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0209                        Proteins  





Table 5.8 represents SPR binding sensorgram where 0209 ligand was used 
against 3 proteins as in previous experiments. However, no binding was 
observed in all 3 cases.  
 
 
According to the Table 5.9 there was a signal at high concentration of 
ligand, and it was clear that parasitic PDEs had stronger signal then 
hPDE4. However, such results could be due to nonspecific binding and no 
formal binding affinity could be deduced from such data.  
Among all 5 compounds only 0074 showed a binding signal at high 
concentrations but this may not be specific binding. However, the previous 
computational analysis, Section 5.4, showed that it may be possible that 
derivatives from 0074 can be further grown towards the P – pocket in 
0074                        Proteins  
 




Table 5.8: SPR data spectra analysis of 3 proteins run with XChem hit 0209 ligand 
Table 5.9: SPR data spectra analysis of 3 proteins run with XChem hit 0074 ligand 
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order to improve its affinity and potentially selectivity. To analyse this 





According to the Table 5.10 a binding signal can be observed in all 3 
instances, at different concentrations. Again, the data quality does not 
allow determination of a KD but there seems to be a qualitative indication 
of an increase binding affinity.  Further experiments and enumeration of 
similar compounds grown in this direction would be required to confirm 
the hypothesis. However, protein was prone to precipitation hence it is 
required to re-run the SPR screen.  
The main outcome of SPR experiment was:  TbrB1 – 0074 showed the 
most promising result where parasitic protein had higher signal then 
human PDE4 enzyme, as well as the derivative of 0074 that showed higher 
signal with parasitic PDEB1, Table 5.11. 
Fragment SPR response against TbrB1 
TbrB1 - 0218 x 
TbrB1 - 0412 x 
TbrB1 - 0269 x 
TbrB1 - 0209 x 
ZINC813384                        Proteins  
 TbrPDEB1 TbrPDEB2 hPDE4 
 
   
Figure 5.10: SPR data spectra analysis of 3 proteins run with XChem hit 0074 
derivative ZINC813384 ligand. 
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TbrB1 - 0074  





The XChem platform allows the high-throughput screening of ligand-
soaked crystals to access the binding mode of the high number of 
compounds. One of the biggest advantage of using such a screening 
method was that even 10% binding occupancy could be found, however as 
it can be seen from the SPR it may prove difficult to measure and rank 
such fragments on the basis of affinity using SPR.  
It was very important to optimize the system and compare it with other 
biophysical methods that let the users to analyse ligand-protein binding 
mode. In current experiment, TbrPDEB1 protein was used as a target that 
was tested using DSI - Poised library that was provided by the Diamond 
Synchrotron. 466 compounds were used during the XChem run but only 
293 data sets were successfully diffracted and detected ligand binding 
modes were manually analysed for 20 complexes. Each data set has 
multiple binding events. The primary aim was to find the novel interesting 
fragments, whether the ligand was bound in the normal binding site which 
was a hydrophobic clamp or ligand was more orientated towards the 
selective P – pocket. As the P – pocket is a distinct feature that is only 
found in parasitic PDEs, fragments that had moieties or substitution 
vectors directed towards P – pocket would be more desirable as it would 
increase the binding selectivity between human and parasitic PDEs. Out of 
293 analysed diffraction data sets, 20 ligands – protein structures were 
analysed manually. The most interesting ones were chosen to be 6 
Table 5.11: Summary of SPR screen, 2 fragments showed stronger signal against 
TbrB1 enzyme. 
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fragments where more complete refinement was performed, and detailed 
analysis was performed. Out of 6 fragments, 5 were bound in both chains, 
whereas fragment 0248 was only found in chain B in the hydrophobic 
clamp. Such fragments as 0074 and 0268 showed novel binding sites at 
chain B, whereas fragment 0074 had 3 binding sites, 2 in chain B and 1 in 
chain A.  
Such findings led to the next step where in collaboration with the VU 
University, computational analysis of 5 - the most interesting compounds 
was performed in order to see what fragments were the most promising 
and interesting from the chemical and biological point of view.  
Identifying the most promising compounds enabled the experiment to 
proceed further by performing SPR direct binding analysis where 5 
fragments were used together with 1 derivative of the fragment 0074. The 
experiment was performed with 3 different proteins, such as: TbrPDEB1, 
TbrPDEB2 and human PDE4. Out of 5 runs only compound 0074 showed 
association and dissociation curves where the signal was observed, 
however there was also a high probability of unspecific binding.  
The fact that previous experiments by SPR screening had found fragments 
with measurable affinities raises another question: why were the higher 
affinity fragments not found in the XChem screen? One explanation could 
be that at the very high concentration of the fragment soaks used in this 
experiment, the more potent fragments disrupted the crystal lattice, hence 
preventing the detection of some highly potent ligands while leaving the 
weaker binding fragments that couldn’t be detected on other biophysical 
techniques.  
Therefore, the next step would be to test selected inhibitors that have been 
identified previously by SPR as manual X-ray soaks, in order to identify if 
there in any ligand’s concentration dependency of crystal lattice quality.  
 
   175
Chapter VI 
 
Biophysical Analysis of 
TbrPDEB1 using PDE-like Fragment’s from 
ChEMBL by XChem and SPR 
 
6.1 Introduction 
The previous XChem screen (Chapter V) showed that overall from 466 
attempted soaks 290 data sets were accepted by PanDDA and 31 positive 
data events were identified indicative of bound ligands. Since the XChem 
platform is a new development in using X-ray crystallography for 
fragment binding, it was important to see if the approach or the system 
could be optimised in order to minimise false negative experimental errors 
through improving its detection of potential high affinity binders that may 
disrupt the crystal lattice at high concentrations. Refining the current 
technique could have significance to industrial experiments as well as in 
academic studies.   
The aim was to test the hypothesis that using the “standard” high ligand 
concentrations of soaks used in XChem fragment screening could result in 
a number of false negatives due to sample damage. This would be tested 
by using different fragment soaking concentrations as well as using 
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6.2 ChEMBL PDE-like Fragment’s  
A selection of fragments from the ChEMBL datasets with known PDE 
activity (performed by IOTA, PDE4NPD collaborators) were chosen to be 
tested on TbrPDEB1 catalytic domain where 31 fragments were selected, 
purchased and used for manual soaking, using different soaking 
concentrations and soaking times, Table 6.1. 
It was hoped these variables would have allowed us to see if high affinity 
fragments may destroy the crystal lattice and identify the more appropriate 
concentrations and soak times for standard XChem protocols to ensure the 
highest affinity fragments are detected. It was important to perform manual 
soaking before proceeding to an XChem data collection as it would be 
easier to regulate concentration and time variables as compared to varying 
diffusion rates that could occur with echo dispensing used in the XChem 
process.  
There were 5 conditions that were used during manual crystallization: 
ligand concentration of 40 mM and soaking for 24 hours, 30 mM ligand 
concentration for 24 hours of soaking and 40 mM ligand concentration for 
48 hours soaking. 
Ligand Ligand ID 30mM/24hs 40mM/24hs 40mM/48hs 50mM/72hs 50mM/96hs 
1 ChEMBL31877 1.67 x 1.39 X X 
2 ChEMBL88119 1.99 1.63 1.47 X 1.59 
3 ChEMBL131164 2.26 1.99 X X X 
4 ChEMBL124706 1.88 3.58 X X X 
5 ChEMBL760 X X X X X 
6 ChEMBL279898 1.86 X 1.56 X X 
7 ChEMBL189 X 1.78 1.87 X 1.49 
8 ChEMBL58355 X 2.94 X X 1.93 
9 ChEMBL131181 1.83 1.71 1.83 X X 
10 ChEMBL330581 X 1.8 2.14 X 1.75 
11 ChEMBL100112 X 1.97 1.52 X 1.55 
12 ChEMBL1779264 X X 1.48 X X 
13 ChEMBL1779265 X X X X X 
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14 ChEMBL619 X X X X X 
15 ChEMBL255611 X 1.64 2.11 X 1.56 
16 ChEMBL119506 X 1.76 1.84 1.89 X 
17 ChEMBL118193 X 1.76 1.79 X X 
18 ChEMBL372055 X 1.64 1.19 X 1.75 
19 ChEMBL451589 X X 1.85 X X 
20 ChEMBL255421 X X 1.65 X X 
21 ChEMBL190 X X X 1.75 X 
22 ChEMBL2172707 X X 1.79 X X 
23 ChEMBL3622905 X X 1.47 X X 
24 ChEMBL45854 X X 1.69 X 1.47 
25 ChEMBL66732 X X 1.52 X X 
26 ChEMBL270636 X X 1.44 X X 
27 ChEMBL1779267 X X 1.27 1.48 X 
28 ChEMBL270635 X X 1.48 X X 
29 ChEMBL484928 X X 1.52 X X 
30 ChEMBL255130 X X 1.38 X X 
31 ChEMBL255821 X X X X X 
 
6.3 Ligand – Protein Binding Mode Analysis  
After running the XChem analysis 11 ligands were identified that gave the 
most promising, of those 5 ligand data sets were chosen for complete 
structural analysis. The current section represents data that was obtained 
after XChem run.  
Ligand 1, ChEMBL31877, Figure 6.1, was found in chain B in hydrophobic 
clamp that was formed by residues Phe877 and Val840, Figure 6.2. 
Table 6.1: Table 5.1 ChEMBL’s ID and conditions that were used for each ligand 
together with the diffraction limits noted in Å data that was obtained (X denotes no 
processable data set obtained). The best hits were further analysed and refined using 
the CCP4 software suite.  
 




























Figure 6.1: Ligand 1: ChEMBL31877, N-benzylthieno[3,2-d] pyrimidin-4-
amine 
Figure 6.2: crystal structure of TbrPDEB1 catalytic domain and Ligand 1: 
ChEMBL31877, chain B, hydrophobic clamp 





















The binding mode shows the ligand surrounded by amino acids: Met861, 
Gly873, Glu874, Phe844, Val840 and Pheny877, Figure 6.3. 
ChEMBL31877 formed 2 major types of interactions: hydrophobic 
interaction with Phe877 with which the ligand PI stacks and a sulphur 
containing hydrogen bond with one of the water molecule that was present 
in the binding site. An interesting feature of current binding was that it was 
close to the P – pocket residue Met861 and therefore computational 
analysis could reveal that further chemical synthesis could identify new 
Figure 6.3: FLEV plot produced by COOT of the binding site of chain B, first 
binding site, Ligand 1: ChEMBL31877  
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possible derivatives that could be more selective against TbrPDEB1 than 
human PDEs. 
Ligand 3: ChEMBL131164, Figure 6.4, was only bound at 1 site at chain 













According to the Figures 6.5 and 6.6 there was a formation of Hydrogen 
bond between one of the oxygen atom of the benzene ring with the protein 
side chain of Met861 residue that forms a part of the P – pocket.  
Figure 6.4: Ligand: ChEMBL131164, 7 – butyl-3-propyl-2,3,6,7-
tetrahydro-1H-purine-2,6-dione 





























Figure 6.5: crystal structure of T. brucei PDEB1 catalytic domain and Ligand 
3: ChEMBL131164, chain B, hydrophobic clamp 
Figure 6.6: FLEV plot produced by COOT of the binding site of chain B, 
Ligand 3: ChEMBL131164 
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Figure 6.5 shows Hydrogen bond formation between one of the water 
molecule and Glu874. Such interaction improved binding affinity of 
Ligand into the hydrophobic clamp. Figure 6.6 represents ligand binding 
site environment that was build using Coot’s software. According to the 
current figure there was interaction between Phe877 residue and an 
aromatic ring of the ligand.  
The third ligand that was used for ligand binding mode analyses was 






















Figure 6.7: Ligand 22: ChEMBL2172707, 4-chloroquinazoline 
Figure 6.8: crystal structure of T. brucei PDEB1 catalytic domain and Ligand 
22: ChEMBL2172707, chain B, hydrophobic clamp 
















Ligand 22: ChEMBL2172707 was flanked by residues including Gly874, 
Met861, Phe844 and Phe877, Figure 6.9. The benzene ring formed a face-
to-face  - stacking interactions with the aromatic ring of Phe877.  
 
Ligand 12: ChEMBL1779264, Figure 6.10. The ligand was once again 
bound in the hydrophobic clamp of the catalytic domain, Figure 6.11. 
Figure 6.9: FLEV plot produced by COOT of the binding site of chain B, first 
binding site Ligand 22: ChEMBL2172707 
Figure 6.10: Ligand 12: ChEMBL1779264, 2-methyl-5-(methylsulfanyl)-[1,2,4] 
triazol[1,5-c]quinazoline 
   184
The binding mode shows the Ligand ChEMBL1779264 surrounded by 
amino acids: Val840, Phe877, Tyr668, Met785, Met861, Gly873, Phe844 
and Gly874, Figure 6.11. 
ChEMBL1779264 formed 2 hydrogen bond interactions with 2 water 
molecules as well as  - stacking interactions between Phe877 residue of 
the protein and the aromatic triazene ring of the ligand. ChEMBL1779264 
is also located close to the hydrophobic protein residues such as Met861 
and Met868 which are the residues of the P – pocket.  Therefore, the 
current ligand could be used as a starting point for synthesis of derivatives 
that would be directed towards the P – pocket more in order to be more 


















Figure 6.11: FLEV plot produced by COOT of the binding site of chain B, 
first binding site Ligand 12: ChEMBL1779264 























The last ligand that would be refined further was  
















Figure 6.12: crystal structure of T. brucei PDEB1 catalytic domain and Ligand 
ChEMBL1779264, chain B, hydrophobic clamp 
Figure 6.13: Ligand 9: ChEMBL131181, 3-ethyl-2,3,6,7-tetrahydro-1H-purine-2,6-
dione 
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Ligand 9: ChEMBL131181 was found bound in the hydrophobic clamp of 
chain B and was surrounded by residues: Tyr668, Phe877, Phe844, 







































Figure 6.14: crystal structure of T. brucei PDEB1 catalytic domain and Ligand 
9: ChEMBL131181, chain B, hydrophobic clamp 
Figure 6.15: FLEV plot produced by COOT of the binding site of chain B, 
first binding site, Ligand ChEMBL131181 
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There are 2 key interactions between the ligand and the protein: one is the 
formation of  - stacking interactions between Phe877 and the aromatic 
indazole ring of the ligand, and another is the hydrogen bond formed 
between the conserved Gln874 residue and the NH atom of the ligand. 
Such interactions stabilise ligand – protein binding mode.  Ligand 
ChEMBL131181was also bound in chain A and it was similarly positioned 
in the hydrophobic clamp, Figure 6.16. 
 
In this binding mode ligand 9: ChEMBL131181 was surrounded by such 
amino acids as: Phe877, Phe844, Met861, Gly874 and Asp825, Figure 
6.17. Ligand ChEMBL131181 formed 3 hydrogen bonds with 3 water 
molecules and a  - stacking interactions between the indazole ring of 
ligand and aromatic side chain of the protein residue Phe877. In 
comparison to the chain B, where only 1 H bond interaction was present, 
Figure 6.16: crystal structure of T. brucei PDEB1 catalytic domain and Ligand 
ChEMBL131181, chain A, hydrophobic clamp 
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chain A also had water molecules that formed 3 H bonds with the ligand, 






































1 binding site: 
chain B – 
hydrophobic clamp 
Figure 6.17: FLEV plot produced by COOT of the binding site of chain A, 
second binding site Ligand ChEMBL131181 








1 binding site: 








1 binding site: 









1 binding site: 









2 binding sites: 
chain A – 
hydrophobic clamp 
chain B – 
hydrophobic clamp 
 
6.4 XChem of low concentration soaks 
The aim of this experiment was to further identify optimal concentrations 
for 3 chosen ligands that were analysed in Section 6.3, where duration of 
soaking and ligands concentration would be varied.  
Table 6.2: summary of solved structures 
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In the previous section 5.3, 5 compounds were analysed, and its ligand 
binding mode determined when the experiment was performed as manual 
soaking. These compounds were then chosen for an XChem run where 10 
points of concentration gradient were used. It was decided to use 2 time 
periods to soak fragments with the protein: 2 hours and 4 hours. Therefore, 
by using 10 concentrations, 2 soaking time, with 5 compounds there were 
200 samples that would require using 12.5 pucks and 7 hours of beamline. 
To accurately prepare the fragments dilutions a mosquito liquid dispenser 
was used to dispense into an echo compatible 384LDV source plate. The 
final planned concentration of 250 mM was not achievable due to the 20% 
DMSO soak plus 1M stock compound limit, so a 9-point titration was 
designed. The final concentration used were: 1 mM, 3 mM, 5 mM, 10 mM, 
20 mM, 50 mM, 100 mM, 150mM and 200 mM. There were 2 different 
protein crystallisation batches that were used in current experiment. Batch 
1 contained small fragile crystals where 80% of crystals didn’t show any 
diffraction data. Batch 2 contained good size crystals where 150 um loops 
were used. At 4 hours of soaking fragments x0143 (Ligand 
ChEMBL31877) and x0193 (Ligand ChEMBL131181) suffered and the 
crystal lattice was damaged. There were 3 ligands that showed best 
diffraction data, where the binding event could be observed in high 
concentration soaks as well. Unfortunately, due to issues with PanDDA 
maps it was hard to identify the differences in binding intensity between 
different concentrations hence at that time it was not possible to plot an 
accurate dose-dependent curve. These 3 ligands were chosen as interesting 
targets for docking analysis (Ligands 1, 3 and 9), and SPR screening.  
 
6.5 SPR Data Validation  
The XChem experiment revealed that the best binders were 
ChEMBL31877, ChEMBL131164 and ChEMBL131181 that were all 
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xanthine derivatives and where their chemical structures were closely 
related to IBMX ligand. Human PDE4 and TbrPDEB1 catalytic domains 
were immobilised for SPR. The samples purity was accessed on Liquid 
chromatography – mass spectrometry (LC-MS) that separated molecules 
and analysed masses of proteins. The maximum concentration of ligands 
used was 100 µM. The results were as following.  
 















Table 6.3 represented data of protein – ligand binding analysis, where 
there was no confirmed binding in either of the proteins as no association 
and dissociation phases can be observed.  
 
 
Protein T. brucei PDEB1 hPDE4 
SPR data 
  
Figure 6.18: 3-ethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione 
Table 6.3: SPR data of ChEMBL131181, 2 target proteins: T. brucei PDEB1 and 
hPDE4 
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According to the data presented in Table 6.4 there was evidence of specific 
binding between the ligand and human PDE4 while the sensorgram for 
TbrPDEB1inferred unspecific ligand binding.  
The last ligand that was measured on SPR was ChEMBL131181 where the 







Figure 6.19: N-benzylthieno[3,2-d]pyrimidin-4-amine 
Table 6.4: SPR data of ChEMBL31877, 2 target proteins: T. brucei PDEB1 and 
hPDE4 
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Protein T. brucei PDEB1 hPDE4 




According to the data presented in Table 6.5, there was unspecific binding 
between the ligand and TbrPDEB1 while hPDE4 didn’t show any binding 
and no association and dissociation phases were observed.  
 
6.6 Conclusion 
31 compounds were screened manually, of these 30 showed binding at one 
or more concentrations or soak time. 
Manual inspection of these 30 binding events were analysed and revealed 
that only 5 compounds were interesting from the drug discovery 
Figure 6.20: 7 – butyl-3-propyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione,  
Table 6.5: SPR data of ChEMBL131164, 2 target proteins: T. brucei PDEB1 and 
hPDE4 
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perspective point. Hence, these compounds were chosen to be further 
investigated by using XChem platform to explore optimal concentrations 
as well as different soaking time, such as 2 hours and 4 hours.   
Unfortunately, the XChem processing and PanDDA analysis failed for the 
final XChem experiment and it was not possible to build a dose-
dependency curve for calculation of a binding. Out of 5 compounds 3 
compounds were further analysed by the SPR run, to see if any measurable 
binding affinity could be obtained and if any selectivity was present 
between human and parasitic PDE.  
However, it was clear from the manual soaking experiments for 
ChEMBL131181and ChEMBL131164 that there was an indicative dose 
response and negative effect on the crystals for high concentration longer 
duration soaks supporting the hypothesis.  
There were 2 compounds out of 3 that showed SPR response: 
ChEMBL31877 and ChEMBL131164 where 1st fragment showed specific 
binding with human PDE4 protein while the 2nd one showed unspecific 
binding with the parasitic PDEB1. Hence, current results couldn’t be used 
further for drug binding mode validation and current experiment should be 
optimized and rerun again in future.  
The focus of this experiment was to optimise an XChem protocol based on 
high affinity fragments. The protocol could be used by either Academic or 
Industrial projects to ensure that high affinity fragments could be 
crystallographically detected. Some crystal systems can’t withstand high 
concentration soaks or soaking time therefore destruction of crystal lattice 
will affect the effectiveness of the experiment. Unfortunately, due to 
PanDDA issues the failed to determine binding affinities. Therefore, the 
next step would be to repeat the experiment where PanDDA software 
issues will be resolved.  
  





Summary and Discussion  
 
 
7.1 Novel Expression and Purification of Parasitic PDEDs 
from L. infantum, L. donovani and T. brucei 
Previous experiments that were performed by other lab members were 
focused on the expression of PDED from T. brucei and T. cruzi. There was 
no preliminary data about PDED protein expression and purification from 
all 3 species. Previous experiments on T. cruzi using different expression 
systems, such as: bacteria, insect and mammalian cells didn’t show any 
differences in soluble protein expression, either full length or catalytic 
domain protein constructs remained insoluble. Expression studies focused 
initially on the T. cruzi species. Small scale expression of similar 
constructs for L. infantum and L. donovani showed that protein was 
insoluble as it was only observed in a pellet fraction. Since the previous 
work had shown that different expression systems didn’t appear to 
improve PDED solubility it was decided to perform mutations where 
hydrophobic amino acids were mutated into polar amino acids in order to 
make the protein more soluble. Different constructs were designed, and a 
variety of mutations introduced. Unfortunately, no positive outcome was 
observed, and the protein still remained insoluble. The next approach was 
to clone the construct into a pOPIN vectors where solubilisation tags were 
linked to the construct. According to western blot analysis, TcrPDED was 
observed in the supernatant fraction, however the signal was so weak that 
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it was obvious that protein was still predominantly in its insoluble form. 
TbrPDED catalytic domain was also studied and revealed the same pattern 
of protein behaviour as it was only observed in the pellet fraction. Fusing 
the target proteins with solubilizing tags by use of the pOPIN vectors 
resulted in a small amount of soluble expression. This small amount of 
soluble material was sent to the university VU to test the catalytic activity 
of the protein a cAMP assay. Unfortunately, no activity was observed 
probably due to the fact that any expressed protein had degraded.  
As T. brucei and T. cruzi are more closely related species than Leishmania 
it was hoped that studying Leishmania PDEDs would overcome the 
potential issues with the solubility. L. infantum and L. donovani were used 
as targets where catalytic domains and full-length proteins were amplified 
and cloned into a standard pET 15 vector. Standard expression conditions 
were used, and no soluble protein was obtained. It was clear that all PDED 
proteins were prone to misfolding and aggregation. However, it was 
decided to pursue similar optimizations method as attempted with T. cruzi 
where different constructs were designed and cloned into pET vector and 
pOPIN vector suite. Western blot experiment showed similar patterns of 
expression where a signal was only observed in a pellet fraction. There 
were three designed constructs that were cloned into a pET15b vector and 
4 vectors of pOPIN vector suite, such as: pOPINF, pOPINM, pOPINJ and 
pOPINS3C. By using pOPIN vectors it was possible then to use other 
expression systems like insect cells and mammalian cells. There was no 
difference in expression level between the three constructs as well as 
between using different vectors where solubilisation tags didn’t reveal any 
improvement in expression level. Following further analysis of additional 
expression systems, pCold was identified as a more suitable for expressing 
of insoluble proteins. The system has different vectors where each of them 
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contain cold – shock Protein A (cspA), which acted as a promoter for 
expressing recombinant proteins. Induction of protein’s expression was 
performed at low temperature – 15 °C. Low temperature induction was 
used to suppress the expression of E. coli proteins and inhibit protease 
activity that negatively result on recombinant protein expression. There 
were 2 vectors that were used: pColdI and pColdTF. The main difference 
between these 2 vectors was the addition of a trigger factor (TF) into the 
pColdTF vector that was fused with PDED catalytic domain. There was a 
significant difference in protein expression comparing to the protein being 
cloned into pET15b vector and pOPIN vectors. The pColdTF vector gave 
more soluble protein in a supernatant fraction. Trigger factor was acting as 
a chaperone to improve protein solubility. As there was an improvement in 
soluble protein yields with the fused chaperone it was decided to purchase 
Takara plasmid chaperone set where 5 plasmids contained a combination 
of different chaperones. The co-expression was performed using small 
scale culture in order to see which plasmid with chaperones enhance 
protein solubility the most. pGro7 plasmid that contained 2 chaperones 
GroES and GroEL was used in the following experiments as the most 
soluble material was obtained with the co-expression with that plasmid. 
GroEs and GroEL chaperones work together to control the folding of 
proteins from unfolded or partially folded state. It has been proven that 
some recombinant proteins that can’t be expressed in E. coli cells were 
finally successfully purified by co – expressing it with the GroES and 
GroEL complex (102). Main advantage of using such chaperone complex 
is the ability of it to refold proteins from its denatured state as well as if 
protein was partially folded only. Previous experiments performed on 
Rubisco (ribulose bisphosphate carboxylase – oxygenase was denatured 
prior its incubation with the complex and ATP in order to try to renature it) 
using GroES and GroEL showed that 80% of protein could be renatured. 
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There was a substantial difference in protein expression between pColdI 
and pColdTF vectors where in the 2nd place PDED was also fused with the 
trigger factor. So initially protein was promoted by trigger factor whereas 
chaperon complex GroES/GroEL improved and speed up the folding 
reaction. The inside cavity of GroEL is made by hydrophilic side chains 
that speeds up the folding rate. When PDED protein was expressed by 
itself the folding reaction was inhibited by protein aggregation with 
misfolded parts that were observed using SDS-PAGE and Western blot 
analysis.  
Takara chaperone plasmids were used to identify the most preferable 
chaperone complex for TbrPDED solubilisation. In these experiments, 
another Takara plasmid showed the best result, pG-KJE8 which carries 5 
chaperones where 2 of them were GroES/ GroEL complex. Co-expression 
of protein in the presence of chaperones showed that it was possible to 
solubilize it for further purification. However, larger scale expression of 
TbrPDED didn’t yield enough of protein material and also the protein was 
shown to degrade more quickly than in the case of Leishmania PDED, 
hence it was not possible to perform cAMP enzyme activity assays.  
In contrast, LinfPDED that was initially cloned into pColdTF vector and 
was fused with TF was used in Lonza assay and clear enzyme activity was 
detected, but again the fused PDED was still susceptible to protein 
degradation. Attempts to reduce degradation by removal of the trigger 
factor from LinfPDED, and a second Ni-NTA purification run, showed it 
was not possible to separate cleaved material from HisTag-PDED. The 
final outcome of the study showed that expression and purification systems 
have been developed for PDED catalytic domain protein, using different 
cloning and expression approaches, its optimizations and further 
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purification did not yield robust, stable protein for downstream biophysical 
analysis.  
Although low levels of soluble PDED catalytic domain were produced, it 
showed enzymatic activity against secondary messenger cAMP which 
proved that it was a true phosphodiesterase. Unfortunately, it was still clear 
that PDED was prone to aggregation. Therefore, further studies would be 
required to investigate the factors that can be used in order to maintain 
protein structure intact in solution so further biophysical analysis can be 
performed, such as NMR, X-ray and SPR.   
7.2 Biophysical Analysis of Human PDE5 using NMR, XChem 
and SPR 
IN a wider study of fragment screening methods and to find additional 
PDE fragments and as part of the development of Fluoro fragment library 
human PDE5 was used. 589 fluorine containing compounds were provided 
by Maybridge and analysed in NMR, SPR and XChem experiments.  
The first screen was SPR where the strongest binders according to SPR 
sensograms were determined. It was important to run SPR first as being 
less time consuming and resources consuming process among all other 2. 
There were 2 proteins used in SPR analysis: human PDE5 and human 
BRD4-BDE1 domain to help determine if the fragments were specific to 
the target and also because the BRD4 data could be used for further 
studies. Table 4.2 represented SPR data of the strongest hits that were 
observed with human PDE5 where percentage response and Kd values 
were determined.  
As this was a fluorine fragment file 19F CPMG was used where spectra 
should show only 1 peak per Fluorine atom being present in the fragment. 
After spectral analysis, the list of suitable well-behaved fragments was 
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decreased to 421 compounds. Out of 28 mixtures 2 mixtures failed and 
excluded from further experimental analysis. TopSpin software was used 
for analysing and comparing each mixture with the protein and mixture 
without the protein that was used as a control. To classify fragment as a 
strong or a weak binder, integrals of peak drops were calculated using the 
software where the final number was given as a percentage in peak drop. 
More than 50% in signal decrease was considered as a strong binder to 
PDE5 and hence less then 50% as a weak binder. Analysis of each mixture 
revealed that there were 101 fragments that were considered as strong 
binders with drop in signal around 95%. These fragments were further 
selected for manual crystallization since current fragment were positive 
hits in SPR and NMR screens. Then it was important to analyse the drug 
binding mode by analysing its diffraction data. 34 fragments were selected 
for X – ray where 22 fragments were classified as strong binders in NMR 
screen but not in SPR run, 2 fragments out of 34 were strong binders in 
SPR screen but weak binders in NMR run, 10 fragments were confirmed 
as strong binders in both NMR and SPR screens.  Since differences 
between strength of binding was observed X–ray would reveal more 
details regarding ligand – protein binding mode. Out of 34 crystals 32 
diffraction data sets were collected and was analysed manually. X – ray 
showed 13 strong binders that were also confirmed by NMR screen, 11 
fragments that were confirmed by X-ray, NMR and SPR, 3 fragments were 
confirmed by XChem, NMR and manual X – ray but 2 of them were 
missed in SPR run. The final result was that out of 421 compounds only 1 
fragment HTS04341 have been confirmed by all 4 techniques as a strong 
binder.  
One of the main concerns that was raised was why only 3 hits have been 
identified by XChem run while 32 crystals were successfully detected with 
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manual soaking and where 13 fragments showed strong binding mode with 
PDE5 according to SPR and NMR screens.  
This issue could due to the same problem that has been encountered in 
previous XChem experiment with TbrPDEB1.  
Since XChem is as a relatively new platform there is need of further 
protocol optimization to avoid false negatives. A second important 
technical issue that has to be resolved is PanDDA maps analysis where it 
will be possible to design dose-dependence curve hence enabling to 
develop a generic protocol that can be used with different targets.  
 
7.3 Biophysical Analysis of T. brucei PDEB1 using XChem 
platform and SPR screen 
As suitable yields of a parasitic PDED could not be obtained focus 
switched to developing additional ligands for the validated TbrPDEB1, as 
TbrPDEB1 was previously expressed, purified and crystallised and the 
protocols were known. This system could be used to develop tool 
compounds that would be a starting point for developing selective 
fragments for further testing against other parasitic PDEs. A second 
important point was to find the binders that would be classified as strong 
binders by more than one biophysical technique. Since TbrPDEB1 was a 
stable crystal system it was chosen to be used in XChem. The DSI – 
Poised library was provided by Diamond Synchrotron where 466 
fragments in the library. During mounting it was identified that almost 
20% of crystals soaked were destroyed. There were 335 crystal data sets 
loaded into a run. After X-ray data collection the XChem explorer software 
was used where several rounds of analysis were performed, such as: 
DIMPLE and PanDDA inspect where restraints were developed, and even 
low binding affinity sites were found. PanDDA inspect was performed 
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manually and 290 samples were investigated in terms of binding sites and 
how many events were observed in each data set. During the analysis, the 
user can decide if the event is interesting and if the binding site looks 
confident. Out of 215 accepted data by PanDDA 131 samples were 
classified as interesting, with 61 hits being confident. In order to refine 
structures data sets were manually processed with CCP4 i2. After careful 
analysis 20 hits were identified as interesting binders and were refined. 
Next step was to analyse the novelty of fragment protein binding from 
chemical point of view. As it has been mentioned earlier, one of the main 
criteria in current study was to find compounds that would be selective 
between human PDEs and parasitic PDEs. The distinct feature of parasitic 
PDEs was that it has parasitic cavity called P – pocket that wasn’t found in 
human proteins. Therefore, it was important to investigate if any of those 
interesting hits would be suitable for further synthetic chemistry follow up 
in order to grow it towards the P-pocket. Analysis focused on 6 
compounds that were chosen for computational studies in collaboration 
with the Free University of Amsterdam (VU).  
Although XChem gives atomic resolution information on the fragment 
binding interactions the affinity of the interaction is unknown and current 
computational methods are not accurate enough to calculate and rank the 
affinity of fragments. So, the next step was to perform SPR on the 6 
compounds. To check the experiment accuracy as well as to see how 
selective the fragments were 3 proteins were used in the SPR study: 
TbrPDEB1 and PDEB2, and human PDE4. All 3 proteins were PDE 
catalytic domains only. According to the SPR sensograms, no strong 
binders were observed. The only fragment that showed any dose response 
was the derivative ZINC813384 of the compound 0074 where association 
and dissociation curves were observed against all 3 immobilised proteins 
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and it was slightly stronger in TbrPDEB1 and PDEB2 runs than in human 
PDE4.  
The final statistics data were as follows: out of 466 compounds less than 
half of the library (215) was processed through PanDDA inspect and of 20 
fragments classified as interesting hits 6 were screened on SPR. Only 1 
fragment showed a response and was a confirmed binder in both 
biophysical methods.  
Out of all crystals that were used for XChem run 20% of soaks were not 
mounted due to crystal lattice destruction, while the other 30% did not give 
full high resolution data sets. As a result, only 50% of library was 
crystallographically analysed.  
Crystal’s mounting was performed manually, so some crystals were 
soaking for 2 hours and some for 4 hours. Therefore, it can be concluded 
that differences in soaking time could result in lattice destruction as some 
crystals were exposed to fragments longer. Fragments concentrations and 
soaking time could be 2 variables that can be tested in order to identify any 
dependence on crystal lattice quality. Although the highest resolution was 
1.7 A which was a workable data where lots of details in protein – ligand 
binding could be observed.  
7.4 Biophysical Analysis of TbrPDEB1 using XChem platform 
and SPR screen, Low concentration soaks 
For the detailed ligand soak study TbrPDEB1 catalytic domain was chosen 
again and the source of PDE fragments was a subset of the ChEMBL 
library. Manual crystallization was initially used to help optimize and 
identify a general protocol that could be applied to other protein targets in 
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order to maximize the selection of the highest affinity fragments in the 
output of XChem.  
31 PDE active fragments were selected from ChEMBL data. Each 
fragment was soaked individually with TbrPDEB1 catalytic domain where 
5 different soak conditions were used: 40mM/24 hours, 40mM/48 hours, 
30mM/24 hours, 50mM/72 hours and 50mM/96 hours. The longer high 
concentration soaking conditions was soaking for 72 hours and 96 hours 
with 50mM ligand concentration, clearly had a deleterious effect on the 
crystal quality. However, at 96 hours of soaking of 50mM there were still 
some fragments soaks that showed diffraction to high resolution (1.5 Å).  
It is clear from the soaking experiments that not only DMSO has an effect 
on the crystal lattice but the different small fragment compounds 
themselves have differential effects on crystal packing.  
Based on the examination of data that was obtained after manual data 
collection it was decided to use 5 fragments for more detailed multiple 
concentration soaks in XChem analysis to try and identify the 
concentration at which the high affinity fragments could be detected by 
creating a dose response curve.  
From the manual soaks Ligand ChEMBL31877gave the highest resolution 
for 48 hours of soaking with ligand concentration 40mM, higher 
concentration couldn’t be tolerated by the crystal lattice. Ligand 
ChEMBL31877 showed 2 different poses in manual soaks therefore that 
ligand was considered as an interesting target.  
Ligand ChEMBL131164 had lower resolution of 1.99 being the best one 
among 3 soaks of that ligand where the most preferable soaking condition 
was 40mM ligand for 24 hours. When the crystal was visualized under the 
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microscope cracks were observed.  Also, it could be seen that with the 
increase of ligand concentration and soak time the resolution of the 
diffraction was reducing.  
Ligand ChEMBL131181 was also only observed at concentrations of 
40mM and 30mM for 24 hours and 48 hours suggesting that longer time of 
soaking and higher concentration led to crystal lattice disruption. The 
Ligand – protein binding analysis for ligand ChEMBL131181 revealed 
that there were different ligand conformations in a binding site with high 
ligand occupancy suggesting that it may be a strong binder.  
Ligand ChEMBL1779264 was only observed at 40mM concentration for 
48 hours concentration with the resolution being 1.4. Refinement showed 
that it was a good binder. The last ligand was 22 where the only diffraction 
data was obtained at 40mM soaks for 48 hours with the resolution being 
1.79.  It was interesting to see if these last 2 ligands that gave diffraction 
data only at 1 condition will show any differences in XChem and if 
PanDDA will be able to detect the differences in ligand occupancy.  
A dose – dependence curve could help determine a more generic optimized 
protocol where most of the library would be used and hence as much as 
possible diffraction data would be obtained. Perhaps indicating that 
XChem should be run at both low and high concentrations fragment soaks. 
There were 2 soaking times 2 hours and 4 hours with the concentration 
gradients being used:  0.1 mM, 0.5 mM, 1mM, 5mM, 10mM, 20mM, 
50mM, 100mM, and 200mM. According to the data there was no direction 
correlation between crystals lattice quality and correlation as some crystals 
failed to be mounted even at lowest concentration such as 1mM and were 
fine at 200mM. Clearly there must have been variation in the original 
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crystal or there was variation in the local concentration or diffusion rates 
with the small crystallization drops used in the XChem process. Therefore, 
we couldn’t determine the direct dependency upon soaks concentration.  
When the diffraction data for all 5 ligands was analyzed using XChem 
explorer software there was no obvious differences in the maps and ligand 
occupancy between the lowest and the highest concentrations.  
Comparison of the chemical structures for each of the 5 fragments showed 
that they all are similar to IBMX, a known general PDE inhibitor including 
LmjPDEB1.  
One issue was that PanDDA has failed at first place to identify the 
reference map that was the same as it was used in the first run of XChem  
Unfortunately, due to PanDDA issues, it was not possible to plot dose-
dependence curve.  
Ligands ChEMBL131181, ChEMBL31877 and ChEMBL131164 were 
analyzed and were screened on SPR. SPR run revealed that 2 out of 3 
showed binding either between human PDE4 or/and TbrPDEB1. As in 
previous screen with DSI-Poised library fragments human PDE4 was used 
as a control. Ligand ChEMBL31877 showed specific binding with human 
PDE4 and unspecific with TbrPDEB1. Ligand ChEMBL131164 showed 
binding with TbrPDEB1 which was unspecific, and trays were looking 
similar to Ligand ChEMBL31877 where human PDE4 didn’t show any 
binding mode with Ligand ChEMBL31877. Unfortunately, there were no 
resources available with the collaborator to follow up on the hybrid 
compound design based on these data.  
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Table 1 Data collection and refinement statistics for TbrB1 catalytic domain crystals 
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 CC 1/2 99.6 (0.56) 99.6 (41.8) 99.5 (53.7) 99.5 (35.9|) 99.7 (25.9|) 97.3 (56.8) 
I / I 8.3 (1.2) 8.3 (1.0) 5.2 (1.3) 8.2 (1.6) 7.7 (0.3) 6.5 (1.2) 
Completeness (%) 99.7 (99.9) 99.4 (99.1) 97.7 (87) 99.1 (93.9) 99.8 (98.3) 99.4 (99.8) 
       
       
Refinement       
Resolution (Å) 2.42 1.91 1.88 1.64 1.67 2.18 












Rwork / Rfree 0.2/0.263 0.202/0.252 0.222/0.268 0.202/0.238 0.201/0.238 0.194/0.251 
No. atoms       
    Protein 5260 5260 5260 5260 5254 5260 
    Ligand/ion 78/4 72/4 50/4 39/4 49/4 52/4 
    Water 286 312 386 415 445 403 
B-factors       
    Protein 63.91 41.09 37.42 39.92 28.21 37.39 
    Ligand/ion 88.19/43.12 56.4/27.45 56.41/21 59.19/26.22 47.16/15.81 56.97/25.86 
    Water 53.14 41.65 39.81 44.84 34.83 36.31 
R.m.s. deviations       
    Bond lengths 
(Å) 
0.0065 0.0157 0.0095 0.0147 0.0149 0.0143 
    Bond angles () 1.413 1.94 1.639 1.78 1.82 1.84 
      
      
Data were collected from one crystal in each case. All structures will be deposited with the PDB on acceptance 
of the thesis 
 
 
